

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
**Abstral**

---

**Products Affected**

- ABSTRAL

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>ST Criteria</b>	<p>A documented contraindication, intolerance, allergy, or failure of one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)</p>
<b>QL Criteria</b>	<p>120 tablets Per 30 Days</p>
<b>Notes/References</b>	<p>Annual Review: 06/2017</p>
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Acamprosate Calcium

---

## Products Affected

- *acamprosate calcium*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accolate

---

## Products Affected

- ACCOLATE

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Accu-Chek Aviva Plus

## Products Affected

- ACCU-CHEK AVIVA PLUS

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Compact Plus Care

## Products Affected

- ACCU-CHEK COMPACT PLUS CARE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Accu-Chek Multiclix Lancet Dev

## Products Affected

- ACCU-CHEK MULTICLIX LANCET DEV

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Nano SmartView

## Products Affected

- ACCU-CHEK NANO SMARTVIEW

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Acetaminophen-Codeine

## Products Affected

- *acetaminophen-codeine oral solution*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Acetaminophen-Codeine

## Products Affected

- *acetaminophen-codeine oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



## Acetaminophen-Codeine #2

### Products Affected

- *acetaminophen-codeine #2*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

## Acetaminophen-Codeine #3

### Products Affected

- *acetaminophen-codeine #3*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Acetaminophen-Codeine #4

## Products Affected

- *acetaminophen-codeine #4*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# AcipHex Sprinkle

## Products Affected

- ACIPHEX SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required). In addition for approval the following criteria must also be met: Documentation of an inability to swallow tablets/capsules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 02/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Acitretin

---

## Products Affected

- *acitretin*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actemra

## Products Affected

- ACTEMRA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Actemra

## Products Affected

- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
QL Criteria	4 SYRINGES Per 28 DAYs
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actimmune

---

## Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/actimmune.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/actimmune.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Actoplus met XR

---

## Products Affected

- ACTOPLUS MET XR

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aczone

---

## Products Affected

- ACZONE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo and generic dapsone gel
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: November 06, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Adagen

---

## Products Affected

- ADAGEN

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adcirca

## Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Adefovir Dipivoxil

---

## Products Affected

- *adefovir dipivoxil*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adempas

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED 100-50 MCG/DOSE, 250-50  
MCG/DOSE

<b>QL Criteria</b>	1 diskus Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED 500-50 MCG/DOSE

<b>QL Criteria</b>	2 diskus Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair HFA

---

## Products Affected

- ADVAIR HFA

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advate

---

## Products Affected

- ADVATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Advocate Duo

---

## Products Affected

- ADVOCATE DUO DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adynovate

---

## Products Affected

- *adynovate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Adyphren

---

## Products Affected

- ADYPHREN

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adyphren Amp II

---

## Products Affected

- ADYPHREN AMP II

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Adyphren II

---

## Products Affected

- ADYPHREN II

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adzenys XR-ODT

## Products Affected

- ADZENYS XR-ODT

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Aerospan

## Products Affected

- AEROSPAN

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: November 30, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afinitor

## Products Affected

- AFINITOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Afinitor Disperz

---

## Products Affected

- AFINITOR DISPERZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afrezza

## Products Affected

- AFREZZA INHALATION POWDER 12 UNIT, 8 UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin, (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 24, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Afrezza

## Products Affected

- AFREZZA INHALATION POWDER 4 & 8 & 12 UNIT, 4 (30) & 8 (60) UNIT, 4 (90) & 8 (90) UNIT, 4 UNIT, 8 (60)& 12 (30) UNIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	
Required Medical Information	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin, (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: February 24, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Afrezza

## Products Affected

- AFREZZA INHALATION POWDER 4 (60)  
& 8 (30) UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin, (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: February 24, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Afstyla

---

## Products Affected

- AFSTYLA

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix Presto

## Products Affected

- AGAMATRIX PRESTO

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# AirDuo RespiClick 113/14

## Products Affected

- AIRDUO RESPICLICK 113/14

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Asthma
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Breo, Dulera, Symbicort and propionate/salmeterol inhaler (generic Airduo)
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# AirDuo RespiClick 232/14

---

## Products Affected

- AIRDUO RESPICLICK 232/14

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Asthma
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Breo, Dulera, Symbicort and propionate/salmeterol inhaler (generic Airduo)
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



## AirDuo RespiClick 55/14

---

### Products Affected

- AIRDUO RESPICLICK 55/14

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Asthma
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Breo, Dulera, Symbicort and propionate/salmeterol inhaler (generic Airduo)
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Akynzeo

## Products Affected

- AKYNZEO

PA Criteria	Criteria Details
Covered Uses	Prophylaxis of chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	A documented diagnosis of nausea and vomiting associated with cancer chemotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of Akynzeo will be considered medically necessary for those members who have a documented chemotherapy regimen that requires more than two cycles of antiemetic per 30 days
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of a generic 5-HT3 receptor antagonist, such as granisetron or ondansetron, and one month of aprepitant
QL Criteria	2 capsules Per 1 month
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Albenza

---

## Products Affected

- ALBENZA

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aldurazyme

---

## Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Alecensa

## Products Affected

- ALECENSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 10 mg, 40 mg, 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 35 mg*

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alfuzosin HCl ER

---

## Products Affected

- *alfuzosin hcl er*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Alinia

---

## Products Affected

- ALINIA ORAL SUSPENSION  
RECONSTITUTED

<b>QL Criteria</b>	60 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alinia

---

## Products Affected

- ALINIA ORAL TABLET

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Almotriptan Malate

---

## Products Affected

- *almotriptan malate*

<b>QL Criteria</b>	6 tablets Per 30 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin Benzoate

---

## Products Affected

- *alogliptin benzoate*

<b>QL Criteria</b>	1 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Alogliptin-Metformin HCl

---

## Products Affected

- *alogliptin-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin-Pioglitazone

---

## Products Affected

- *alogliptin-pioglitazone*

<b>QL Criteria</b>	1 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Alosetron HCl

## Products Affected

- *alose tron hcl*

PA Criteria	Criteria Details
Covered Uses	severe diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	
Required Medical Information	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month each diphenoxylate/atropine and loperamide
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ALPRAZolam ER

---

## Products Affected

- *alprazolam er*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# ALPRAZolam XR

---

## Products Affected

- *alprazolam xr*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Altoprev

---

## Products Affected

- ALTOPREV

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Alunbrig

## Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Alunbrig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Alunbrig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: June 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alvesco

## Products Affected

- ALVESCO

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: November 30, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Amitiza

---

## Products Affected

- AMITIZA

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine Besylate-Valsartan

---

## Products Affected

- *amlodipine besylate-valsartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Amlodipine-Olmesartan

---

## Products Affected

- *amlodipine-olmesartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine-Valsartan-HCTZ

---

## Products Affected

- *amlodipine-valsartan-hctz*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Amnesteem

---

## Products Affected

- *amnesteem*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amphetamine-Dextroamphet ER

---

## Products Affected

- *amphetamine-dextroamphet er*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Amphetamine-Dextroamphetamine

---

## Products Affected

- *amphetamine-dextroamphetamine*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ampyra

## Products Affected

- AMPYRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL 20.25 MG/1.25GM (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 1.25 gm packet Per 1 day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL 40.5 MG/2.5GM (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	5 grams-2 packets Per 1 day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# AndroGel Pump

## Products Affected

- ANDROGEL PUMP TRANSDERMAL  
GEL 20.25 MG/ACT (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 pumps Per 1 day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Anoro Ellipta

---

## Products Affected

- ANORO ELLIPTA

<b>QL Criteria</b>	60 BLISTERS Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Antara

---

## Products Affected

- ANTARA ORAL CAPSULE 30 MG, 90 MG

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Anzemet

---

## Products Affected

- ANZEMET ORAL

<b>QL Criteria</b>	5 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# APAP-Caff-Dihydrocodeine

## Products Affected

- *apap-caff-dihydrocodeine oral capsule*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Apidra

---

## Products Affected

- APIDRA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Apidra SoloStar

---

## Products Affected

- APIDRA SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aprepitant

---

## Products Affected

- *aprepitant oral capsule 125 mg, 40 mg, 80 mg*

<b>QL Criteria</b>	5 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aprepitant

---

## Products Affected

- *aprepitant oral capsule 80 & 125 mg*

<b>QL Criteria</b>	9 capsules Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apriso

---

## Products Affected

- APRISO

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptensio XR

## Products Affected

- APTENSIO XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptiom

---

## Products Affected

- APTIOM ORAL TABLET 200 MG, 600 MG

<b>QL Criteria</b>	2 TABS Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Aptiom

---

## Products Affected

- APTIOM ORAL TABLET 400 MG, 800 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aralast NP

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



## Aranesp (Albumin Free)

### Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML SOLUTION PREFILLED SYRINGE 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML SOLUTION PREFILLED SYRINGE 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythroipoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythroipoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arcalyst

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Arcalyst.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Arcalyst.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Arcapta Neohaler

## Products Affected

- ARCAPTA NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Serevent
QL Criteria	1 capsule Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# ARIPiprazole

---

## Products Affected

- *aripiprazole oral solution*

<b>QL Criteria</b>	30 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# ARIPiprazole

---

## Products Affected

- *aripiprazole oral tablet*
- *aripiprazole oral tablet dispersible*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Armodafinil

## Products Affected

- *armodafinil oral tablet 150 mg*
- *armodafinil oral tablet 200 mg, 250 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 Day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Armodafinil

## Products Affected

- *armodafinil oral tablet 50 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# ArmonAir RespiClick 113

---

## Products Affected

- ARMONAIR RESPICLICK 113

PA Criteria	Criteria Details
Covered Uses	Maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Exclusion Criteria	Not indicated for the relief of acute bronchospasm
Required Medical Information	A documented diagnosis of Asthma
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## ArmonAir RespiClick 232

---

### Products Affected

- ARMONAIR RESPICLICK 232

PA Criteria	Criteria Details
Covered Uses	Maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Exclusion Criteria	Not indicated for the relief of acute bronchospasm
Required Medical Information	A documented diagnosis of Asthma
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ArmonAir RespiClick 55

---

## Products Affected

- ARMONAIR RESPICLICK 55

PA Criteria	Criteria Details
<b>Covered Uses</b>	Maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
<b>Exclusion Criteria</b>	Not indicated for the relief of acute bronchospasm
<b>Required Medical Information</b>	A documented diagnosis of Asthma
<b>Age Restrictions</b>	12 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Arnuity Ellipta

---

## Products Affected

- ARNUITY ELLIPTA

<b>QL Criteria</b>	1 blister Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arymo ER

## Products Affected

- ARYMO ER

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	120 tablets Per 3 Days
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Arzerra

---

## Products Affected

- ARZERRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Arzerra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Arzerra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Asacol HD

---

## Products Affected

- ASACOL HD

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of Delzicol, Lialda, or Pentasa
<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ascomp-Codeine

## Products Affected

- *ascomp-codeine*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Astagraf XL

---

## Products Affected

- ASTAGRAF XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 0.5 MG

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Astagraf XL

---

## Products Affected

- ASTAGRAF XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 1 MG

<b>QL Criteria</b>	4 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atacand

---

## Products Affected

- ATACAND ORAL TABLET 32 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Atomoxetine HCl

---

## Products Affected

- *atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg, 60 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atomoxetine HCl

---

## Products Affected

- *atomoxetine hcl oral capsule 100 mg, 80 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Atorvastatin Calcium

---

## Products Affected

- *atorvastatin calcium oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atripla

---

## Products Affected

- ATRIPLA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Atrovent HFA

---

## Products Affected

- ATROVENT HFA

<b>QL Criteria</b>	2 inhalers Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aubagio

## Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Austedo

## Products Affected

- AUSTEDO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Austedo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Austedo.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Austedo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Austedo.html</a>
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 09, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avandia

---

## Products Affected

- AVANDIA ORAL TABLET 2 MG, 4 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Avita

## Products Affected

- *avita external cream*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	50 grams Per 1 fill
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Avita

## Products Affected

- *avita external gel*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Avonex

## Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	4 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex Pen

## Products Affected

- AVONEX PEN INTRAMUSCULAR  
AUTO-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	4 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Avonex Prefilled

## Products Affected

- AVONEX PREFILLED  
INTRAMUSCULAR PREFILLED  
SYRINGE KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	4 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Azilect

---

## Products Affected

- AZILECT

<b>QL Criteria</b>	1 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Azor

---

## Products Affected

- AZOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of amlodipine in combination with two of the following: Atacand, Avapro, Cozaar, Micardis
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Balsalazide Disodium

---

## Products Affected

- *balsalazide disodium*

<b>QL Criteria</b>	9 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Banzel

---

## Products Affected

- BANZEL ORAL TABLET

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Basaglar KwikPen

---

## Products Affected

- BASAGLAR KWIKPEN

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Levemir and Tresiba
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Baxdela

## Products Affected

- BAXDELA ORAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria
<b>Exclusion Criteria</b>	Known hypersensitivity to Baxdela or other fluoroquinolones
<b>Required Medical Information</b>	A documented diagnosis of acute bacterial skin and skin structure infections (ABSSSI) caused by one the following susceptible pathogens: Gram-positive organisms include Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillinsusceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, or Enterococcus faecalis. Gram-negative organisms include: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bayer Contour Link Monitor

## Products Affected

- BAYER CONTOUR LINK MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bayer Contour Monitor

## Products Affected

- BAYER CONTOUR MONITOR KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next EZ

## Products Affected

- BAYER CONTOUR NEXT EZ

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Bayer Contour next Link

### Products Affected

- BAYER CONTOUR NEXT LINK

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next Monitor

## Products Affected

- BAYER CONTOUR NEXT MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Beconase AQ

---

## Products Affected

- BECONASE AQ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Belbuca

## Products Affected

- BELBUCA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 films Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Belsomra

---

## Products Affected

- BELSOMRA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of zolpidem, zolpidem er, or zaleplon
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Benicar

---

## Products Affected

- BENICAR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Atacand, Avapro, Cozaar, Micardis
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benicar HCT

---

## Products Affected

- BENICAR HCT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of any two preferred alternatives from the following: candesartan/hctz, eprosartan/hctz, irbesartan/hctz, losartan/hctz, telmisartan/hctz, or valsartan/hctz
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benlysta

## Products Affected

- BENLYSTA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benlysta

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/benlysta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/benlysta.html</a>
QL Criteria	4 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Berinert

## Products Affected

- BERINERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Betamethasone Dipropionate Aug

---

## Products Affected

- *betamethasone dipropionate aug external gel ointment*
- *betamethasone dipropionate aug external*

<b>QL Criteria</b>	100 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Betamethasone Dipropionate Aug

---

## Products Affected

- *betamethasone dipropionate aug external lotion*

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Betaseron

## Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bethkis

---

## Products Affected

- BETHKIS

<b>QL Criteria</b>	56 ampules Per 30 DAYSS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bevespi Aerosphere

## Products Affected

- BEVESPI AEROSPHERE

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month each of Anoro Ellipta and Stiolto
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bevyxxa

## Products Affected

- BEVYXXA

PA Criteria	Criteria Details
<b>Covered Uses</b>	Prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
<b>Exclusion Criteria</b>	Active pathological bleeding, severe hypersensitivity reaction to Bevyxxa, or for anyone with prosthetic heart valves.
<b>Required Medical Information</b>	Member is requesting product for use of prophylaxis of VTE and is currently taking Bevyxxa during hospitalization and will be continuing therapy following discharge from the hospital.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of enoxaparin or dalteparin, or heparin
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 04, 2017 Step Therapy: October 05, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Bexarotene

---

## Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Targretin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Targretin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Bicalutamide

---

## Products Affected

- *bicalutamide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bimatoprost

## Products Affected

- *bimatoprost ophthalmic*

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: December 07, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bosulif

## Products Affected

- BOSULIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Botox

## Products Affected

- BOTOX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Botox Cosmetic

## Products Affected

- BOTOX COSMETIC INTRAMUSCULAR SOLUTION RECONSTITUTED 50 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bravelle

---

## Products Affected

- BRAVELLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Breo Ellipta

---

## Products Affected

- BREO ELLIPTA

<b>QL Criteria</b>	2 blister Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Breo Ellipta

---

## Products Affected

- BREO ELLIPTA

<b>QL Criteria</b>	2 inhalation Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Brilinta

---

## Products Affected

- BRILINTA

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brisdelle

---

## Products Affected

- BRISDELLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Moderate to severe vasomotor symptoms associated with menopause
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of moderate to severe vasomotor symptoms associated with menopause
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 28, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Briviact

## Products Affected

- BRIVIACT ORAL SOLUTION

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 ML Per 1 Day
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Briviact

## Products Affected

- BRIVIACT ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Brovana

## Products Affected

- BROVANA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Serevent (Step Therapy will not apply to members who have a documented inability to use an inhaler)
QL Criteria	4 milliliters Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Budesonide

## Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception allowed for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory and for Nasal Polyps when all criteria met: A diagnosis of chronic sinusitis with nasal polyposis, endoscopic sinus surgery has been performed, and standard nasal steroid sprays have been used as part of post-operative management and have failed.
QL Criteria	4 ML Per 1 Day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: January 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bunavail

---

## Products Affected

- BUNAVAIL BUCCAL FILM 2.1-0.3 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	6 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bunavail

---

## Products Affected

- BUNAVAIL BUCCAL FILM 4.2-0.7 MG,  
6.3-1 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	3 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Buprenorphine

## Products Affected

- *buprenorphine*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Buprenorphine HCl

---

## Products Affected

- *buprenorphine hcl sublingual*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine HCl-Naloxone HCl

---

## Products Affected

- *buprenorphine hcl-naloxone hcl*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# BuPROPion HCl

---

## Products Affected

- *bupropion hcl oral*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (Smoking Det)

---

### Products Affected

- *bupropion hcl er (smoking det)*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (SR)

---

### Products Affected

- *bupropion hcl er (sr)*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (XL)

---

### Products Affected

- *bupropion hcl er (xl)*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Butalbital-APAP-Caff-Cod

## Products Affected

- *butalbital-apap-caff-cod*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Butalbital-ASA-Caff-Codeine

## Products Affected

- *butalbital-asa-caff-codeine*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Butorphanol Tartrate

## Products Affected

- *butorphanol tartrate nasal*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 bottles Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Butrans

## Products Affected

- BUTRANS

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Bydureon

---

## Products Affected

- BYDUREON SUBCUTANEOUS PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Victoza and Trulicity
<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Byetta 10 MCG Pen

---

## Products Affected

- BYETTA 10 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Victoza and Trulicity
<b>QL Criteria</b>	1 pen Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Byetta 5 MCG Pen

---

## Products Affected

- BYETTA 5 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Victoza and Trulicity
<b>QL Criteria</b>	1 pen Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bystolic

## Products Affected

- BYSTOLIC ORAL TABLET 10 MG, 5 MG • BYSTOLIC ORAL TABLET 2.5 MG

PA Criteria	Criteria Details
Covered Uses	Treatment of hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two generic beta-blockers
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: April 03, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Bystolic

## Products Affected

- BYSTOLIC ORAL TABLET 20 MG

PA Criteria	Criteria Details
Covered Uses	Treatment of hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two generic beta-blockers
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: April 03, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Byvalson

## Products Affected

- BYVALSON

PA Criteria	Criteria Details
Covered Uses	Treatment of hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 2 generic beta-blockers and 2 generic angiotensin receptor blockers (ARBs)
QL Criteria	1 tablet Per 1 Day
Notes/References	Annual Review: 08/2017
Revision Date	Prior Authorization: April 03, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cabometyx

---

## Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Calcipotriene

---

## Products Affected

- *calcipotriene external cream*
- *calcipotriene external ointment*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



## Calcitonin (Salmon)

---

### Products Affected

- *calcitonin (salmon)*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Calcitrene

---

## Products Affected

- *calcitrene*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Canasa

---

## Products Affected

- CANASA

<b>QL Criteria</b>	1 suppository Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Candesartan Cilexetil

---

## Products Affected

- *candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Candesartan Cilexetil-HCTZ

---

## Products Affected

- *candesartan cilexetil-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Capecitabine

## Products Affected

- *capecitabine*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Caprelsa

## Products Affected

- CAPRELSA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Caprelsa

## Products Affected

- CAPRELSA ORAL TABLET 300 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Carbaglu

---

## Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cardizem LA

---

## Products Affected

- CARDIZEM LA ORAL TABLET  
EXTENDED RELEASE 24 HOUR 120 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cardura XL

---

## Products Affected

- CARDURA XL

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 120 mg, 300 mg*
- *cartia xt oral capsule extended release 24 hour 180 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cayston

---

## Products Affected

- CAYSTON

<b>QL Criteria</b>	3 vials Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cefixime

---

## Products Affected

- *cefixime*

<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Celecoxib

---

## Products Affected

- *celecoxib oral*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Cerdelga

## Products Affected

- CERDELGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cerezyme

## Products Affected

- CEREZYME INTRAVENOUS SOLUTION  
RECONSTITUTED 400 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cesamet

---

## Products Affected

- CESAMET

<b>QL Criteria</b>	2 capsules Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cetrotide

## Products Affected

- CETROTIDE SUBCUTANEOUS KIT 0.25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cevimeline HCl

---

## Products Affected

- *cevimeline hcl*

<b>QL Criteria</b>	3 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chantix

---

## Products Affected

- CHANTIX

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Chantix Continuing Month Pak

---

## Products Affected

- CHANTIX CONTINUING MONTH PAK

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chantix Starting Month Pak

---

## Products Affected

- CHANTIX STARTING MONTH PAK

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Chenodal

## Products Affected

- CHENODAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	For treatment of cholesterol-type gallstones in patients over 18 years of age and have tried and failed 2 years of generic Actigall (ursodiol) therapy and are not able to undergo surgery due to systemic disease or age, and for treatment of diagnosed Cerebrotendinous Xanthomatosis (CTX) in patients over 18 years of age
<b>Exclusion Criteria</b>	Intrahepatic duct calculus, Chronic constipation in patients with cholesterol gallstones, Prophylaxis of recurrent gallstones, Hyperlipidemia, Rheumatoid Arthritis
<b>Required Medical Information</b>	Prior to initial coverage for gallstone disease, a cholecystogram or other appropriate imaging studies is required to determine presence of radiolucent gallstones, stones that are transparent to x-rays. Due to high risk of hepatotoxicity and adverse effects, for the first 3 months, authorization is required each month pending hepatic function tests (for both gallstones and CTX). After initial 3 months, authorization required every 3 months for length of treatment, pending hepatic function tests. At 6 months prior to authorization, the following results are required, serum cholesterol levels, hepatic function test, and cholecystogram (monitor dissolution of stones). Safety of use beyond a total of 24 months has not been established
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month (initial authorization), 3 month (reauthorization)
<b>Other Criteria</b>	Max authorization up to 2 years
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cholbam

## Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Cholbam.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Cholbam.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chorionic Gonadotropin

---

## Products Affected

- *chorionic gonadotropin intramuscular*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cialis

## Products Affected

- CIALIS ORAL TABLET 2.5 MG
- CIALIS ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	diagnosis of benign prostatic hyperplasia
Exclusion Criteria	Erectile dysfunction (ED) diagnosis is not covered except for members with ED benefit rider or Fully Insured (FI) members in the state of NY.
Required Medical Information	A documented diagnosis of diagnosis of benign prostatic hyperplasia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year (30 tablets every 30 days)
Other Criteria	Member has failed two alpha blockers (e.g. Cardura (doxazosin), Hytrin (terazosin), Flomax (tamsulosin), Uroxatral (alfuzosin), Rapaflo (silodosin) and failed one 5-alpha reductase inhibitor (e.g. Avodart (dutasteride), Proscar (finasteride), Jalyn (dutasteride/tamsulosin).
QL Criteria	1 tablets Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ciclofan

## Products Affected

- CICLOFAN EXTERNAL SOLUTION

PA Criteria	Criteria Details
Covered Uses	Onychomycosis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Failure of an adequate trial of one systemic oral alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), OR If member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ciclopirox

## Products Affected

- *ciclopirox external solution*

PA Criteria	Criteria Details
Covered Uses	Onychomycosis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Failure of an adequate trial of one systemic oral alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), OR If member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cimzia

## Products Affected

- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Cimzia Prefilled

## Products Affected

- CIMZIA PREFILLED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cimzia Starter Kit

---

## Products Affected

- CIMZIA STARTER KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cinqair

---

## Products Affected

- CINQAIR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Cinqair.html">http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Cinqair.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cinryze

## Products Affected

- CINRYZE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet 10 mg, 20 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet 40 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Claravis

---

## Products Affected

- *claravis*

<b>QL Criteria</b>	2 Capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clarinet-D 12 Hour

---

## Products Affected

- CLARINEX-D 12 HOUR

<b>QL Criteria</b>	2 TB12 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



## Clever Chek Auto-Code

---

### Products Affected

- CLEVER CHEK AUTO-CODE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Choice Micro System

## Products Affected

- CLEVER CHOICE MICRO SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Climara Pro

---

## Products Affected

- CLIMARA PRO

<b>QL Criteria</b>	1 box (4 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clobetasol Propionate

---

## Products Affected

- *clobetasol propionate external cream*
- *clobetasol propionate external gel*
- *clobetasol propionate external ointment*

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Clobetasol Propionate

---

## Products Affected

- *clobetasol propionate external foam*
- *clobetasol propionate external solution*

<b>QL Criteria</b>	100 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clobetasol Propionate

---

## Products Affected

- *clobetasol propionate external liquid*

<b>QL Criteria</b>	125 ML Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clobetasol Propionate

---

## Products Affected

- *clobetasol propionate external lotion*
- *clobetasol propionate external shampoo*

<b>QL Criteria</b>	236 ML Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clobetasol Propionate E

---

## Products Affected

- *clobetasol propionate e*

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Clobetasol Propionate Emulsion

---

## Products Affected

- *clobetasol propionate emulsion*

<b>QL Criteria</b>	100 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clodan

---

## Products Affected

- *clodan external shampoo*

<b>QL Criteria</b>	236 ML Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloNIDine HCl ER

## Products Affected

- *clonidine hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clopidogrel Bisulfate

---

## Products Affected

- *clopidogrel bisulfate oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 100 mg*
- *clozapine oral tablet dispersible 100 mg*

<b>QL Criteria</b>	9 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 25 mg, 50 mg*
- *clozapine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 12.5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 150 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Coagadex

## Products Affected

- COAGADEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Codeine Sulfate

## Products Affected

- *codeine sulfate oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Colchicine

---

## Products Affected

- *colchicine oral*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CombiPatch

---

## Products Affected

- COMBIPATCH

<b>QL Criteria</b>	8 patches Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Combivent Respimat

---

## Products Affected

- COMBIVENT RESPIMAT

<b>QL Criteria</b>	2 inhalers Per 1 month
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



## Cometriq (100 mg Daily Dose)

### Products Affected

- COMETRIQ (100 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (140 mg Daily Dose)

---

### Products Affected

- COMETRIQ (140 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 caupsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Cometriq (60 mg Daily Dose)

---

### Products Affected

- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Complera

---

## Products Affected

- COMPLERA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Copaxone

## Products Affected

- COPAXONE SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE 40  
MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cordran

---

## Products Affected

- CORDRAN EXTERNAL TAPE

<b>QL Criteria</b>	1 roll Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Coreg CR

---

## Products Affected

- COREG CR

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Corlanor

## Products Affected

- CORLANOR

PA Criteria	Criteria Details
Covered Uses	FDA labeled use for heart failure
Exclusion Criteria	
Required Medical Information	Documentation of stable, symptomatic chronic heart failure with left ventricular ejection fraction less than or equal to 35%, who are in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, and who are on maximally tolerated doses of beta-blockers (bisoprolol/bisoprolol-HCTZ, carvedilol, carvedilol CR, metoprolol succinate/metoprolol succinate-HCTZ, nebivolol) or have a documented contraindication to beta-blocker use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of one of the following: ACE Inhibitor or ACE Inhibitor/HCTZ combination or Angiotensin-Receptor Blocker or Angiotensin-Receptor Blocker/HCTZ combination
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: July 25, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Cormax Scalp Application

---

## Products Affected

- CORMAX SCALP APPLICATION

<b>QL Criteria</b>	100 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cosentyx

## Products Affected

- COSENTYX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cosentyx Sensoready Pen

---

## Products Affected

- COSENTYX SENSOREADY PEN  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR 150 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cosentyx.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cotellic

## Products Affected

- COTELLIC

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	63 tablets Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cotempla XR-ODT

## Products Affected

- COTEMPLA XR-ODT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
<b>Age Restrictions</b>	Approved for patients 6 to 17 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Crestor

---

## Products Affected

- CRESTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two generic statin medications: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cuprimine

## Products Affected

- CUPRIMINE ORAL CAPSULE 250 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CVS Nicotine

---

## Products Affected

- *cvs nicotine transdermal patch 24 hour*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# CVS Nicotine Polacrilex

---

## Products Affected

- *cvs nicotine polacrilex mouth/throat lozenge*  
4 mg

<b>QL Criteria</b>	20 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CVS NTS Step 1

---

## Products Affected

- *cvs nts step 1*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cycloset

---

## Products Affected

- CYCLOSET

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cystadane

## Products Affected

- CYSTADANE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Cystagon

## Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cystaran

## Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ML Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Daklinza

## Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daklinza

## Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Daliresp

## Products Affected

- DALIRESP

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disease (COPD)
Exclusion Criteria	
Required Medical Information	A Documented diagnosis of severe COPD associated with chronic bronchitis and a history of exacerbations.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: Breo, Symbicort, Anoro, Stiolto, Incruse, or Spiriva
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: July 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dapsone

---

## Products Affected

- *dapsone external*

<b>QL Criteria</b>	60 grams Per 30 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Darifenacin Hydrobromide ER

---

## Products Affected

- *darifenacin hydrobromide er*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daytrana

## Products Affected

- DAYTRANA

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	1 patch Per 1 day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Delzicol

---

## Products Affected

- DELZICOL

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Depen Titratabs

## Products Affected

- DEPEN TITRATABS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Descovy

## Products Affected

- DESCOVY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desloratadine

---

## Products Affected

- *desloratadine*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Desvenlafaxine ER

---

## Products Affected

- *desvenlafaxine er*

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desvenlafaxine Succinate ER

## Products Affected

- *desvenlafaxine succinate er*

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 05/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dexilant

## Products Affected

- DEXILANT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	1 capsule Per 1 day
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

# Dexmethylphenidate HCl

---

## Products Affected

- *dexmethylphenidate hcl*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexmethylphenidate HCl ER

---

## Products Affected

- *dexmethylphenidate hcl er*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dextroamphetamine Sulfate

---

## Products Affected

- *dextroamphetamine sulfate oral solution*

<b>QL Criteria</b>	40 milliliters Per 1 day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate

---

## Products Affected

- *dextroamphetamine sulfate oral tablet*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Dextroamphetamine Sulfate ER

---

## Products Affected

- *dextroamphetamine sulfate er*

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DiazePAM

---

## Products Affected

- *diazepam rectal*

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Diclegis

## Products Affected

- DICLEGIS

PA Criteria	Criteria Details
Covered Uses	Nausea and vomiting in pregnant women
Exclusion Criteria	
Required Medical Information	A documented diagnosis of nausea and vomiting in a pregnant woman who does not respond to conservative management (i.e. trigger avoidance, small frequent meals, etc) and a documented contraindication, intolerance, allergy, or failure of an adequate trial of one week of any of the following: otc doxylamine, or otc pyridoxine (vit B6), or metoclopramide, or promethazine, or ondansetron
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 01, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Diclofenac Sodium

---

## Products Affected

- *diclofenac sodium transdermal gel 1 %*

<b>QL Criteria</b>	200 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Differin

---

## Products Affected

- DIFFERIN EXTERNAL LOTION

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dificid

---

## Products Affected

- DIFICID

<b>QL Criteria</b>	20 tablets Per 1 fill
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dihydroergotamine Mesylate

---

## Products Affected

- *dihydroergotamine mesylate nasal*

<b>ST Criteria</b>	A documented step through one month each of generic Migranal and two of the following: naratriptan, rizatriptan, sumatriptan, zolmitriptan
<b>QL Criteria</b>	9 ML Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
24 hour 120 mg, 180 mg

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
24 hour 240 mg

<b>QL Criteria</b>	2 Capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DiltiaZEM CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
24 hour 300 mg

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER

---

## Products Affected

- *diltiazem hcl er oral capsule extended release 12 hour 120 mg*
- *diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER

---

## Products Affected

- *diltiazem hcl er oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg, 360 mg*
- *diltiazem hcl er beads oral capsule extended release 24 hour 420 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg*
- *diltiazem hcl er coated beads oral capsule extended release 24 hour 360 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Coated Beads

---

## Products Affected

- diltiazem hcl er coated beads oral capsule  
extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 Capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# DilTIAZem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule*  
*extended release 24 hour 300 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dilt-XR

---

## Products Affected

- *dilt-xr oral capsule extended release 24 hour*  
*120 mg, 180 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dilt-XR

---

## Products Affected

- *dilt-xr oral capsule extended release 24 hour*  
240 mg

<b>QL Criteria</b>	2 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dipentum

---

## Products Affected

- DIPENTUM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of mesalamine DR (generic Asacol HD), Delzicol, Lialda, or Pentasa
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dolophine

## Products Affected

- DOLOPHINE ORAL TABLET 10 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Donepezil HCl

## Products Affected

- *donepezil hcl oral tablet 10 mg*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Donepezil HCl

## Products Affected

- *donepezil hcl oral tablet 23 mg, 5 mg*
- *donepezil hcl oral tablet dispersible*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Doxepin HCl

---

## Products Affected

- *doxepin hcl external*

<b>QL Criteria</b>	45 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Doxercalciferol

---

## Products Affected

- *doxercalciferol oral*

<b>QL Criteria</b>	1 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dronabinol

## Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Covered Uses	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	2 capsules Per 1 day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: July 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duavee

---

## Products Affected

- DUAVEE

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dulera

---

## Products Affected

- DULERA

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 20 mg, 60 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 30 mg*
- *duloxetine hcl oral capsule delayed release particles 40 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dupixent

## Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Dupixent.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Dupixent.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: May 09, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Durolane

## Products Affected

- DUROLANE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dutasteride

---

## Products Affected

- *dutasteride*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Duzallo

## Products Affected

- DUZALLO

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
<b>Exclusion Criteria</b>	For the treatment of asymptomatic hyperuricemia, severe renal impairment, end stage renal disease, kidney transplant recipients, or patients on dialysis, tumor lysis syndrome or Lesch-Nyhan syndrome, or for anyone with a known hypersensitivity to allopurinol, including previous occurrence of skin rash.
<b>Required Medical Information</b>	A documented diagnosis of hyperuricemia associated with gout and the member has a documented trial of allopurinol and has not achieved target serum uric acid levels.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of allopurinol or febuxostat
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 03, 2017 Step Therapy: October 04, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dyanavel XR

## Products Affected

- DYANAVEL XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	240 ML Per 30 days
Notes/References	
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Dysport

## Products Affected

- DYSPOORT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Econazole Nitrate

---

## Products Affected

- *econazole nitrate external*

<b>QL Criteria</b>	85 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edarbi

---

## Products Affected

- EDARBI

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Atacand, Avapro, Cozaar, Micardis
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edarbyclor

---

## Products Affected

- EDARBYCLOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of any two preferred alternatives from the following: candesartan/hctz, eprosartan/hctz, irbesartan/hctz, losartan/hctz, telmisartan/hctz, or valsartan/hctz
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Edurant

---

## Products Affected

- EDURANT

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Effient

## Products Affected

- EFFIENT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acute coronary syndrome (ACS) managed with percutaneous coronary intervention which includes unstable angina or non-ST elevation myocardial infarction or ST elevation myocardial infarction (MI)
<b>Exclusion Criteria</b>	History of Stroke or transient ischemic attack (TIA)
<b>Required Medical Information</b>	Member has a documented diagnosis of acute coronary syndrome (ACS) and is managed by percutaneous coronary intervention (PCI), which includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST -elevation myocardial infarction (STEMI) managed with primary or delayed PCI and member has no prior history of stroke or transient ischemic attack (TIA)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: May 22, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Elaprase

---

## Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elelyso

---

## Products Affected

- ELELYSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Elestrin

---

## Products Affected

- ELESTRIN

<b>QL Criteria</b>	52 GM Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eletriptan Hydrobromide

---

## Products Affected

- *eletriptan hydrobromide*

<b>QL Criteria</b>	6 tablets Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Elidel

## Products Affected

- ELIDEL

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis
Exclusion Criteria	
Required Medical Information	FOR MEMBERS LESS THAN 2 YEARS OF AGE: Covered for the treatment of mild to moderate atopic dermatitis (eczema) for short-term use (up to 3 months). FOR MEMBERS OVER 2 YEARS OF AGE: A documented diagnosis of atopic dermatitis (eczema) and has a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for their condition, or they are being treated for atopic dermatitis (eczema) in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Less than 2 years of age: 3 months. Over 2 years of age: 1 year.
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patients condition
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: October 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Eligard

---

## Products Affected

- ELIGARD

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Elmiron

---

## Products Affected

- ELMIRON

<b>QL Criteria</b>	90 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embeda

## Products Affected

- EMBEDA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Emend

---

## Products Affected

- EMEND ORAL CAPSULE 125 MG, 80 MG • EMEND ORAL CAPSULE 40 MG

<b>QL Criteria</b>	5 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Emsam

---

## Products Affected

- EMSAM

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emtriva

---

## Products Affected

- EMTRIVA ORAL CAPSULE

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Emverm

---

## Products Affected

- EMVERM

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enablex

---

## Products Affected

- ENABLEX

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Enablex

---

## Products Affected

- ENABLEX

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
<b>QL Criteria</b>	1 tablet Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

## Products Affected

- ENBREL SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 25 MG/0.5ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Enbrel

## Products Affected

- ENBREL SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 50 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	8 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

## Products Affected

- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	8 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Enbrel Mini

## Products Affected

- ENBREL MINI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	8 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel SureClick

## Products Affected

- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	8 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Endocet

## Products Affected

- *endocet oral tablet 10-325 mg, 5-325 mg*
- *endocet oral tablet 7.5-325 mg*
- ENDOCET ORAL TABLET 2.5-325 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Enoxaparin Sodium

---

## Products Affected

- *enoxaparin sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enstilar

---

## Products Affected

- ENSTILAR

<b>QL Criteria</b>	60 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Entecavir

---

## Products Affected

- *entecavir*

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entecavir

---

## Products Affected

- *entecavir*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Entresto

---

## Products Affected

- ENTRESTO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Heart Failure
<b>Exclusion Criteria</b>	Known or suspected pregnancy
<b>Required Medical Information</b>	A documented diagnosis of chronic heart failure (NYHA Class II-IV) and reduced ejection fraction
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 08/2017
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Entyvio

## Products Affected

- ENTYVIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Entyvio.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Entyvio.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Entyvio.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Entyvio.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Epaned

---

## Products Affected

- EPANED ORAL SOLUTION

<b>QL Criteria</b>	1 bottle Per 30 Days
<b>Notes/ References</b>	Annual Review: 08/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epclusa

## Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# EPINEPHrine

---

## Products Affected

- *epinephrine injection solution auto-injector*

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EpiPen 2-Pak

---

## Products Affected

- EPIPEN 2-PAK INJECTION SOLUTION  
AUTO-INJECTOR

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# EpiPen Jr 2-Pak

---

## Products Affected

- EPIPEN JR 2-PAK INJECTION  
SOLUTION AUTO-INJECTOR

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EPIsnap

---

## Products Affected

- EPISNAP

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Epogen

## Products Affected

- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epoprostenol Sodium

---

## Products Affected

- *epoprostenol sodium*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Eprosartan Mesylate

---

## Products Affected

- *eprosartan mesylate*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EQ Nicotine

---

## Products Affected

- *eq nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Erivedge

## Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esbriet

---

## Products Affected

- ESBRIET ORAL CAPSULE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	9 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Esbriet

## Products Affected

- ESBRIET ORAL TABLET 267 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	9 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esbriet

## Products Affected

- ESBRIET ORAL TABLET 801 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral solution*

<b>QL Criteria</b>	20 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 10 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 20 mg, 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esomeprazole Magnesium

---

## Products Affected

- *esomeprazole magnesium oral capsule  
delayed release 40 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Estradiol

---

## Products Affected

- *estradiol transdermal patch twice weekly*

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol

---

## Products Affected

- *estradiol transdermal patch weekly*

<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol-Norethindrone Acet

---

## Products Affected

- *estradiol-norethindrone acet*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estrogel

---

## Products Affected

- ESTROGEL

<b>QL Criteria</b>	50 grams Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Eszopiclone

---

## Products Affected

- *eszopiclone*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Euflexxa

---

## Products Affected

- EUFLEXXA INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Evamist

---

## Products Affected

- EVAMIST

<b>QL Criteria</b>	2 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evekeo

## Products Affected

- EVEKEO

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD) OR Narcolepsy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	120 tablets Per 30 Days
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: January 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Exalgo

## Products Affected

- EXALGO ORAL TABLET ER 24 HOUR  
ABUSE-DETERRENT 32 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Exjade

---

## Products Affected

- EXJADE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Extavia

## Products Affected

- EXTAVIA SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ezetimibe

---

## Products Affected

- *ezetimibe*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ezetimibe-Simvastatin

---

## Products Affected

- *ezetimibe-simvastatin*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fabior

---

## Products Affected

- FABIOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fabrazyme

---

## Products Affected

- FABRAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# FaLessa

---

## Products Affected

- FALESSA ORAL KIT 20-1-0.1 MCG-MG

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Famciclovir

---

## Products Affected

- *famciclovir oral tablet 125 mg, 250 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Famciclovir

---

## Products Affected

- *famciclovir oral tablet 500 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fanapt

---

## Products Affected

- FANAPT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fanapt Titration Pack

---

## Products Affected

- FANAPT TITRATION PACK

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Farxiga

---

## Products Affected

- FARXIGA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Farydak

## Products Affected

- FARYDAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 EA Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Faslodex

## Products Affected

- FASLODEX INTRAMUSCULAR SOLUTION 250 MG/5ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Felodipine ER

---

## Products Affected

- *felodipine er*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Femring

---

## Products Affected

- FEMRING

<b>QL Criteria</b>	1 ring Per 90 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fenofibrate

---

## Products Affected

- *fenofibrate oral capsule*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate

---

## Products Affected

- *fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate Micronized

---

## Products Affected

- *fenofibrate micronized*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibric Acid

---

## Products Affected

- *fenofibric acid oral tablet*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FentaNYL

## Products Affected

- *fentanyl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	20 patches Per 30 Days
<b>Notes/ References</b>	Annual Review: 09/2016
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# FentaNYL Citrate

---

## Products Affected

- *fentanyl citrate buccal*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one week each of two (2) immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone
<b>QL Criteria</b>	120 Lozenges Per 30 Days
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Fentora

## Products Affected

- FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ferriprox

---

## Products Affected

- FERRIPROX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fetzima

## Products Affected

- FETZIMA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 05/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fetzima Titration

## Products Affected

- FETZIMA TITRATION

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 CP24 Per 1 DAYS
Notes/References	Annual Review: 05/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fiasp

---

## Products Affected

- FIASP

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fiasp FlexTouch

---

## Products Affected

- FIASP FLEXTOUCH

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fibricor

---

## Products Affected

- FIBRICOR

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Finasteride

## Products Affected

- *finasteride oral tablet 5 mg*

PA Criteria	Criteria Details
Covered Uses	Benign prostatic hyperplasia
Exclusion Criteria	
Required Medical Information	Member is greater than 50 years old or has diagnosis of BPH (Benign Prostatic Hyperplasia). For female members, must have a documented diagnosis of hirsutism secondary to ovarian or adrenal dysfunction (for example, polycystic ovary syndrome, adrenal or ovarian tumor)and must not be pregnant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fioricet/Codeine

## Products Affected

- FIORICET/CODEINE ORAL CAPSULE  
50-300-40-30 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Firmagon

---

## Products Affected

- FIRMAGON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Flebogamma DIF

---

## Products Affected

- FLEBOGAMMA DIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flolan

---

## Products Affected

- FLOLAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Flovent Diskus

---

## Products Affected

- FLOVENT DISKUS

<b>QL Criteria</b>	2 blisters Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flovent HFA

---

## Products Affected

- FLOVENT HFA

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fluocinonide

---

## Products Affected

- *fluocinonide external cream 0.05 %*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of betamethasone dipropionate (cream/ointment/lotion)
<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluocinonide

---

## Products Affected

- *fluocinonide external cream 0.1 %*
- *fluocinonide external gel*
- *fluocinonide external ointment*
- *fluocinonide external solution*

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule delayed release*

<b>QL Criteria</b>	4 capsules Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 20 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 60 mg*

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluticasone-Salmeterol

---

## Products Affected

- *fluticasone-salmeterol*

<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fluvastatin Sodium

---

## Products Affected

- *fluvastatin sodium*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvoxamine Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fluvoxamine Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 25 mg*
- *fluvoxamine maleate oral tablet 50 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvoxamine Maleate ER

---

## Products Affected

- *fluvoxamine maleate er*

<b>QL Criteria</b>	2 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Focalin XR

---

## Products Affected

- FOCALIN XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 25 MG,  
EXTENDED RELEASE 24 HOUR 20 MG 35 MG
- FOCALIN XR ORAL CAPSULE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Follistim AQ

## Products Affected

- FOLLISTIM AQ INJECTION SOLUTION 75 UNT/0.5ML
- FOLLISTIM AQ SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Fondaparinux Sodium

---

## Products Affected

- *fondaparinux sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D10 2-in-1 Monitor

---

## Products Affected

- FORA D10 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FORA D15g 2-in-1 Monitor

---

## Products Affected

- FORA D15G 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D20 2-in-1 Monitor

---

## Products Affected

- FORA D20 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Forteo

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION  
600 MCG/2.4ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fosamax Plus D

---

## Products Affected

- FOSAMAX PLUS D

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fragmin

---

## Products Affected

- FRAGMIN SUBCUTANEOUS SOLUTION  
10000 UNIT/ML, 12500 UNIT/0.5ML,  
15000 UNIT/0.6ML, 18000 UNT/0.72ML,  
2500 UNIT/0.2ML, 5000 UNIT/0.2ML,  
7500 UNIT/0.3ML, 95000 UNIT/3.8ML

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Flash System

## Products Affected

- FREESTYLE FLASH SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# FreeStyle Freedom Lite

## Products Affected

- FREESTYLE FREEDOM LITE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FreeStyle InsuLinx System

## Products Affected

- FREESTYLE INSULINX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FreeStyle InsuLinx Test

---

## Products Affected

- FREESTYLE INSULINX TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Lite Test

---

## Products Affected

- FREESTYLE LITE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FreeStyle Precision Neo Test

---

## Products Affected

- FREESTYLE PRECISION NEO TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle System

## Products Affected

- FREESTYLE SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# FreeStyle Test

---

## Products Affected

- FREESTYLE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Frova

---

## Products Affected

- FROVA

<b>QL Criteria</b>	9 tablets Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Frovatriptan Succinate

---

## Products Affected

- *frovatriptan succinate*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fuzeon

## Products Affected

- FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Fycompa

---

## Products Affected

- FYCOMPA ORAL TABLET

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral capsule*

<b>QL Criteria</b>	6 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gabapentin

---

## Products Affected

- *gabapentin oral tablet*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabril

---

## Products Affected

- GABITRIL ORAL TABLET 12 MG

<b>QL Criteria</b>	4 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gabril

---

## Products Affected

- GABITRIL ORAL TABLET 16 MG

<b>QL Criteria</b>	3 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Galantamine Hydrobromide

---

## Products Affected

- *galantamine hydrobromide*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Galantamine Hydrobromide ER

---

## Products Affected

- *galantamine hydrobromide er*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gammaplex

## Products Affected

- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/200ML, 20 GM/400ML, 5 GM/100ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gamunex-C

---

## Products Affected

- GAMUNEX-C

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ganirelix Acetate

---

## Products Affected

- *ganirelix acetate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gattex

---

## Products Affected

- GATTEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gattex.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gattex.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GaviLyte-C

---

## Products Affected

- *gavilyte-c*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# GaviLyte-G

---

## Products Affected

- *gavilyte-g*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gelnique

---

## Products Affected

- GELNIQUE TRANSDERMAL GEL 10 %

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Gel-One

## Products Affected

- GEL-ONE INTRA-ARTICULAR  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gelsyn-3

### Products Affected

- GELSYN-3

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# GenVisc 850

## Products Affected

- GENVISC 850

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Genvoya

## Products Affected

- GENVOYA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Giazo

## Products Affected

- GIAZO

PA Criteria	Criteria Details
Covered Uses	Ulcerative colitis
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild to moderate ulcerative colitis in males. Note: Per Product Labeling, Giazo effectiveness was not demonstrated in female patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of mesalamine DR (generic Asacol HD), Delzicol, Lialda, or Pentasa
QL Criteria	6 tablets Per 1 day
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gilenya

## Products Affected

- GILENYA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gilotrif

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glassia

---

## Products Affected

- GLASSIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Glatopa

## Products Affected

- *glatopa*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucaGen Diagnostic

---

## Products Affected

- GLUCAGEN DIAGNOSTIC

<b>QL Criteria</b>	1 vial Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# GlucaGen HypoKit

---

## Products Affected

- GLUCAGEN HYPOKIT

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glyxambi

---

## Products Affected

- GLYXAMBI

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Invokana/Invokamet and either Januvia/Janumet and either Tradjenta/Jentadueto
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Gonal-f

---

## Products Affected

- GONAL-F

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f RFF

---

## Products Affected

- GONAL-F RFF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

## Gonal-f RFF Rediject

---

### Products Affected

- GONAL-F RFF REDIJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 300 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 600 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise Starter

---

## Products Affected

- GRALISE STARTER

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	1 starter pack Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Granix

## Products Affected

- GRANIX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GuanFACINE HCl ER

## Products Affected

- *guanfacine hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Haegarda

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
QL Criteria	16 kits Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Halobetasol Propionate

---

## Products Affected

- *halobetasol propionate*

<b>QL Criteria</b>	50 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Harvoni

---

## Products Affected

- HARVONI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Heather

---

## Products Affected

- *heather*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Helixate FS

---

## Products Affected

- HELIXATE FS INTRAVENOUS KIT 3000 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hemangeol

## Products Affected

- HEMANGEOL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Proliferating infantile hemangioma
<b>Exclusion Criteria</b>	History of asthma or bronchospasms
<b>Required Medical Information</b>	A documented diagnosis of proliferating infantile hemangioma requiring systemic therapy and documented all of the following: (1) Member was not born prematurely with a corrected age of less than 5 weeks, (2) Member does not weigh less than 2kg, have sustained heart rate less than 80 beats per minute, have greater than first degree heart block, or have decompensated heart failure, and (3) Member does not have sustained blood pressure less than 50/ 30mmHg.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: July 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Hetlioz

## Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/sedative-hypnotics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/sedative-hypnotics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HM Nicotine

---

## Products Affected

- *hm nicotine*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# HM Nicotine Polacrilex

---

## Products Affected

- *hm nicotine polacrilex mouth/throat lozenge*  
2 mg

<b>QL Criteria</b>	20 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Horizant

## Products Affected

- HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG

PA Criteria	Criteria Details
Covered Uses	Post-herpetic neuralgia and Restless leg syndrome
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Restless Leg Syndrome (RLS) or Post Herpetic Neuralgia (shingles)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR POST-HERPETIC NEURALGIA: A documented contraindication, intolerance, allergy, or failure of one month of gabapentin. FOR RESTLESS LEG SYNDROME:A documented contraindication, intolerance, allergy, or failure of one month of pramipexole, or ropinirole.
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: February 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Horizant

## Products Affected

- HORIZANT ORAL TABLET EXTENDED  
RELEASE 600 MG

PA Criteria	Criteria Details
Covered Uses	Post-herpetic neuralgia and Restless leg syndrome
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Restless Leg Syndrome (RLS) or Post Herpetic Neuralgia (shingles)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR POST-HERPETIC NEURALGIA: A documented contraindication, intolerance, allergy, or failure of one month of gabapentin. FOR RESTLESS LEG SYNDROME:A documented contraindication, intolerance, allergy, or failure of one month of pramipexole, or ropinirole.
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: February 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# HP Acthar

---

## Products Affected

- HP ACTHAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/acthar.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/acthar.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Humira

## Products Affected

- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.2ML, 20 MG/0.4ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	2 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira

## Products Affected

- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Humira Pediatric Crohns Start

## Products Affected

- HUMIRA PEDIATRIC CROHNS START  
SUBCUTANEOUS PREFILLED SYRINGE  
KIT 40 MG/0.8ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Humira Pen

## Products Affected

- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Humira Pen-Crohns Starter

## Products Affected

- HUMIRA PEN-CROHNS STARTER  
SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pen-Psoriasis Starter

---

## Products Affected

- HUMIRA PEN-PSORIASIS STARTER  
SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# HumuLIN 70/30

---

## Products Affected

- HUMULIN 70/30

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HumuLIN N

---

## Products Affected

- HUMULIN N

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Hyalgan

## Products Affected

- HYALGAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hycamtin

---

## Products Affected

- HYCAMTIN ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Hydrocodone-Acetaminophen

## Products Affected

- *hydrocodone-acetaminophen oral solution*  
2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Hydrocodone-Acetaminophen

## Products Affected

- *hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Hydrocodone-Ibuprofen

## Products Affected

- *hydrocodone-ibuprofen oral tablet 10-200 mg*
- *hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# HYDRomorphone HCl

## Products Affected

- *hydromorphone hcl oral liquid*
- *hydromorphone hcl rectal*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# HYDRomorphone HCl

## Products Affected

- *hydromorphone hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# HYDRORmorphone HCl ER

## Products Affected

- *hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 12 mg, 32 mg, 8 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# HYDRomorphone HCl ER

## Products Affected

- *hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 16 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Hymovis

## Products Affected

- HYMOVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hyqvia

---

## Products Affected

- HYQVIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Hysingla ER

## Products Affected

- HYSINGLA ER

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Ibandronate Sodium

---

## Products Affected

- *ibandronate sodium intravenous solution 3 mg/3ml*

<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibandronate Sodium

---

## Products Affected

- *ibandronate sodium oral*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate 70mg
<b>QL Criteria</b>	1 tablet Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ibrance

## Products Affected

- IBRANCE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	21 EA Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibudone

## Products Affected

- *ibudone oral tablet 5-200 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Iclusig

## Products Affected

- ICLUSIG ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Iclusig

## Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Idelvion

## Products Affected

- IDELVION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# IDHIFA

## Products Affected

- IDHIFA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/I/dhifa.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/I/dhifa.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ilaris

---

## Products Affected

- ILARIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Ilaris (150mg Delivered)

### Products Affected

- ILARIS (150MG DELIVERED)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imatinib Mesylate

## Products Affected

- *imatinib mesylate oral tablet 100 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Imatinib Mesylate

## Products Affected

- *imatinib mesylate oral tablet 400 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imbruvica

## Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Imiquimod

---

## Products Affected

- *imiquimod external*

<b>QL Criteria</b>	48 packets Per 365 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex

---

## Products Affected

- IMITREX NASAL SOLUTION 20  
MG/ACT

<b>QL Criteria</b>	0.27 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Imitrex

---

## Products Affected

- IMITREX NASAL SOLUTION 5 MG/ACT

<b>QL Criteria</b>	0.21 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex STATdose System

---

## Products Affected

- IMITREX STATDOSE SYSTEM  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR 6 MG/0.5ML

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Impavido

## Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Covered Uses	Leishmaniasis
Exclusion Criteria	Known or suspected pregnancy
Required Medical Information	A documented diagnosis of any of the following leishmaniasis infections: Visceral leishmaniasis due to <i>Leishmania donovani</i> , Cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> , <i>Leishmania guyanensis</i> , and <i>Leishmania panamensis</i> , or Mucosal leishmaniasis due to <i>Leishmania braziliensis</i>
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	28 days
Other Criteria	
QL Criteria	84 capsules Per 28 days
Notes/References	
Revision Date	Prior Authorization: August 16, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Increlex

---

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Increlex.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Increlex.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Inderal XL

---

## Products Affected

- INDERAL XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 80 MG

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Indomethacin

---

## Products Affected

- *indomethacin oral*

<b>QL Criteria</b>	3 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Inflectra

## Products Affected

- INFLECTRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Inflectra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Inflectra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Inflectra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Inflectra.html</a>
Notes/References	
Revision Date	Prior Authorization: December 13, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ingrezza

## Products Affected

- INGREZZA ORAL CAPSULE 40 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Ingrezza.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Ingrezza.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: June 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ingrezza

## Products Affected

- INGREZZA ORAL CAPSULE 80 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Ingrezza.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Ingrezza.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: June 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Inlyta

---

## Products Affected

- INLYTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# InnoPran XL

---

## Products Affected

- INNOPRAN XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 120 MG

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# InnoPran XL

---

## Products Affected

- INNOPRAN XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 80 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 100 MG, 25 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 200 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intrarosa

---

## Products Affected

- INTRAROSA

<b>QL Criteria</b>	1 insert Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intron A

---

## Products Affected

- INTRON A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Invokamet

---

## Products Affected

- INVOKAMET

<b>QL Criteria</b>	2 tablets Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokamet XR

---

## Products Affected

- INVOKAMET XR

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Invokana

---

## Products Affected

- INVOKANA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ipratropium Bromide

---

## Products Affected

- *ipratropium bromide nasal*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Iprivask

---

## Products Affected

- IPRIVASK

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Irbesartan

---

## Products Affected

- *irbesartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Irbesartan-Hydrochlorothiazide

---

## Products Affected

- *irbesartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iressa

## Products Affected

- IRESSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Iressa.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Iressa.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET CHEWABLE

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Isentress HD

---

## Products Affected

- ISENTRESS HD

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Itraconazole

---

## Products Affected

- *itraconazole oral*

<b>QL Criteria</b>	4 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Ixinity

---

## Products Affected

- IXINITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jadenu

---

## Products Affected

- JADENU

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Jadenu Sprinkle

---

## Products Affected

- JADENU SPRINKLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jakafi

---

## Products Affected

- JAKAFI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Janumet

---

## Products Affected

- JANUMET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 100-  
1000 MG, 50-500 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 50-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Januvia

---

## Products Affected

- JANUVIA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Jardiance

---

## Products Affected

- JARDIANCE

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto

---

## Products Affected

- JENTADUETO

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Jentaduetto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 2.5-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 5-1000  
MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Jetrea

## Products Affected

- JETREA INTRAVITREAL SOLUTION  
0.375 MG/0.3ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/ophthalmic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/ophthalmic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jevtana

## Products Affected

- JEVTANA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/jevtana.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/jevtana.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Jinteli

---

## Products Affected

- *jinteli*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jolivette

---

## Products Affected

- *jolivette*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Jublia

## Products Affected

- JUBLIA

PA Criteria	Criteria Details
Covered Uses	Onychomycosis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Failure of an adequate trial of one systemic oral alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), OR If member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one systemic (oral) alternative such as terbinafine, itraconazole, or griseofulvin
Notes/References	Annual Review: 07/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Juxtapid

## Products Affected

- JUXTAPID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kadian

## Products Affected

- KADIAN ORAL CAPSULE EXTENDED  
RELEASE 24 HOUR 200 MG, 40 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Kalbitor

## Products Affected

- KALBITOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kalydeco

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalydeco

---

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Kanuma

---

## Products Affected

- KANUMA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kazano

---

## Products Affected

- KAZANO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentaduetto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kepivance

---

## Products Affected

- KEPIVANCE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kerydin

## Products Affected

- KERYDIN

PA Criteria	Criteria Details
Covered Uses	Onychomycosis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Failure of an adequate trial of one systemic oral alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), OR If member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one systemic (oral) alternative such as terbinafine, itraconazole, or griseofulvin
Notes/References	Annual Review: 07/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ketoconazole

---

## Products Affected

- *ketoconazole oral*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ketorolac Tromethamine

---

## Products Affected

- *ketorolac tromethamine ophthalmic*

<b>QL Criteria</b>	1 vial Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ketorolac Tromethamine

---

## Products Affected

- *ketorolac tromethamine oral*

<b>QL Criteria</b>	20 tablets Per 28 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Keveyis

## Products Affected

- KEVEYIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/carb onic_anhydrase_inhibitor.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/carb onic_anhydrase_inhibitor.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kevzara

## Products Affected

- KEVZARA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Kevzara.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Kevzara.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Kevzara.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Kevzara.html</a>
QL Criteria	2 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: June 23, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Khedezla

## Products Affected

- KHEDEZLA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 TB24 Per 1 DAYS
Notes/References	Annual Review: 05/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kineret

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html</a>
QL Criteria	1 syringe Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Kisqali 200 Dose

---

### Products Affected

- KISQALI 200 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Kisqali 400 Dose

### Products Affected

- KISQALI 400 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Kisqali 600 Dose

### Products Affected

- KISQALI 600 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



## Kisqali Femara 200 Dose

### Products Affected

- KISQALI FEMARA 200 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Kisqali Femara 400 Dose

---

### Products Affected

- KISQALI FEMARA 400 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Kisqali Femara 600 Dose

---

### Products Affected

- KISQALI FEMARA 600 DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Kisqali.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 05, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kogenate FS

## Products Affected

- KOGENATE FS INTRAVENOUS KIT  
3000 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kogenate FS Bio-Set

---

## Products Affected

- KOGENATE FS BIO-SET INTRAVENOUS  
KIT 3000 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 2.5-1000  
MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentadueto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 5-1000  
MG, 5-500 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentadueto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Korlym

---

## Products Affected

- KORLYM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/anti-diabetic-agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/anti-diabetic-agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Kroger Blood Glucose

## Products Affected

- KROGER BLOOD GLUCOSE KIT  
W/DEVICE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kroger Premium Blood Glucose

## Products Affected

- KROGER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Krystexxa

## Products Affected

- KRYSTEXXA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gout.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gout.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gout.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gout.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kuvan

---

## Products Affected

- KUVAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Kynamro

## Products Affected

- KYNAMRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
QL Criteria	4 SOLN Per 30 DAYs
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 100 mg, 200 mg*

<b>QL Criteria</b>	2 TAB Per 1 DAILY
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	6 TAB Per 1 DAILY
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 50 mg*

<b>QL Criteria</b>	3 TAB Per 1 DAILY
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 100 mg, 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 200 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
24 hour 250 mg, 300 mg

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 50 mg*

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lantus

---

## Products Affected

- LANTUS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Levemir and Tresiba
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lantus SoloStar

---

## Products Affected

- LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Levemir and Tresiba
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Larin Fe 1.5/30

---

## Products Affected

- LARIN FE 1.5/30

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 60 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 80 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lazanda

---

## Products Affected

- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>ST Criteria</b>	<p>A documented contraindication, intolerance, allergy, or failure of one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)</p>
<b>QL Criteria</b>	<p>15 bottles Per 1 fill</p>
<b>Notes/References</b>	<p>Annual Review: 06/2017</p>
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lazanda

---

## Products Affected

- LAZANDA NASAL SOLUTION 300 MCG/ACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>ST Criteria</b>	<p>A documented contraindication, intolerance, allergy, or failure of one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)</p>
<b>QL Criteria</b>	<p>4 bottles Per 30 days</p>
<b>Notes/References</b>	<p>Annual Review: 06/2017</p>
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Leflunomide

---

## Products Affected

- *leflunomide oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lemtrada

## Products Affected

- LEMTRADA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	6 ML Per 365 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Lenvima 10 MG Daily Dose

---

## Products Affected

- LENVIMA 10 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lenvima 14 MG Daily Dose

---

## Products Affected

- LENVIMA 14 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lenvima 18 MG Daily Dose

---

## Products Affected

- LENVIMA 18 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 20 MG Daily Dose

---

## Products Affected

- LENVIMA 20 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lenvima 24 MG Daily Dose

---

## Products Affected

- LENVIMA 24 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lenvima 8 MG Daily Dose

---

## Products Affected

- LENVIMA 8 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Letairis

---

## Products Affected

- LETAIRIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leukine

## Products Affected

- LEUKINE INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Leuprolide Acetate

## Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release*  
*24 hour 500 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release*  
*24 hour 750 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levorphanol Tartrate

## Products Affected

- *levorphanol tartrate oral*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Levulan Kerastick

---

## Products Affected

- LEVULAN KERASTICK

<b>QL Criteria</b>	1 stick Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lialda

---

## Products Affected

- LIALDA

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine

## Products Affected

- *lidocaine external ointment*

PA Criteria	Criteria Details
<b>Covered Uses</b>	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
<b>Exclusion Criteria</b>	Documentation of any of the following: Planned area of application includes non-intact skin, sensitivity to amide-type local anesthetics or any other component of the product, planned use on large surface area of the body as this can lead to increased toxicity, planned area of application includes severely traumatized skin (e.g., mucosal or skin abrasion, eczema, burns), the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), or if the product will be compounded with other products that would alter the total dose/dosage form being administered
<b>Required Medical Information</b>	A documented need for temporary anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>*Topical lidocaine ointment is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Approval can made up to an additional 50gms per 30 days. Higher additional quantities are not approvable *FOR ADULTS: A single application should not exceed 5 g of Lidocaine Ointment 5%, containing 250 mg of lidocaine base (equivalent chemically to approximately 300 mg of lidocaine hydrochloride). This is roughly equivalent to squeezing a six (6) inch length of ointment from the tube. In a 70 kg adult this dose equals 3.6 mg/kg (1.6 mg/lb) lidocaine base. No more than one-half tube, approximately 17-20 g of ointment or 850-1000 mg lidocaine base, should be administered in any one day. FOR CHILDREN: For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg when calculated according to Clark's rule. In any case, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight ***Lidocaine toxicity resulting from transcutaneous absorption is theoretically possible. Signs and symptoms of systemic lidocaine toxicity include CNS excitation and/or depression, nervousness, confusion, dizziness, tinnitus, blurred or double vision, vomiting, twitching, tremors, seizures, unconsciousness, respiratory depression, bradycardia, hypotension, and cardiopulmonary arrest. If there is suspicion of lidocaine-related systemic toxicity, check lidocaine blood concentrations</p>
<b>QL Criteria</b>	50 GM Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Lidocaine

## Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Covered Uses	Neuropathic pain (i.e. post-herpetic neuralgia)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of neuropathic pain (i.e. post-herpetic neuralgia)
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of generic gabapentin or Lyrica
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: April 03, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lidocaine PAK

---

## Products Affected

- *lidocaine pak*

<b>QL Criteria</b>	50 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine-Prilocaine

## Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
<b>Covered Uses</b>	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Exclusion Criteria</b>	Documentation of any of the following: Planned area of application includes non-intact skin, Sensitivity to amide-type local anesthetics or any other component of the product, Planned use on large surface area of the body or for a period of time over 3 hours as this can lead to increased toxicity, the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), Use in situations where the drug may migrate into the middle ear, beyond the tympanic membrane, History of methemoglobinemia, or if the product will be compounded with other products that would alter the total dose/dosage form being administered
<b>Required Medical Information</b>	A documented need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	*Topical lidocaine/prilocaine cream is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Up to an additional 30 grams per 30 days. Higher additional quantities are not approvable.
<b>QL Criteria</b>	30 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine-Tetracaine

---

## Products Affected

- *lidocaine-tetracaine*

<b>QL Criteria</b>	30 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Linezolid

---

## Products Affected

- *linezolid oral suspension reconstituted*

<b>QL Criteria</b>	150 ml Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linezolid

---

## Products Affected

- *linezolid oral tablet*

<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Linzess

---

## Products Affected

- LINZESS

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linzess

---

## Products Affected

- LINZESS

<b>QL Criteria</b>	1 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lipofen

---

## Products Affected

- LIPOFEN

<b>QL Criteria</b>	1 CAPS Per 1 DAY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Livalo

---

## Products Affected

- LIVALO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two generic statin medications: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lonsurf

## Products Affected

- LONSURF ORAL TABLET 15-6.14 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	100 tablets Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lonsurf

## Products Affected

- LONSURF ORAL TABLET 20-8.19 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	80 tablets Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lorcet

## Products Affected

- LORCET

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Lorcet HD

## Products Affected

- LORCET HD

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Lorcet Plus

## Products Affected

- LORCET PLUS ORAL TABLET 7.5-325 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Losartan Potassium

---

## Products Affected

- *losartan potassium oral tablet 25 mg, 50 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lovastatin

---

## Products Affected

- *lovastatin*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lucentis

## Products Affected

- LUCENTIS INTRAVITREAL SOLUTION  
 PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lumigan

## Products Affected

- LUMIGAN OPHTHALMIC SOLUTION  
0.01 %

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: December 07, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Lumizyme

## Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupaneta Pack

---

## Products Affected

- LUPANETA PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Lupron Depot (1-Month)

---

## Products Affected

- LUPRON DEPOT (1-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Lupron Depot (3-Month)

---

### Products Affected

- LUPRON DEPOT (3-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Lupron Depot (4-Month)

### Products Affected

- LUPRON DEPOT (4-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupron Depot (6-Month)

---

## Products Affected

- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

## Lupron Depot-Ped (1-Month)

---

### Products Affected

- LUPRON DEPOT-PED (1-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Lupron Depot-Ped (3-Month)

---

### Products Affected

- LUPRON DEPOT-PED (3-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Lynparza

## Products Affected

- LYNPARZA ORAL CAPSULE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lynparza

## Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Lyza

---

## Products Affected

- LYZA

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Macugen

---

## Products Affected

- MACUGEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Makena

## Products Affected

- MAKENA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/hydroxyprogesterone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/hydroxyprogesterone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maprotiline HCl

---

## Products Affected

- *maprotiline hcl*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hour 180 mg, 300 mg, 360 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Mavyret

## Products Affected

- MAVYRET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	3 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Meijer Blood Glucose

## Products Affected

- MEIJER BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Meijer Premium Blood Glucose

## Products Affected

- MEIJER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Mekinist

## Products Affected

- MEKINIST ORAL TABLET 0.5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Mekinist

## Products Affected

- MEKINIST ORAL TABLET 2 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Memantine HCl

---

## Products Affected

- *memantine hcl oral tablet 10 mg, 5 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menopur

## Products Affected

- MENOPUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menostar

---

## Products Affected

- MENOSTAR

<b>QL Criteria</b>	1 box (4 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Meperidine HCl

## Products Affected

- *meperidine hcl oral solution*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Meperidine HCl

## Products Affected

- *meperidine hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Mephyton

---

## Products Affected

- MEPHYTON

<b>QL Criteria</b>	25 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mesalamine

---

## Products Affected

- *mesalamine oral tablet delayed release 1.2*

*gm*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

# Mesalamine

---

## Products Affected

- *mesalamine oral tablet delayed release 800 mg*

<b>QL Criteria</b>	6 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate ER

---

## Products Affected

- METADATE ER ORAL TABLET  
EXTENDED RELEASE 20 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Metaxalone

---

## Products Affected

- *metaxalone oral tablet 400 mg*

<b>QL Criteria</b>	56 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

---

## Products Affected

- *methadone hcl oral concentrate*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methadone HCl

---

## Products Affected

- *methadone hcl oral solution 10 mg/5ml*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>QL Criteria</b>	30 mg Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methadone HCl

---

## Products Affected

- *methadone hcl oral solution 5 mg/5ml*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	



PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>QL Criteria</b>	60 mg Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methadone HCl

---

## Products Affected

- *methadone hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methadone HCl Intensol

---

## Products Affected

- *methadone hcl intensol*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Methamphetamine HCl

## Products Affected

- *methamphetamine hcl*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methergine

---

## Products Affected

- METHERGINE ORAL

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 10 mg/5ml*

<b>QL Criteria</b>	30 milliliters Per 1 day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 5 mg/5ml*

<b>QL Criteria</b>	60 milliliters Per 1 day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral tablet*

<b>QL Criteria</b>	6 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 10 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 18 mg, 27 mg, 54 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 20 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 36 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 54 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hour 36 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (CD)

---

## Products Affected

- *methylphenidate hcl er (cd)*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl ER (LA)

---

## Products Affected

- *methylphenidate hcl er (la) oral capsule extended release 24 hour 20 mg*
- *methylphenidate hcl er (la) oral capsule extended release 24 hour 40 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (LA)

---

## Products Affected

- *methylphenidate hcl er (la) oral capsule  
extended release 24 hour 30 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	Annual Review: 09/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Methylphenidate HCl ER (LA)

---

## Products Affected

- *methylphenidate hcl er (la) oral capsule  
extended release 24 hour 60 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 100 mg, 50 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 200 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Miacalcin

## Products Affected

- MIACALCIN INJECTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mimvey

---

## Products Affected

- *mimvey*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Mircera

## Products Affected

- MIRCERA INJECTION SOLUTION  
 PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirtazapine

---

## Products Affected

- *mirtazapine oral*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mitigare

---

## Products Affected

- MITIGARE

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Modafinil

## Products Affected

- *modafinil oral tablet 100 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with modafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Modafinil

## Products Affected

- *modafinil oral tablet 200 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with modafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Mononine

## Products Affected

- MONONINE INTRAVENOUS SOLUTION  
RECONSTITUTED 1000 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Monovisc

---

## Products Affected

- MONOVISC

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 pack Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# MorphaBond ER

## Products Affected

- MORPHABOND ER

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate

## Products Affected

- *morphine sulfate oral solution*
- *morphine sulfate rectal*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate

## Products Affected

- *morphine sulfate oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate (Concentrate)

## Products Affected

- *morphine sulfate (concentrate) oral solution*  
100 mg/5ml, 20 mg/ml

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral capsule extended release 24 hour*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral tablet extended release 100 mg, 30 mg, 60 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral tablet extended release 15 mg, 200 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Morphine Sulfate ER Beads

## Products Affected

- *morphine sulfate er beads*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Mozobil

---

## Products Affected

- MOZOBIL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Mozobil.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Mozobil.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Multaq

---

## Products Affected

- MULTAQ

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mupirocin

---

## Products Affected

- *mupirocin external*

<b>QL Criteria</b>	60 gram Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mupirocin Calcium

---

## Products Affected

- *mupirocin calcium*

<b>QL Criteria</b>	60 gram Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myalept

## Products Affected

- MYALEPT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/myalept.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/myalept.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	0.5 VIAL Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Mydayis

## Products Affected

- MYDAYIS

PA Criteria	Criteria Details
Covered Uses	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
Age Restrictions	13 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: July 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Myobloc

## Products Affected

- MYOBLOC INTRAMUSCULAR  
SOLUTION 2500 UNIT/0.5ML, 5000  
UNIT/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Myorisan

---

## Products Affected

- *myorisan oral capsule 10 mg, 20 mg, 40 mg*
- MYORISAN ORAL CAPSULE 30 MG

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myrbetriq

---

## Products Affected

- MYRBETRIQ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one preferred generic (i.e. trospium, trospium ER, tolterodine, tolterodine ER, oxybutynin)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Mytesi

## Products Affected

- MYTESI

PA Criteria	Criteria Details
Covered Uses	Non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy
Exclusion Criteria	
Required Medical Information	Covered for adult members who have a documented diagnosis of noninfectious diarrhea associated with HIV/AIDS infection that has lasted at least for one month and who are currently stable on anti-retroviral therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of at least one anti-motility agent (loperamide, diphenoxylate/atropine, bismuth subsalicylate)
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: September 12, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Myzilra

---

## Products Affected

- *myzilra*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Naglazyme

---

## Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda XR

---

## Products Affected

- NAMENDA XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Namzarin

---

## Products Affected

- NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namzarin

---

## Products Affected

- NAMZARIC ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 14-10  
MG, 28-10 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Naratriptan HCl

---

## Products Affected

- *naratriptan hcl*

<b>QL Criteria</b>	9 tablets Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nasonex

---

## Products Affected

- NASONEX

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Natpara

---

## Products Affected

- NATPARA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ctg Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nerlynx

---

## Products Affected

- NERLYNX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Nerlynx.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Nerlynx.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 02, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nesina

---

## Products Affected

- NESINA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentadueto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neulasta

---

## Products Affected

- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Neupogen

## Products Affected

- NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML
- NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neupro

---

## Products Affected

- NEUPRO

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Neutek 2Tek Glucose/Pressure

---

## Products Affected

- NEUTEK 2TEK GLUCOSE/PRESSURE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release 24 hour 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release 24 hour 400 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexAVAR

## Products Affected

- NEXAVAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NexIUM

---

## Products Affected

- NEXIUM ORAL PACKET

<b>QL Criteria</b>	1 pack Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexIUM 24HR

---

## Products Affected

- NEXIUM 24HR

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nexplanon

---

## Products Affected

- NEXPLANON

<b>QL Criteria</b>	1 implant Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Next Choice One Dose

---

### Products Affected

- *next choice one dose*

<b>QL Criteria</b>	1 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nicoderm CQ

---

## Products Affected

- NICODERM CQ

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicorelief

---

## Products Affected

- *nicorelief mouth/throat gum*

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nicorette

---

## Products Affected

- NICORETTE MOUTH/THROAT GUM

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine

---

## Products Affected

- *nicotine transdermal patch 24 hour*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine Step 1

---

## Products Affected

- *nicotine step 1*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Nicotine Step 2

---

### Products Affected

- *nicotine step 2*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine Step 3

---

## Products Affected

- *nicotine step 3*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotrol

---

## Products Affected

- NICOTROL

<b>QL Criteria</b>	3 boxes-504 ctrtg Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nicotrol NS

---

## Products Affected

- NICOTROL NS

<b>QL Criteria</b>	4 bottles Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifediac CC

---

## Products Affected

- *nifediac cc oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Nifedical XL

---

## Products Affected

- *nifedical xl oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release 24 hour 30 mg, 90 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hour 30 mg, 90 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nikki

---

## Products Affected

- NIKKI

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ninlaro

## Products Affected

- NINLARO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	3 capsules Per 28 days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 25.5 mg, 34 mg, 40 mg, 8.5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nitroglycerin

---

## Products Affected

- *nitroglycerin translingual solution*

<b>QL Criteria</b>	12 grams Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nitrostat

---

## Products Affected

- NITROSTAT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of nitroglycerin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nityr

---

## Products Affected

- NITYR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nora-BE

---

## Products Affected

- *nora-be*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norditropin FlexPro

## Products Affected

- NORDITROPIN FLEXPRO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Norlyroc

---

## Products Affected

- NORLYROC

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Northera

## Products Affected

- NORTHERA ORAL CAPSULE 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Northera.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Northera.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Northera

## Products Affected

- NORTHERA ORAL CAPSULE 200 MG,  
300 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Northera.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Northera.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Novarel

## Products Affected

- *novarel intramuscular solution reconstituted*  
*10000 unit*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NovoLIN 70/30

---

## Products Affected

- NOVOLIN 70/30

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLIN 70/30 ReliOn

---

## Products Affected

- NOVOLIN 70/30 RELION

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NovoLIN N

---

## Products Affected

- NOVOLIN N

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLIN N ReliOn

---

## Products Affected

- NOVOLIN N RELION

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NovoLIN R

---

## Products Affected

- NOVOLIN R

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLIN R ReliOn

---

## Products Affected

- NOVOLIN R RELION

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# NovoLOG

---

## Products Affected

- NOVOLOG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG FlexPen

---

## Products Affected

- NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NovoLOG Mix 70/30

---

## Products Affected

- NOVOLOG MIX 70/30

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG Mix 70/30 FlexPen

---

## Products Affected

- NOVOLOG MIX 70/30 FLEXPEN  
SUBCUTANEOUS SUSPENSION PEN-  
INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# NovoLOG PenFill

---

## Products Affected

- NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of one preferred alternative insulin, Humulin or Humalog
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Noxafil

---

## Products Affected

- NOXAFIL ORAL TABLET DELAYED RELEASE

<b>QL Criteria</b>	93 TBEC Per 30 DAYSS
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nucala

## Products Affected

- NUCALA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Interleukin%20Antagonist.html">http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Interleukin Antagonist.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 injection Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucynta

## Products Affected

- NUCYNTA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: morphine, oxycodone, hydromorphone
<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Nucynta ER

## Products Affected

- NUCYNTA ER

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	FOR A DIAGNOSIS OF PAIN: A documented contraindication, intolerance, allergy, or failure of two of Butrans, Hysingla ER, or Oxycontin. FOR A DIAGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY: A documented contraindication, intolerance, allergy, or failure of Cymbalta and Lyrica.
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuedexta

---

## Products Affected

- NUEDEXTA

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nuplazid

## Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Nuplazid.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/Nuplazid.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nutropin AQ NuSpin 10

---

## Products Affected

- NUTROPIN AQ NUSPIN 10

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

## Nutropin AQ NuSpin 20

### Products Affected

- NUTROPIN AQ NUSPIN 20

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nutropin AQ NuSpin 5

## Products Affected

- NUTROPIN AQ NUSPIN 5

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# NuvaRing

---

## Products Affected

- NUVARING

<b>QL Criteria</b>	1 ring Per 28 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuvigil

## Products Affected

- NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nuvigil

## Products Affected

- NUVIGIL ORAL TABLET 50 MG

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Nymalize

---

## Products Affected

- NYMALIZE ORAL SOLUTION 60  
MG/20ML

<b>QL Criteria</b>	135.2 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ocaliva

## Products Affected

- OCALIVA ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Primary_Biliary_Cholagitis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Primary_Biliary_Cholagitis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Primary_Biliary_Cholagitis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Primary_Biliary_Cholagitis.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Octagam

## Products Affected

- OCTAGAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Octreotide Acetate

---

## Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Odefsey

---

## Products Affected

- ODEFSEY

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Odomzo

## Products Affected

- ODOMZO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Odomzo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Odomzo.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ofev

## Products Affected

- OFEV

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg*
- *olanzapine oral tablet dispersible*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 2.5 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine-FLUoxetine HCl

---

## Products Affected

- *olanzapine-fluoxetine hcl*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olmesartan Medoxomil

---

## Products Affected

- *olmesartan medoxomil oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Olmesartan Medoxomil-HCTZ

---

## Products Affected

- *olmesartan medoxomil-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olmesartan-Amlodipine-HCTZ

---

## Products Affected

- *olmesartan-amlodipine-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Olysio

## Products Affected

- OLYSIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 CAPS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omega-3-acid Ethyl Esters

---

## Products Affected

- *omega-3-acid ethyl esters*

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Omnaris

---

## Products Affected

- OMNARIS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of two of the following: flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omnitrope

---

## Products Affected

- OMNITROPE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OneTouch Ultra 2

---

## Products Affected

- ONETOUCH ULTRA 2

<b>QL Criteria</b>	1 KIT Per 365 DAYSS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Ultra Blue

---

## Products Affected

- ONETOUCH ULTRA BLUE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# OneTouch Ultra Mini

---

## Products Affected

- ONETOUCH ULTRA MINI

<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Verio

---

## Products Affected

- ONETOUCH VERIO IN VITRO STRIP

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# OneTouch Verio IQ System

---

## Products Affected

- ONETOUCH VERIO IQ SYSTEM

<b>QL Criteria</b>	1 KIT Per 365 DAYSS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onfi

---

## Products Affected

- ONFI ORAL TABLET 10 MG, 20 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Onglyza

---

## Products Affected

- ONGLYZA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentaducto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onzetra Xsail

---

## Products Affected

- ONZETRA XSAIL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of sumatriptan nasal spray
<b>QL Criteria</b>	1 kit Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Opana ER

## Products Affected

- OPANA ER ORAL TABLET ER 12 HOUR  
ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Opana ER

## Products Affected

- OPANA ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	4 tablets Per 1 DAYS
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Opsumit

## Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oravig

---

## Products Affected

- ORAVIG

<b>QL Criteria</b>	14 tablets Per 1 fill
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Orencia

## Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia

## Products Affected

- ORENCIA SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 125 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Orencia

## Products Affected

- ORENCIA SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 50 MG/0.4ML, 87.5  
 MG/0.7ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Orencia ClickJect

## Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Orenitram

## Products Affected

- ORENITRAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orfadin

## Products Affected

- ORFADIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Orkambi

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orkambi

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# OrthoVisc

## Products Affected

- ORTHOVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oseltamivir Phosphate

---

## Products Affected

- *oseltamivir phosphate oral capsule*

<b>QL Criteria</b>	20 capsules Per 365 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Oseni

---

## Products Affected

- OSENI

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentaduetto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Osphena

---

## Products Affected

- OSPHENA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Otezla

## Products Affected

- OTEZLA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
QL Criteria	2 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Otezla

## Products Affected

- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Otrexup

---

## Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION  
AUTO-INJECTOR 10 MG/0.4ML, 12.5  
MG/0.4ML, 15 MG/0.4ML, 17.5  
MG/0.4ML, 20 MG/0.4ML, 22.5  
MG/0.4ML, 25 MG/0.4ML

<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otrexup_Rasuvo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otrexup_Rasuvo.html</a>
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ovidrel

---

## Products Affected

- OVIDREL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Oxaydo

## Products Affected

- OXAYDO

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 150 MG,  
300 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 600 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Oxybutynin Chloride

---

## Products Affected

- *oxybutynin chloride oral tablet*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxybutynin Chloride ER

---

## Products Affected

- *oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Oxybutynin Chloride ER

---

## Products Affected

- *oxybutynin chloride er oral tablet extended release 24 hour 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral capsule*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral concentrate 100 mg/5ml*
- *oxycodone hcl oral solution*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyCODONE HCl ER

## Products Affected

- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 20 mg, 40 mg, 80 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyCODONE HCl ER

## Products Affected

- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 15 mg, 30 mg, 60 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxycodone-Acetaminophen

## Products Affected

- *oxycodone-acetaminophen oral solution*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxycodone-Acetaminophen

## Products Affected

- *oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxycodone-Aspirin

## Products Affected

- *oxycodone-aspirin oral tablet 4.8355-325 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxycodone-Ibuprofen

## Products Affected

- *oxycodone-ibuprofen*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyCONTIN

## Products Affected

- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Oxymorphone HCl

## Products Affected

- *oxymorphone hcl*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# OxyMORphone HCl ER

## Products Affected

- *oxymorphone hcl er*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
*24 hour 1.5 mg, 3 mg, 6 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
24 hour 9 mg

<b>QL Criteria</b>	1 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pancreaze

---

## Products Affected

- PANCREAZE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Creon and Zenpep
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Paricalcitol

---

## Products Affected

- *paricalcitol oral*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 10 mg, 20 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 30 mg, 40 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl ER

---

## Products Affected

- *paroxetine hcl er oral tablet extended release*  
24 hour 12.5 mg, 37.5 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# PARoxetine HCl ER

---

## Products Affected

- *paroxetine hcl er oral tablet extended release*  
24 hour 25 mg

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine Mesylate

---

## Products Affected

- *paroxetine mesylate*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Paxil

---

## Products Affected

- PAXIL ORAL SUSPENSION

<b>QL Criteria</b>	30 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PEG 3350/Electrolytes

---

## Products Affected

- *peg 3350/electrolytes*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# PEG-3350/Electrolytes

---

## Products Affected

- *peg-3350/electrolytes*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pegasys

## Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Pegasys ProClick

---

## Products Affected

- PEGASYS PROCLICK

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PegIntron

---

## Products Affected

- PEGINTRON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE EXTENDED  
RELEASE 250 MG

<b>QL Criteria</b>	16 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE EXTENDED  
RELEASE 500 MG

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pentazocine-Naloxone HCl

## Products Affected

- *pentazocine-naloxone hcl*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Perforomist

## Products Affected

- PERFOROMIST

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Serevent (Step Therapy will not apply to members who have a documented inability to use an inhaler)
QL Criteria	4 milliliters Per 1 day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Pertzye

---

## Products Affected

- PERTZYE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Creon and Zenpep
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Phenoxybenzamine HCl

## Products Affected

- *phenoxybenzamine hcl oral*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Picato

---

## Products Affected

- PICATO EXTERNAL GEL 0.015 %

<b>QL Criteria</b>	3 unit dose tubes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Picato

---

## Products Affected

- PICATO EXTERNAL GEL 0.05 %

<b>QL Criteria</b>	2 unit dose tubes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl

---

## Products Affected

- *pioglitazone hcl*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pioglitazone HCl-Glimepiride

---

## Products Affected

- *pioglitazone hcl-glimepiride*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl-Metformin HCl

---

## Products Affected

- *pioglitazone hcl-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Plegridy

## Products Affected

- PLEGRIDY SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	28 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy

## Products Affected

- PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Plegridy Starter Pack

## Products Affected

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 kit Per 365 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Plegridy Starter Pack

---

## Products Affected

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Plexion Cleansing Cloth

---

## Products Affected

- PLEXION CLEANSING CLOTH  
EXTERNAL PAD

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of generic Retin-A
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pomalyst

## Products Affected

- POMALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pradaxa

---

## Products Affected

- PRADAXA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Eliquis and Xarelto
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Praluent

---

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pramipexole Dihydrochloride ER

---

## Products Affected

- *pramipexole dihydrochloride er*

<b>QL Criteria</b>	1 TAB Per 1 DAILY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pramipexole Dihydrochloride ER

---

## Products Affected

- *pramipexole dihydrochloride er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Prasugrel HCl

## Products Affected

- *prasugrel hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acute coronary syndrome (ACS) managed with percutaneous coronary intervention which includes unstable angina or non-ST elevation myocardial infarction or ST elevation myocardial infarction (MI)
<b>Exclusion Criteria</b>	History of Stroke or transient ischemic attack (TIA)
<b>Required Medical Information</b>	Member has a documented diagnosis of acute coronary syndrome (ACS) and is managed by percutaneous coronary intervention (PCI), which includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST -elevation myocardial infarction (STEMI) managed with primary or delayed PCI and member has no prior history of stroke or transient ischemic attack (TIA)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 22, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pravastatin Sodium

---

## Products Affected

- *pravastatin sodium*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Precision PCx

---

## Products Affected

- PRECISION PCX

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision PCX Plus Test

---

## Products Affected

- PRECISION PCX PLUS TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Precision Point of Care Test

---

## Products Affected

- PRECISION POINT OF CARE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision QID Test

---

## Products Affected

- PRECISION QID TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Precision Sof-Tact Test

---

## Products Affected

- PRECISION SOF-TACT TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision Xtra Blood Glucose

---

## Products Affected

- PRECISION XTRA BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Prefest

---

## Products Affected

- PREFEST

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pregnyl

---

## Products Affected

- *pregnyl*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Premarin

---

## Products Affected

- PREMARIN ORAL

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Premphase

---

## Products Affected

- PREMPHASE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Prempro

---

## Products Affected

- PREMPRO

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prevacid SoluTab

## Products Affected

- PREVACID SOLUTAB

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required). In addition for approval the following criteria must also be met: Documentation of an inability to swallow tablets/capsules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 02/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Prezista

---

## Products Affected

- PREZISTA ORAL SUSPENSION

<b>QL Criteria</b>	2 bottles Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 800 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# PriLOSEC OTC

---

## Products Affected

- PRILOSEC OTC

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Primlev

## Products Affected

- PRIMLEV

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Pristiq

## Products Affected

- PRISTIQ

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 05/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Procrit

---

## Products Affected

- PROCRIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Procysbi

## Products Affected

- PROCYSBI ORAL CAPSULE DELAYED  
RELEASE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
QL Criteria	8 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procysbi

## Products Affected

- PROCYSBI ORAL CAPSULE DELAYED  
RELEASE 75 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
QL Criteria	25 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Prodigy AutoCode Blood Glucose

## Products Affected

- PRODIGY AUTOCODE BLOOD  
GLUCOSE KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Progesterone Micronized

---

## Products Affected

- *progesterone micronized oral*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Prolastin-C

---

## Products Affected

- PROLASTIN-C INTRAVENOUS  
SOLUTION RECONSTITUTED 1000 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1%20Antitrypsin%20Inhibitor%20Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prolia

## Products Affected

- PROLIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Promacta

---

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Promacta

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Propafenone HCl ER

---

## Products Affected

- *propafenone hcl er*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Proventil HFA

---

## Products Affected

- PROVENTIL HFA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Ventolin HFA and ProAir
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Prudoxin

---

## Products Affected

- PRUDOXIN

<b>QL Criteria</b>	45 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmicort Flexhaler

## Products Affected

- PULMICORT FLEXHALER

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Asmanex and QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: November 30, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Pulmozyme

---

## Products Affected

- PULMOZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ampules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Purixan

## Products Affected

- PURIXAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	3.5 ML Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Qbrelis

---

## Products Affected

- QBRELIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Hypertension, Heart Failure, Myocardial Infarction
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of hypertension (Approved only for ages 6 and older), Heart failure, or Myocardial Infarction AND must have a documented inability to swallow tablets/capsules
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qnasl

---

## Products Affected

- QNASL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Qnasl Childrens

---

## Products Affected

- QNASL CHILDRENS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qudexy XR

---

## Products Affected

- QUDEXY XR ORAL CAPSULE ER 24  
HOUR SPRINKLE 100 MG, 25 MG, 50 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Qudexy XR

---

## Products Affected

- QUDEXY XR ORAL CAPSULE ER 24 HOUR SPRINKLE 150 MG, 200 MG

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 100 mg, 50 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 25 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 300 mg, 400 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 300 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 400 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 50 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QuilliChew ER

## Products Affected

- QUILLICHEW ER ORAL TABLET  
CHEWABLE EXTENDED RELEASE 20  
MG, 40 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# QuilliChew ER

## Products Affected

- QUILLICHEW ER ORAL TABLET  
CHEWABLE EXTENDED RELEASE 30  
MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Quillivant XR

## Products Affected

- QUILLIVANT XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
QL Criteria	12 milliliters Per 1 day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: May 16, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# RA Nicotine

---

## Products Affected

- *ra nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RABEprazole Sodium

## Products Affected

- *rabeprazole sodium*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Ranexa

---

## Products Affected

- RANEXA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rasagiline Mesylate

---

## Products Affected

- *rasagiline mesylate oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rasuvo

---

## Products Affected

- RASUVO SUBCUTANEOUS SOLUTION  
AUTO-INJECTOR 10 MG/0.2ML, 12.5  
MG/0.25ML, 15 MG/0.3ML, 17.5  
MG/0.35ML, 20 MG/0.4ML, 22.5  
MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML,  
7.5 MG/0.15ML

<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Otr_exup_Rasuvo.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Otr_exup_Rasuvo.html</a>
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ravicti

## Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
QL Criteria	20 bottles Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rayaldee

## Products Affected

- RAYALDEE

PA Criteria	Criteria Details
Covered Uses	Treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease (CKD)
Exclusion Criteria	Patients with stage 5 CKD or in patients with end stage renal disease (ESRD) on dialysis
Required Medical Information	A documented diagnosis of secondary hyperparathyroidism and Stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D level is less than 30 ng/mL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of calcitriol
QL Criteria	1 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 13, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rayos

---

## Products Affected

- RAYOS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of prednisone
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebetol

---

## Products Affected

- REBETOL ORAL SOLUTION

<b>QL Criteria</b>	5 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif

## Products Affected

- REBIF SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Rebif Rebidose

## Products Affected

- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif Rebidoose Titration Pack

---

## Products Affected

- REBIF REBIDOSE TITRATION PACK  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rebif Titration Pack

---

## Products Affected

- REBIF TITRATION PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rectiv

---

## Products Affected

- RECTIV

<b>QL Criteria</b>	1 tube Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Regranex

## Products Affected

- REGRANEX

PA Criteria	Criteria Details
Covered Uses	Treatment of lower extremity diabetic neuropathic ulcers
Exclusion Criteria	Documentation that the patient has NONE of the following: Neoplasm(s) at the sites(s) of application, will not be using in pressure ulcers, venous stasis ulcers, or ischemic diabetic ulcers, exposed joints, tendons, ligaments, and bone (at application site), or will not be using in wounds that close by primary intention (such as suturing or gluing)
Required Medical Information	A documented diagnosis of diabetes with lower extremity neuropathic ulcers that extend into the subcutaneous tissue or beyond with adequate blood supply
Age Restrictions	16 years or older
Prescriber Restrictions	
Coverage Duration	20 weeks
Other Criteria	NOTE: The safety and efficacy of treatment beyond 20 weeks have not been determined.
QL Criteria	30 grams Per 30 Days
Notes/References	
Revision Date	Prior Authorization: April 03, 2017 Step Therapy: August 25, 2015 Quantity Limits: November 06, 2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Relenza Diskhaler

---

## Products Affected

- RELENZA DISKHALER

<b>QL Criteria</b>	40 disks Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Relistor

## Products Affected

- RELISTOR ORAL

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain and documented concomitant use of opioid therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 tablets Per 1 day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	0.6 ML Per 1 Day
<b>Notes/References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION 8 MG/0.4ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	0.4 ML Per 1 Day
<b>Notes/References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Relpax

---

## Products Affected

- RELPAX

<b>QL Criteria</b>	6 tablets Per 30 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Remicade

## Products Affected

- REMICADE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Remodulin

---

## Products Affected

- REMODULIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Repaglinide-Metformin HCl

---

## Products Affected

- *repaglinide-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha

## Products Affected

- REPATHA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 units Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Repatha Pushtronex System

---

## Products Affected

- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	1 syringe Per 30 days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Repatha SureClick

---

## Products Affected

- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 units Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Rescula

---

## Products Affected

- RESCULA

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: December 07, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Retin-A Micro Pump

## Products Affected

- RETIN-A MICRO PUMP EXTERNAL GEL  
0.08 %

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Revatio

---

## Products Affected

- REVATIO INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Revatio

## Products Affected

- REVATIO ORAL SUSPENSION  
RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Revlimid

---

## Products Affected

- REVLIMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rexulti

## Products Affected

- REXULTI

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Schizophrenia
Exclusion Criteria	
Required Medical Information	Documented diagnosis of major depressive disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR SCHIZOPHRENIA: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	1 tablet Per 1 Day
Notes/References	Annual Review: 08/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: October 27, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 150 MG
- REYATAZ ORAL CAPSULE 300 MG

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 200 MG

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rhofade

---

## Products Affected

- RHOFADE

<b>QL Criteria</b>	4 tubes Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Riluzole

## Products Affected

- *riluzole*

PA Criteria	Criteria Details
Covered Uses	amyotrophic lateral sclerosis (ALS)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 150 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate 70mg
<b>QL Criteria</b>	1 tablet Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 30 mg, 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 35 mg* *release*
- *risedronate sodium oral tablet delayed*

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *risperidone oral tablet dispersible 0.5 mg*
- *risperidone oral tablet dispersible 1 mg, 2 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 3 mg*
- *risperidone oral tablet dispersible 3 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 4 mg*
- *risperidone oral tablet dispersible 4 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 0.5 MG, 1 MG, 2 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 3 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 4 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rituxan

## Products Affected

- RITUXAN INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rivastigmine

---

## Products Affected

- *rivastigmine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rivastigmine Tartrate

---

## Products Affected

- *rivastigmine tartrate*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rixubis

---

## Products Affected

- RIXUBIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Rizatriptan Benzoate

---

## Products Affected

- *rizatriptan benzoate*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release*  
*24 hour 12 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release*  
24 hour 2 mg, 4 mg, 6 mg, 8 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rosuvastatin Calcium

---

## Products Affected

- *rosuvastatin calcium*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Rozerem

---

## Products Affected

- ROZEREM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of zolpidem, zaleplon, or eszopiclone
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 08/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rubraca

---

## Products Affected

- RUBRACA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Rubraca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Rubraca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: January 09, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ruconest

## Products Affected

- RUCONEST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rydapt

## Products Affected

- RYDAPT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Rydapt.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Rydapt.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: June 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Sabril

## Products Affected

- SABRIL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 packets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sabril

## Products Affected

- SABRIL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Saizen

## Products Affected

- SAIZEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Saizen Click.Easy

---

## Products Affected

- SAIZEN CLICK.EASY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Samsca

## Products Affected

- SAMSCA ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Samsca

## Products Affected

- SAMSCA ORAL TABLET 30 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Sancuso

---

## Products Affected

- SANCUSO

<b>QL Criteria</b>	1 patch Per 1 month
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SandoSTATIN LAR Depot

---

## Products Affected

- SANDOSTATIN LAR DEPOT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



# Santyl

---

## Products Affected

- SANTYL

<b>QL Criteria</b>	60 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Saphris

---

## Products Affected

- SAPHRIS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Savaysa

---

## Products Affected

- SAVAYSA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Eliquis and Xarelto
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Savella

---

## Products Affected

- SAVELLA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of duloxetine and Lyrica
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Savella Titration Pack

---

## Products Affected

- SAVELLA TITRATION PACK

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of duloxetine and Lyrica
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Seebri Neohaler

## Products Affected

- SEEBRI NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month each of Spiriva and Incruse Ellipta
QL Criteria	2 capsules Per 1 Day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Selzentry

---

## Products Affected

- SELZENTRY ORAL SOLUTION

<b>QL Criteria</b>	8 bottles Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 150 MG
- SELZENTRY ORAL TABLET 75 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 25 MG

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sensipar

---

## Products Affected

- SENSIPAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/myalept.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/myalept.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Serevent Diskus

---

## Products Affected

- SEREVENT DISKUS

<b>QL Criteria</b>	2 blisters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel XR

## Products Affected

- SEROQUEL XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 150 MG,  
200 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR A DIAGNOSIS OF BIPOLAR DISORDER OR SCHIZOPHRENIA: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 06/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>Revision Date</b>	Prior Authorization: December 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# SEROquel XR

## Products Affected

- SEROQUEL XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 300 MG,  
400 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR A DIAGNOSIS OF BIPOLAR DISORDER OR SCHIZOPHRENIA: A documented contraindication, intolerance, allergy, or failure of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 06/2017

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>Revision Date</b>	Prior Authorization: December 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Serostim

## Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 100 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 50 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sharobel

---

## Products Affected

- SHAROBEL

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Signifor

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Signifor.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Signifor.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 SOLN Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sildenafil Citrate

## Products Affected

- *sildenafil citrate oral*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Siliq

## Products Affected

- SILIQ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Siliq.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Siliq.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Siliq.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Siliq.html</a>
QL Criteria	2 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: July 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Simponi

## Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html</a>
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Simponi Aria

---

## Products Affected

- SIMPONI ARIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Simponi_Aria.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Simponi_Aria.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Simponi_Aria.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Simponi_Aria.html</a>
QL Criteria	1 vial Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simvastatin

---

## Products Affected

- *simvastatin oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Sirturo

---

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antimycobacterial_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antimycobacterial_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	188 EA Per 365 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sivextro

---

## Products Affected

- SIVEXTRO ORAL

<b>QL Criteria</b>	6 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Skyla

---

## Products Affected

- SKYLA

<b>QL Criteria</b>	1 IUD Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SM Nicotine

---

## Products Affected

- *sm nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sodium Phenylbutyrate

## Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp* • *sodium phenylbutyrate oral tablet*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Solia

---

## Products Affected

- *solia*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Soliqua

---

## Products Affected

- SOLIQUA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one of the following: Victoza, Byetta, Bydureon, Tanzeum, Trulicity, Adylixin, Lantus, Toujeo, Levemir, Tresiba, Basaglar
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Somatuline Depot

---

## Products Affected

- SOMATULINE DEPOT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Somavert

## Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Soolantra

---

## Products Affected

- SOOLANTRA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of any of the preferred topical generic alternatives, metronidazole or sulfacetamide sodium with sulfur
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sovaldi

## Products Affected

- SOVALDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spiriva HandiHaler

---

## Products Affected

- SPIRIVA HANDIHALER

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Spiriva Respimat

---

## Products Affected

- SPIRIVA RESPIMAT

<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spritam

---

## Products Affected

- SPRITAM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of immediate release levitiracetam tablets
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Stelara

## Products Affected

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stelara

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Stiolto Respimat

---

## Products Affected

- STIOLTO RESPIMAT

<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stivarga

## Products Affected

- STIVARGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Strattera

---

## Products Affected

- STRATTERA ORAL CAPSULE 10 MG, 18 MG, 25 MG, 40 MG, 60 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Strattera

---

## Products Affected

- STRATTERA ORAL CAPSULE 100 MG, 80 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 14 days each of 3 of the following medications: amphetamine/dextroamphetamine/sr, dexamethylphenidate/sr, dextroamphetamine, methamphetamine, methylphenidate/er/sr, atomoxetine or Vyvanse
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Strensiq

---

## Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stribild

---

## Products Affected

- STRIBILD

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Striverdi Respimat

## Products Affected

- STRIVERDI RESPIMAT

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one month of Serevent
QL Criteria	1 inhaler Per 1 month
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Suboxone

---

## Products Affected

- SUBOXONE SUBLINGUAL FILM 12-3  
MG

<b>QL Criteria</b>	2 films Per 1 day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Suboxone

---

## Products Affected

- SUBOXONE SUBLINGUAL FILM 2-0.5  
MG, 4-1 MG, 8-2 MG

<b>QL Criteria</b>	3 films Per 1 day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Subsys

---

## Products Affected

- SUBSYS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>ST Criteria</b>	<p>A documented contraindication, intolerance, allergy, or failure of one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)</p>
<b>QL Criteria</b>	<p>120 sprays Per 30 Days</p>
<b>Notes/References</b>	<p>Annual Review: 06/2017</p>
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# SulfaSALazine

---

## Products Affected

- *sulfasalazine oral*

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Sulfazine

---

## Products Affected

- *sulfazine*

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan

---

## Products Affected

- *sumatriptan nasal*

<b>QL Criteria</b>	3 nasal sprays Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate oral*

<b>QL Criteria</b>	9 tablets Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous solution*  
6 mg/0.5ml

<b>QL Criteria</b>	8 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml*

<b>QL Criteria</b>	2 boxes (4 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml*

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# SUMatriptan Succinate Refill

---

## Products Affected

- *sumatriptan succinate refill subcutaneous solution cartridge*

<b>QL Criteria</b>	2 boxes (4 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Supartz

## Products Affected

- SUPARTZ INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Supartz FX

---

## Products Affected

- SUPARTZ FX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Supprelin LA

---

## Products Affected

- SUPPRELIN LA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 12.5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 37.5 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sylatron

## Products Affected

- SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Symbicort

---

## Products Affected

- SYMBICORT

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SymlinPen 120

## Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA Approved uses
<b>Exclusion Criteria</b>	Poor compliance with current insulin regimen, Poor compliance with prescribed self-blood glucose monitorings, An A1C greater than 9%, Recurrent severe hypoglycemia requiring assistance during the previous 6 months, Presence of hypoglycemia unawareness, Confirmed diagnosis of gastroparesis, Need for medications that stimulate GI motility , Patient is less than 18 years old, Concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
<b>Required Medical Information</b>	A documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin). For extended renewals: a documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin), and the patient demonstrated an expected reduction in HbA1c since starting this therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	initial: 6 months - extended: 12 months
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# SymlinPen 60

## Products Affected

- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA Approved uses
<b>Exclusion Criteria</b>	Poor compliance with current insulin regimen, Poor compliance with prescribed self-blood glucose monitorings, An A1C greater than 9%, Recurrent severe hypoglycemia requiring assistance during the previous 6 months, Presence of hypoglycemia unawareness, Confirmed diagnosis of gastroparesis, Need for medications that stimulate GI motility , Patient is less than 18 years old, Concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
<b>Required Medical Information</b>	A documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin). For extended renewals: a documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin), and the patient demonstrated an expected reduction in HbA1c since starting this therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	initial: 6 months - extended: 12 months
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Symproic

## Products Affected

- SYMPROIC

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain
<b>Exclusion Criteria</b>	Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction or with a history of a hypersensitivity reaction to naldemedine
<b>Required Medical Information</b>	A documented diagnosis of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain and the patient has been taking opioids for 4 weeks or more
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Movantik
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 06, 2017 Step Therapy: November 06, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Synagis

---

## Products Affected

- SYNAGIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Synagis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Synagis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synalgos-DC

## Products Affected

- SYNALGOS-DC

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Synarel

---

## Products Affected

- SYNAREL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Synera

---

## Products Affected

- SYNERA

<b>QL Criteria</b>	10 patches Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synjardy

---

## Products Affected

- SYNJARDY

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Synjardy XR

---

## Products Affected

- SYNJARDY XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 10-1000  
MG, 12.5-1000 MG, 5-1000 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synjardy XR

---

## Products Affected

- SYNJARDY XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 25-1000  
MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Synribo

## Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synvisc

## Products Affected

- SYNVISC INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Synvisc One

## Products Affected

- SYNVISC ONE INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Syprine

## Products Affected

- SYPRINE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Taclonex

---

## Products Affected

- TACLONEX EXTERNAL SUSPENSION

<b>QL Criteria</b>	60 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tacrolimus

## Products Affected

- *tacrolimus external*

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis, Vitiligo
Exclusion Criteria	
Required Medical Information	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks (14 days) of one preferred alternative topical corticosteroid (triamcinolone acetonide, fluocinonide cream, augmented betamethasone gel, betamethasone dipropionate, hydrocortisone valerate, or fluticasone propionate ointment)
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: October 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tafinlar

## Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tagrisso

## Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Tagrisso.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Tagrisso.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Take Action

---

## Products Affected

- *take action*

<b>QL Criteria</b>	1 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taltz

## Products Affected

- TALTZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Taltz.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Taltz.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Taltz.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Taltz.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tamiflu

---

## Products Affected

- TAMIFLU ORAL CAPSULE

<b>QL Criteria</b>	20 capsules Per 365 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tamiflu

---

## Products Affected

- TAMIFLU ORAL SUSPENSION  
RECONSTITUTED 6 MG/ML

<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tanzeum

---

## Products Affected

- TANZEUM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Victoza and Trulicity
<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Tarceva

---

## Products Affected

- TARCEVA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Targretin

---

## Products Affected

- TARGRETIN EXTERNAL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Targretin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Targretin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tasigna

## Products Affected

- TASIGNA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tazarotene

---

## Products Affected

- *tazarotene external*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Acne Vulgaris, plaque psoriasis
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of Acne Vulgaris or plaque psoriasis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tazorac

---

## Products Affected

- TAZORAC

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris, plaque psoriasis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Acne Vulgaris or plaque psoriasis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Epiduo
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg, 360 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tecfidera

## Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 CPDR Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Tecfidera

## Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Technivie

## Products Affected

- TECHNIVIE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tekturna

---

## Products Affected

- TEKTURNA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekturna HCT

---

## Products Affected

- TEKTURNA HCT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Telmisartan

---

## Products Affected

- *telmisartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telmisartan-Amlodipine

---

## Products Affected

- *telmisartan-amlodipine*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of amlodipine in combination with two of the following: Atacand, Avapro, Cozaar, Micardis
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Telmisartan-HCTZ

---

## Products Affected

- *telmisartan-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Temazepam

---

## Products Affected

- *temazepam oral capsule 22.5 mg, 7.5 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Temovate

---

## Products Affected

- TEMOVATE EXTERNAL CREAM

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Temozolomide

---

## Products Affected

- *temozolomide*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Testosterone

---

## Products Affected

- *testosterone transdermal gel 10 mg/act (2%)*

<b>QL Criteria</b>	4 grams Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Testosterone

## Products Affected

- *testosterone transdermal gel 12.5 mg/act (1%)*
- *testosterone transdermal gel 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 Day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Testosterone

## Products Affected

- *testosterone transdermal gel 25 mg/2.5gm (1%)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2.5 grams Per 1 Day

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Testosterone

## Products Affected

- *testosterone transdermal solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	A documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	6 ml Per 1 day
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>Revision Date</b>	Prior Authorization: May 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Testosterone Cypionate

---

## Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml*

<b>QL Criteria</b>	10 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Testosterone Cypionate

---

## Products Affected

- *testosterone cypionate intramuscular solution 200 mg/ml*

<b>QL Criteria</b>	10 ml Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tetrabenazine

## Products Affected

- *tetrabenazine oral tablet 12.5 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 31, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tetrabenazine

## Products Affected

- *tetrabenazine oral tablet 25 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 31, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Blood Glucose Monitoring

## Products Affected

- TGT BLOOD GLUCOSE MONITORING

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# TGT Nicotine Step One

---

## Products Affected

- *tgt nicotine step one*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Nicotine Step Three

---

## Products Affected

- *tgt nicotine step three*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# TGT Nicotine Step Two

---

## Products Affected

- *tgt nicotine step two*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Thalomid

## Products Affected

- THALOMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Thiola

## Products Affected

- THIOLA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Thrive

---

## Products Affected

- *thrive mouth/throat gum 2 mg*

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 2 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 4 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tirosint

---

## Products Affected

- TIROSINT

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivorbex

---

## Products Affected

- TIVORBEX

<b>QL Criteria</b>	3 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tobi Podhaler

---

## Products Affected

- TOBI PODHALER

<b>QL Criteria</b>	1 CAPS Per 28 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tobramycin

---

## Products Affected

- *tobramycin inhalation*

<b>QL Criteria</b>	10 ml Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tolterodine Tartrate ER

---

## Products Affected

- *tolterodine tartrate er*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toujeo SoloStar

---

## Products Affected

- TOUJEO SOLOSTAR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Levemir and Tresiba
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Toviaz

---

## Products Affected

- TOVIAZ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tracleer

---

## Products Affected

- TRACLEER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Tradjenta

---

## Products Affected

- TRADJENTA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl

## Products Affected

- *tramadol hcl oral*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl ER

## Products Affected

- *tramadol hcl er oral tablet extended release  
24 hour*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl ER (Biphasic)

## Products Affected

- *tramadol hcl er (biphasic)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Tramadol-Acetaminophen

## Products Affected

- *tramadol-acetaminophen*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Tranexamic Acid

---

## Products Affected

- *tranexamic acid oral*

<b>QL Criteria</b>	30 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trelegy Ellipta

---

## Products Affected

- TRELEGY ELLIPTA

<b>QL Criteria</b>	2 blisters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trelstar Mixject

---

## Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tremfya

## Products Affected

- TREMFYA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Tremfya.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Tremfya.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Tremfya.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Tremfya.html</a>
QL Criteria	1 injection Per 56 days
Notes/References	
Revision Date	Prior Authorization: August 02, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretinoin

## Products Affected

- *tretinoin external cream*
- *tretinoin external gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tretinoin Microsphere

## Products Affected

- *tretinoin microsphere*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update



<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tretinoin Microsphere Pump

## Products Affected

- *tretinoin microsphere pump*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tretin-X

## Products Affected

- TRETIN-X EXTERNAL CREAM 0.075 %

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin and Epiduo

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Trezix

## Products Affected

- TREZIX ORAL CAPSULE 320.5-30-16 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Tribenzor

---

## Products Affected

- TRIBENZOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of amlodipine in combination with two of the following: Atacand HCT, Avalide, Hyzaar, Micardis HCT
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Trintellix

## Products Affected

- TRINTELLIX

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For quantities over the allowed amount for the prescribed medication, a member must meet one of the following: (1) Member requires a dose including half tablets, (2) member's dose is being titrated by physician (3-month limit), (3) member has had intolerance to drug administered as a single daily dose, or (4) member's dose cannot be achieved with proposed quantity limits for a given strength (ex. needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose.)
ST Criteria	A documented contraindication, intolerance, allergy, or failure of 3 different antidepressants from at least two different therapeutic subclasses. Examples include SSRIs (fluoxetine, citalopram), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and heterocyclic antidepressants (mirtazapine, trazodone).
QL Criteria	1 tablet Per 1 Day
Notes/References	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Triptodur

---

## Products Affected

- TRIPTODUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Triumeq

---

## Products Affected

- TRIUMEQ

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Trokendi XR

---

## Products Affected

- TROKENDI XR

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trospium Chloride

---

## Products Affected

- *trospium chloride*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Trospium Chloride ER

---

## Products Affected

- *trospium chloride er*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TRUEresult Blood Glucose

## Products Affected

- TRUERESULT BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# TrueTrack Blood Glucose

## Products Affected

- TRUETRACK BLOOD GLUCOSE KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TrueTrack Smart System

## Products Affected

- TRUETRACK SMART SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Trulicity

---

## Products Affected

- TRULICITY

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Truvada

---

## Products Affected

- TRUVADA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tudorza Pressair

---

## Products Affected

- TUDORZA PRESSAIR INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of Spiriva and Incruse Ellipta
<b>QL Criteria</b>	1 inhaler Per 30 fills
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TussiCaps

---

## Products Affected

- TUSSICAPS

<b>QL Criteria</b>	20 capsules Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tybost

---

## Products Affected

- TYBOST

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tykerb

## Products Affected

- TYKERB

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Tymlos

## Products Affected

- TYMLOS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
QL Criteria	1 pen Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tysabri

## Products Affected

- TYSABRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tyvaso

## Products Affected

- TYVASO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 SOLN Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tyvaso Refill

## Products Affected

- TYVASO REFILL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Tyvaso Starter

---

## Products Affected

- TYVASO STARTER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uceris

---

## Products Affected

- UCERIS ORAL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Asacol HD, Delzicol, Lialda or Pentasa
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Uceris

## Products Affected

- UCERIS RECTAL

PA Criteria	Criteria Details
Covered Uses	Active mild to moderate ulcerative colitis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ACTIVE mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge, requiring induction of remission.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 canisters Per 1 month
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ulesfia

---

## Products Affected

- ULESFIA

<b>QL Criteria</b>	3 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Uloric

---

## Products Affected

- ULORIC

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ultravate

---

## Products Affected

- ULTRAVATE EXTERNAL LOTION

<b>QL Criteria</b>	120 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uptravi

## Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 400 MCG, 600 MCG, 800 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uptravi

## Products Affected

- UPTRAVI ORAL TABLET 200 MCG                      PACK
- UPTRAVI ORAL TABLET THERAPY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Utibron Neohaler

## Products Affected

- UTIBRON NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Valchlor

---

## Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 GM Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Valcyte

---

## Products Affected

- VALCYTE ORAL SOLUTION  
RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ValGANciclovir HCl

## Products Affected

- *valganciclovir hcl oral solution reconstituted*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1000 ML Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# ValGANciclovir HCl

## Products Affected

- *valganciclovir hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	102 TABS Per 30 DAYs
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Valsartan

---

## Products Affected

- *valsartan*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Valsartan-Hydrochlorothiazide

---

## Products Affected

- *valsartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vantas

---

## Products Affected

- VANTAS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Varubi

---

## Products Affected

- VARUBI ORAL

<b>QL Criteria</b>	4 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vascepa

---

## Products Affected

- VASCEPA ORAL CAPSULE 0.5 GM

<b>QL Criteria</b>	8 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vascepa

---

## Products Affected

- VASCEPA ORAL CAPSULE 1 GM

<b>QL Criteria</b>	4 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vecamyl

## Products Affected

- VECAMYL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html</a>
QL Criteria	10 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Veletri

---

## Products Affected

- VELETRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Veltassa

---

## Products Affected

- VELTASSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Veltassa.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Veltassa.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 packet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Veltin

---

## Products Affected

- VELTIN

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vemlidy

## Products Affected

- VEMLIDY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Vemlidy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Vemlidy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Vemlidy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/Vemlidy.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 13, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Venclexta

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	40 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venclexta

## Products Affected

- VENCLEXTA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Venclexta

## Products Affected

- VENCLEXTA ORAL TABLET 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venclexta Starting Pack

---

## Products Affected

- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Venclexta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 pack Per 28 days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 100 mg, 25 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 37.5 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 50 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 75 mg*

<b>QL Criteria</b>	5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 150 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg, 75 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral tablet extended release 24 hour 225 mg*

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ventavis

---

## Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 100 mg, 300 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 200 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verdrocet

## Products Affected

- VERDROCET

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Versacloz

---

## Products Affected

- VERSACLOZ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Clozaril tablets
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verzenio

## Products Affected

- VERZENIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Verzenio.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Verzenio.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# VESicare

---

## Products Affected

- VESICARE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one preferred generic (i.e. trospium, trospium ER, tolterodine, tolterodine ER, oxybutynin)
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viberzi

## Products Affected

- VIBERZI

PA Criteria	Criteria Details
Covered Uses	Diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	No known or suspected history of any of the following: does not have a gallbladder, diagnosis of pancreatitis, diagnosis of alcoholism, member drinks more than 3 alcoholic beverages/day, severe (Child-Pugh C) hepatic impairment, or anatomic or biochemical abnormalities of the gastrointestinal tract (e.g., biliary duct obstruction, sphincter of Oddi dysfunction, or severe constipation)
Required Medical Information	A documented diagnosis of diarrhea-predominant irritable bowel syndrome (IBS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: April 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Vicodin

## Products Affected

- *vicodin oral tablet 5-300 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Vicodin ES

## Products Affected

- *vicodin es oral tablet 7.5-300 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Vicodin HP

## Products Affected

- *vicodin hp oral tablet 10-300 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Victoza

---

## Products Affected

- VICTOZA SUBCUTANEOUS SOLUTION  
PEN-INJECTOR

<b>QL Criteria</b>	1 box-2 or 3 pens Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viekira Pak

## Products Affected

- VIEKIRA PAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Viekira XR

## Products Affected

- VIEKIRA XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vigabatrin

## Products Affected

- *vigabatrin*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 packets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Viibryd

---

## Products Affected

- VIIBRYD ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimizim

---

## Products Affected

- VIMIZIM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Vimpat

---

## Products Affected

- VIMPAT ORAL SOLUTION

<b>QL Criteria</b>	40 ML Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimpat

---

## Products Affected

- VIMPAT ORAL TABLET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Viokace

---

## Products Affected

- VIOKACE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Creon and Zenpep
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viorele

---

## Products Affected

- *viorele*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Viread

---

## Products Affected

- VIREAD ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vistogard

---

## Products Affected

- VISTOGARD

<b>QL Criteria</b>	20 packs Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Vivlodex

---

## Products Affected

- VIVLODEX

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two generic non steroidal anti-inflammatory drugs
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Voltaren

---

## Products Affected

- VOLTAREN TRANSDERMAL

<b>QL Criteria</b>	200 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vonvendi

---

## Products Affected

- VONVENDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vosevi

## Products Affected

- VOSEVI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Votrient

## Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vpriv

---

## Products Affected

- VPRIV

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 1.5 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) plus Latuda
<b>QL Criteria</b>	4 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 3 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) plus Latuda
<b>QL Criteria</b>	2 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) plus Latuda
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE THERAPY PACK

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) plus Latuda
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vytorin

---

## Products Affected

- VYTORIN

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of generic simvastatin in combination with generic ezetimibe, or generic ezetimibe-simvastatin
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vyvanse

---

## Products Affected

- VYVANSE

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Vyvanse

---

## Products Affected

- VYVANSE

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xadago

## Products Affected

- XADAGO

PA Criteria	Criteria Details
Covered Uses	Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Parkinson's disease and concurrent use of levodopa/carbidopa
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of rasagaline or selegiline
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: June 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Xalkori

---

## Products Affected

- XALKORI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xatmep

## Products Affected

- XATMEP

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of acute lymphoblastic leukemia (ALL) or polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of Acute Lymphoblastic Leukemia (ALL) in a pediatric patient (18 years and younger) as part of a multi-phase, combination chemotherapy maintenance regimen or a diagnosis of Polyarticular Juvenile Idiopathic Arthritis (PJIA) in pediatric patients (18 years and younger) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Regardless of diagnosis, the patient must have a documented inability to swallow tablets/capsules.
<b>Age Restrictions</b>	Approved for those 18 years of age or younger
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: July 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xeljanz

## Products Affected

- XELJANZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeljanz XR

## Products Affected

- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xeomin

## Products Affected

- XEOMIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xermelo

## Products Affected

- XERMELO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Xermelo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Xermelo.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xgeva

## Products Affected

- XGEVA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xifaxan

---

## Products Affected

- XIFAXAN ORAL TABLET 200 MG

<b>QL Criteria</b>	9 tablets Per 1 fill
<b>Notes/ References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Xifaxan

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Covered Uses	Hepatic Encephalopathy, Irritable Bowel Syndrome (IBS) with Diarrhea.
Exclusion Criteria	
Required Medical Information	FOR HEPATIC ENCEPHALOPATHY: Member must have a documented diagnosis and be 18 years and older. FOR IBS WITH DIARRHEA: Member must have a documented diagnosis and must have been prescribed a 14-day course of therapy with three times a day dosing. For reauthorization of 2nd or 3rd course of therapy, there must be at least a 10-week treatment free period from the previous course of therapy.
Age Restrictions	18 years or older
Prescriber Restrictions	
Coverage Duration	HEPATIC ENCEPHALOPATHY: 1 year. IBS: 14 days.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: November 29, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET EXTENDED  
RELEASE 24 HOUR 10-1000 MG, 10-500  
MG, 5-500 MG

<b>QL Criteria</b>	1 TAB Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET EXTENDED  
RELEASE 24 HOUR 5-1000 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xolair

---

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Xolair.html">http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Xolair.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Xolair.html">http://www.aetna.com/products/rxnonmedicare/data/2017/RESP/Xolair.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xopenex HFA

---

## Products Affected

- XOPENEX HFA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Ventolin HFA and ProAir
<b>QL Criteria</b>	2 inhalers Per 1 fill
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtampza ER

## Products Affected

- XTAMPZA ER

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtandi

## Products Affected

- XTANDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Xulane

---

## Products Affected

- XULANE

<b>QL Criteria</b>	1 box (3 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xultophy

---

## Products Affected

- XULTOPHY

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one of the following: Victoza, Byetta, Bydureon, Tanzeum, Trulicity, Adylixin, Lantus, Toujeo, Levemir, Tresiba, Basaglar
<b>QL Criteria</b>	5 pens Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xuriden

---

## Products Affected

- XURIDEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 packets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xylon

---

## Products Affected

- XYLON

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Xyrem

---

## Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/cataplxy-xyrem.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/cataplxy-xyrem.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Yervoy

---

## Products Affected

- YERVOY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/yervoy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/yervoy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zafirlukast

---

## Products Affected

- *zafirlukast*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zaleplon

---

## Products Affected

- *zaleplon*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Zaltrap

---

## Products Affected

- ZALTRAP

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/zaltrap.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/zaltrap.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zarxio

---

## Products Affected

- ZARXIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zavesca

## Products Affected

- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ENDO/gaucher_disease.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zegerid OTC

---

## Products Affected

- ZEGERID OTC

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zejula

---

## Products Affected

- ZEJULA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Zejula.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Zejula.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 09, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zelboraf

## Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	8 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zemaira

## Products Affected

- ZEMAIRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alp ha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zembrace SymTouch

---

## Products Affected

- ZEMBRACE SYMTOUCH

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of generic Imitrex injection
<b>QL Criteria</b>	8 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Zenatane

---

## Products Affected

- *zenatane oral capsule 10 mg, 20 mg, 40 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zenatane

---

## Products Affected

- ZENATANE ORAL CAPSULE 30 MG

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zenzedi

---

## Products Affected

- ZENZEDI ORAL TABLET 10 MG, 5 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zepatier

## Products Affected

- ZEPATIER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zetia

---

## Products Affected

- ZETIA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of ezetimibe
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zetonna

---

## Products Affected

- ZETONNA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ziana

---

## Products Affected

- ZIANA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Epiduo
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zileuton ER

---

## Products Affected

- *zileuton er*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Zinbryta

## Products Affected

- ZINBRYTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 injection Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zioptan

---

## Products Affected

- ZIOPTAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: December 07, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Ziprasidone HCl

---

## Products Affected

- *ziprasidone hcl*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zohydro ER

## Products Affected

- ZOHYDRO ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
Age Restrictions	
Prescriber Restrictions	

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of two preferred alternatives which include Hysingla ER, Embeda and Oxycontin
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

# Zoladex

---

## Products Affected

- ZOLADEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zoledronic Acid

---

## Products Affected

- *zoledronic acid intravenous concentrate*
- *zoledronic acid intravenous solution*

<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolinza

## Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet 2.5 mg*

<b>QL Criteria</b>	6 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet 5 mg*

<b>QL Criteria</b>	3 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet dispersible 2.5 mg*

<b>QL Criteria</b>	6 tablets Per 30 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet dispersible 5 mg*

<b>QL Criteria</b>	30 tablet Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zolpidem Tartrate

---

## Products Affected

- *zolpidem tartrate oral*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolpidem Tartrate ER

---

## Products Affected

- *zolpidem tartrate er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zomig

---

## Products Affected

- ZOMIG NASAL SOLUTION 5 MG

<b>QL Criteria</b>	1 box (6 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zonalon

---

## Products Affected

- ZONALON

<b>QL Criteria</b>	45 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Zontivity

## Products Affected

- ZONTIVITY

PA Criteria	Criteria Details
<b>Covered Uses</b>	Reduction of the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)
<b>Exclusion Criteria</b>	Do not use in patients with history of stroke, history of transient ischemic attack (TIA), or history of intracranial hemorrhage (ICH), or active pathological bleeding
<b>Required Medical Information</b>	Documented diagnosis or history of myocardial infarction (MI) or peripheral arterial disease (PAD) and concurrent use of aspirin or clopidogrel.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: July 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zorbtive

---

## Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zorvolex

---

## Products Affected

- ZORVOLEX

<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zubsolv

---

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 0.7-0.18 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zubsolv

---

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 1.4-0.36 MG, 11.4-2.9 MG,  
2.9-0.71 MG, 5.7-1.4 MG, 8.6-2.1 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zurampic

## Products Affected

- ZURAMPIC

PA Criteria	Criteria Details
Covered Uses	Treatment of hyperuricemia associated with gout
Exclusion Criteria	
Required Medical Information	A documented diagnosis of gout, and will be used in combination with a xanthine oxidase inhibitor (allopurinol OR febuxostat)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of allopurinol or febuxostat
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: October 04, 2017 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zyban

---

## Products Affected

- ZYBAN

<b>QL Criteria</b>	2 tablet Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zydelig

---

## Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



# Zyflo

---

## Products Affected

- ZYFLO

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zyflo CR

---

## Products Affected

- ZYFLO CR

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zykadia

## Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	5 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zytiga

## Products Affected

- ZYTIGA ORAL TABLET 250 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

# Zytiga

## Products Affected

- ZYTIGA ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Index

ABSTRAL.....	1	<i>afeditab cr oral tablet extended release 24</i>	
<i>acamprosate calcium</i> .....	3	<i>hour 30 mg</i> .....	42
ACCOLATE.....	4	<i>afeditab cr oral tablet extended release 24</i>	
ACCU-CHEK AVIVA PLUS.....	5	<i>hour 60 mg</i> .....	43
ACCU-CHEK COMPACT PLUS		AFINITOR.....	44
CARE.....	6	AFINITOR DISPERZ.....	45
ACCU-CHEK MULTICLIX LANCET		AFREZZA INHALATION POWDER	
DEV.....	7	12 UNIT, 8 UNIT.....	46
ACCU-CHEK NANO SMARTVIEW.....	8	AFREZZA INHALATION POWDER	
<i>acetaminophen-codeine #2</i> .....	13	4 & 8 & 12 UNIT, 4 (30) & 8 (60) UNIT,	
<i>acetaminophen-codeine #3</i> .....	15	4 (90) & 8 (90) UNIT, 4 UNIT, 8 (60)&	
<i>acetaminophen-codeine #4</i> .....	17	12 (30) UNIT.....	47
<i>acetaminophen-codeine oral solution</i> .....	9	AFREZZA INHALATION POWDER	
<i>acetaminophen-codeine oral tablet</i> .....	11	4 (60) & 8 (30) UNIT.....	48
ACIPHEX SPRINKLE.....	19	AFSTYLA.....	49
<i>acitretin</i> .....	21	AGAMATRIX PRESTO.....	50
ACTEMRA INTRAVENOUS.....	22	AIRDUO RESPICLICK 113/14.....	51
ACTEMRA SUBCUTANEOUS.....	23	AIRDUO RESPICLICK 232/14.....	52
ACTIMMUNE.....	24	AIRDUO RESPICLICK 55/14.....	53
ACTOPLUS MET XR.....	25	AKYNZEO.....	54
ACZONE.....	26	ALBENZA.....	55
ADAGEN.....	27	ALDURAZYME.....	56
ADCIRCA.....	28	ALECENSA.....	57
<i>adefovir dipivoxil</i> .....	29	<i>alendronate sodium oral tablet 10 mg, 40</i>	
ADEMPAS.....	30	<i>mg, 5 mg</i> .....	58
ADVAIR DISKUS INHALATION		<i>alendronate sodium oral tablet 35 mg</i> .....	59
AEROSOL POWDER BREATH		<i>alfuzosin hcl er</i> .....	60
ACTIVATED 100-50 MCG/DOSE,		ALINIA ORAL SUSPENSION	
250-50 MCG/DOSE.....	31	RECONSTITUTED.....	61
ADVAIR DISKUS INHALATION		ALINIA ORAL TABLET.....	62
AEROSOL POWDER BREATH		<i>almotriptan malate</i> .....	63
ACTIVATED 500-50 MCG/DOSE.....	32	<i>alogliptin benzoate</i> .....	64
ADVAIR HFA.....	33	<i>alogliptin-metformin hcl</i> .....	65
ADVATE.....	34	<i>alogliptin-pioglitazone</i> .....	66
ADVOCATE DUO DEVICE.....	35	<i>alose tron hcl</i> .....	67
<i>adynovate</i> .....	36	<i>alprazolam er</i> .....	68
ADYPHREN.....	37	<i>alprazolam xr</i> .....	69
ADYPHREN AMP II.....	38	ALTOPREV.....	70
ADYPHREN II.....	39	ALUNBRIG.....	71
ADZENYS XR-ODT.....	40	ALVESCO.....	72
AEROSPAN.....	41	AMITIZA.....	73

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>amlodipine besylate-valsartan</i> .....	74	ARANESP (ALBUMIN FREE)	
<i>amlodipine-olmesartan</i> .....	75	INJECTION SOLUTION	
<i>amlodipine-valsartan-hctz</i> .....	76	PREFILLED SYRINGE 100	
<i>amnesteam</i> .....	77	MCG/0.5ML, 150 MCG/0.3ML, 200	
<i>amphetamine-dextroamphet er</i> .....	78	MCG/0.4ML, 25 MCG/0.42ML, 300	
<i>amphetamine-dextroamphetamine</i> .....	79	MCG/0.6ML, 40 MCG/0.4ML, 500	
AMPYRA.....	80	MCG/ML, 60 MCG/0.3ML.....	101
ANDROGEL PUMP		ARCALYST.....	102
TRANSDERMAL GEL 20.25		ARCAPTA NEOHALER.....	103
MG/ACT (1.62%).....	85	<i>aripiprazole oral solution</i> .....	104
ANDROGEL TRANSDERMAL GEL		<i>aripiprazole oral tablet</i> .....	105
20.25 MG/1.25GM (1.62%).....	81	<i>aripiprazole oral tablet dispersible</i> .....	105
ANDROGEL TRANSDERMAL GEL		<i>armodafinil oral tablet 150 mg</i> .....	106
40.5 MG/2.5GM (1.62%).....	83	<i>armodafinil oral tablet 200 mg, 250 mg</i> ...	106
ANORO ELLIPTA.....	87	<i>armodafinil oral tablet 50 mg</i> .....	108
ANTARA ORAL CAPSULE 30 MG,		ARMONAIR RESPICLICK 113.....	110
90 MG.....	88	ARMONAIR RESPICLICK 232.....	111
ANZEMET ORAL.....	89	ARMONAIR RESPICLICK 55.....	112
<i>apap-caff-dihydrocodeine oral capsule</i> .....	90	ARNUITY ELLIPTA.....	113
APIDRA.....	92	ARYMO ER.....	114
APIDRA SOLOSTAR		ARZERRA.....	116
SUBCUTANEOUS SOLUTION PEN-		ASACOL HD.....	117
INJECTOR.....	93	<i>ascomp-codeine</i> .....	118
<i>aprepitant oral capsule 125 mg, 40 mg, 80</i>		ASTAGRAF XL ORAL CAPSULE	
<i>mg</i> .....	94	EXTENDED RELEASE 24 HOUR 0.5	
<i>aprepitant oral capsule 80 &amp; 125 mg</i> .....	95	MG.....	120
APRISO.....	96	ASTAGRAF XL ORAL CAPSULE	
APTENSIO XR.....	97	EXTENDED RELEASE 24 HOUR 1	
APTIOM ORAL TABLET 200 MG,		MG.....	121
600 MG.....	98	ATACAND ORAL TABLET 32 MG...	122
APTIOM ORAL TABLET 400 MG,		<i>atomoxetine hcl oral capsule 10 mg, 18</i>	
800 MG.....	99	<i>mg, 25 mg, 40 mg, 60 mg</i> .....	123
ARALAST NP INTRAVENOUS		<i>atomoxetine hcl oral capsule 100 mg, 80</i>	
SOLUTION RECONSTITUTED 1000		<i>mg</i> .....	124
MG, 500 MG.....	100	<i>atorvastatin calcium oral</i> .....	125
ARANESP (ALBUMIN FREE)		ATRIPLA.....	126
INJECTION SOLUTION 100		ATROVENT HFA.....	127
MCG/ML, 200 MCG/ML, 25		AUBAGIO.....	128
MCG/ML, 300 MCG/ML, 40		AUSTEDO.....	129
MCG/ML, 60 MCG/ML.....	101	AVANDIA ORAL TABLET 2 MG, 4	
		MG.....	130
		<i>avita external cream</i> .....	131

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<i>avita external gel</i> .....	133	BOSULIF.....	167
AVONEX.....	135	BOTOX.....	168
AVONEX PEN INTRAMUSCULAR		BOTOX COSMETIC	
AUTO-INJECTOR KIT.....	136	INTRAMUSCULAR SOLUTION	
AVONEX PREFILLED		RECONSTITUTED 50 UNIT.....	169
INTRAMUSCULAR PREFILLED		BRAVELLE.....	170
SYRINGE KIT.....	137	BREO ELLIPTA.....	171
AZILECT.....	138	BREO ELLIPTA.....	172
AZOR.....	139	BRILINTA.....	173
<i>balsalazide disodium</i> .....	140	BRISDELLE.....	174
BANZEL ORAL TABLET.....	141	BRIVIACT ORAL SOLUTION.....	175
BASAGLAR KWIKPEN.....	142	BRIVIACT ORAL TABLET.....	176
BAXDELA ORAL.....	143	BROVANA.....	177
BAYER CONTOUR LINK		<i>budesonide inhalation</i> .....	178
MONITOR.....	144	BUNAVAIL BUCCAL FILM 2.1-0.3	
BAYER CONTOUR MONITOR KIT.....	145	MG.....	179
BAYER CONTOUR NEXT EZ.....	146	BUNAVAIL BUCCAL FILM 4.2-0.7	
BAYER CONTOUR NEXT LINK.....	147	MG, 6.3-1 MG.....	180
BAYER CONTOUR NEXT		<i>buprenorphine</i> .....	181
MONITOR.....	148	<i>buprenorphine hcl sublingual</i> .....	183
BECONASE AQ.....	149	<i>buprenorphine hcl-naloxone hcl</i> .....	184
BELBUCA.....	150	<i>bupropion hcl er (smoking det)</i> .....	186
BELSOMRA.....	152	<i>bupropion hcl er (sr)</i> .....	187
BENICAR.....	153	<i>bupropion hcl er (xl)</i> .....	188
BENICAR HCT.....	154	<i>bupropion hcl oral</i> .....	185
BENLYSTA INTRAVENOUS.....	155	<i>butalbital-apap-caff-cod</i> .....	189
BENLYSTA SUBCUTANEOUS.....	156	<i>butalbital-asa-caff-codeine</i> .....	191
BERINERT.....	157	<i>butorphanol tartrate nasal</i> .....	193
<i>betamethasone dipropionate aug external</i>		BUTRANS.....	195
<i>gel</i> .....	158	BYDUREON SUBCUTANEOUS	
<i>betamethasone dipropionate aug external</i>		PEN-INJECTOR.....	197
<i>lotion</i> .....	159	BYETTA 10 MCG PEN	
<i>betamethasone dipropionate aug external</i>		SUBCUTANEOUS SOLUTION PEN-	
<i>ointment</i> .....	158	INJECTOR.....	198
BETASERON SUBCUTANEOUS KIT		BYETTA 5 MCG PEN	
.....	160	SUBCUTANEOUS SOLUTION PEN-	
BETHKIS.....	161	INJECTOR.....	199
BEVESPI AEROSPHERE.....	162	BYSTOLIC ORAL TABLET 10 MG, 5	
BEVYXXA.....	163	MG.....	200
<i>bexarotene</i> .....	164	BYSTOLIC ORAL TABLET 2.5 MG..	200
<i>bicalutamide</i> .....	165	BYSTOLIC ORAL TABLET 20 MG...	201
<i>bimatoprost ophthalmic</i> .....	166	BYVALSON.....	202

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



CABOMETYX.....	203	CIALIS ORAL TABLET 2.5 MG.....	233
<i>calcipotriene external cream</i> .....	204	CIALIS ORAL TABLET 5 MG.....	233
<i>calcipotriene external ointment</i> .....	204	CICLODAN EXTERNAL SOLUTION	
<i>calcitonin (salmon)</i> .....	205	.....	234
<i>calcitrene</i> .....	206	<i>ciclopirox external solution</i> .....	235
CANASA.....	207	CIMZIA PREFILLED.....	237
<i>candesartan cilexetil oral tablet 16 mg, 4</i>		CIMZIA STARTER KIT.....	238
<i>mg, 8 mg</i> .....	208	CIMZIA SUBCUTANEOUS KIT 2 X	
<i>candesartan cilexetil-hctz</i> .....	209	200 MG.....	236
<i>capecitabine</i> .....	210	CINQAIR.....	239
CAPRELSA ORAL TABLET 100 MG	211	CINRYZE.....	240
CAPRELSA ORAL TABLET 300 MG	212	<i>citalopram hydrobromide oral tablet 10</i>	
CARBAGLU.....	213	<i>mg, 20 mg</i> .....	241
CARDIZEM LA ORAL TABLET		<i>citalopram hydrobromide oral tablet 40</i>	
EXTENDED RELEASE 24 HOUR 120		<i>mg</i> .....	242
MG.....	214	<i>claravis</i> .....	243
CARDURA XL.....	215	CLARINEX-D 12 HOUR.....	244
<i>cartia xt oral capsule extended release 24</i>		CLEVER CHEK AUTO-CODE.....	245
<i>hour 120 mg, 300 mg</i> .....	216	CLEVER CHOICE MICRO SYSTEM	246
<i>cartia xt oral capsule extended release 24</i>		CLIMARA PRO.....	247
<i>hour 180 mg</i> .....	216	<i>clobetasol propionate e</i> .....	252
<i>cartia xt oral capsule extended release 24</i>		<i>clobetasol propionate emulsion</i> .....	253
<i>hour 240 mg</i> .....	217	<i>clobetasol propionate external cream</i> .....	248
CAYSTON.....	218	<i>clobetasol propionate external foam</i> .....	249
<i>cefixime</i> .....	219	<i>clobetasol propionate external gel</i> .....	248
<i>celecoxib oral</i> .....	220	<i>clobetasol propionate external liquid</i> .....	250
CERDELGA.....	221	<i>clobetasol propionate external lotion</i> .....	251
CEREZYME INTRAVENOUS		<i>clobetasol propionate external ointment</i> ..	248
SOLUTION RECONSTITUTED 400		<i>clobetasol propionate external shampoo</i> ..	251
UNIT.....	222	<i>clobetasol propionate external solution</i> ...	249
CESAMET.....	223	<i>clodan external shampoo</i> .....	254
CETROTIDE SUBCUTANEOUS KIT		<i>clonidine hcl er</i> .....	255
0.25 MG.....	224	<i>clopidogrel bisulfate oral</i> .....	256
<i>cevimeline hcl</i> .....	225	<i>clozapine oral tablet 100 mg</i> .....	257
CHANTIX.....	226	<i>clozapine oral tablet 200 mg</i> .....	258
CHANTIX CONTINUING MONTH		<i>clozapine oral tablet 25 mg, 50 mg</i> .....	259
PAK.....	227	<i>clozapine oral tablet dispersible 100 mg</i> ...	257
CHANTIX STARTING MONTH PAK		<i>clozapine oral tablet dispersible 12.5 mg</i> ..	260
.....	228	<i>clozapine oral tablet dispersible 150 mg</i> ...	261
CHENODAL.....	229	<i>clozapine oral tablet dispersible 200 mg</i> ...	262
CHOLBAM.....	231	<i>clozapine oral tablet dispersible 25 mg</i> .....	259
<i>chorionic gonadotropin intramuscular</i> .....	232	COAGADEX.....	263

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>codeine sulfate oral tablet</i> .....	264	<i>desvenlafaxine er</i> .....	301
<i>colchicine oral</i> .....	266	<i>desvenlafaxine succinate er</i> .....	302
COMBIPATCH.....	267	DEXILANT.....	304
COMBIVENT RESPIMAT.....	268	<i>dexmethylphenidate hcl</i> .....	305
COMETRIQ (100 MG DAILY DOSE).....	269	<i>dexmethylphenidate hcl er</i> .....	306
COMETRIQ (140 MG DAILY DOSE).....	270	<i>dextroamphetamine sulfate er</i> .....	309
COMETRIQ (60 MG DAILY DOSE).....	271	<i>dextroamphetamine sulfate oral solution</i> .....	307
COMPLERA.....	272	<i>dextroamphetamine sulfate oral tablet</i> .....	308
COPAXONE SUBCUTANEOUS		<i>diazepam rectal</i> .....	310
SOLUTION PREFILLED SYRINGE		DICLEGIS.....	311
40 MG/ML.....	273	<i>diclofenac sodium transdermal gel 1 %</i> .....	312
CORDRAN EXTERNAL TAPE.....	274	DIFFERIN EXTERNAL LOTION.....	313
COREG CR.....	275	DIFICID.....	314
CORLANOR.....	276	<i>dihydroergotamine mesylate nasal</i> .....	315
CORMAX SCALP APPLICATION.....	277	<i>diltiazem cd oral capsule extended release</i>	
COSENTYX.....	278	<i>24 hour 120 mg, 180 mg</i> .....	316
COSENTYX SENSOREADY PEN		<i>diltiazem cd oral capsule extended release</i>	
SUBCUTANEOUS SOLUTION		<i>24 hour 240 mg</i> .....	317
AUTO-INJECTOR 150 MG/ML.....	279	<i>diltiazem cd oral capsule extended release</i>	
COTELLIC.....	280	<i>24 hour 300 mg</i> .....	318
COTEMPLA XR-ODT.....	281	<i>diltiazem hcl er beads oral capsule</i>	
CRESTOR.....	282	<i>extended release 24 hour 120 mg, 180 mg,</i>	
CUPRIMINE ORAL CAPSULE 250		<i>300 mg, 360 mg</i> .....	321
MG.....	283	<i>diltiazem hcl er beads oral capsule</i>	
<i>cvs nicotine polacrilex mouth/throat</i>		<i>extended release 24 hour 240 mg</i> .....	322
<i>lozenge 4 mg</i> .....	285	<i>diltiazem hcl er beads oral capsule</i>	
<i>cvs nicotine transdermal patch 24 hour</i> .....	284	<i>extended release 24 hour 420 mg</i> .....	321
<i>cvs nts step 1</i> .....	286	<i>diltiazem hcl er coated beads oral capsule</i>	
CYCLOSET.....	287	<i>extended release 24 hour 120 mg, 180 mg</i> .....	323
CYSTADANE.....	288	<i>diltiazem hcl er coated beads oral capsule</i>	
CYSTAGON.....	289	<i>extended release 24 hour 240 mg</i> .....	324
CYSTARAN.....	290	<i>diltiazem hcl er coated beads oral capsule</i>	
DAKLINZA.....	291	<i>extended release 24 hour 300 mg</i> .....	325
DAKLINZA.....	292	<i>diltiazem hcl er coated beads oral capsule</i>	
DALIRESP.....	293	<i>extended release 24 hour 360 mg</i> .....	323
<i>dapsone external</i> .....	294	<i>diltiazem hcl er oral capsule extended</i>	
<i>darifenacin hydrobromide er</i> .....	295	<i>release 12 hour 120 mg</i> .....	319
DAYTRANA.....	296	<i>diltiazem hcl er oral capsule extended</i>	
DELZICOL.....	297	<i>release 24 hour 120 mg, 180 mg</i> .....	319
DEPEN TITRATABS.....	298	<i>diltiazem hcl er oral capsule extended</i>	
DESCOVY.....	299	<i>release 24 hour 240 mg</i> .....	320
<i>desloratadine</i> .....	300		

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg</i> .....	326	EMEND ORAL CAPSULE 40 MG.....	360
<i>dilt-xr oral capsule extended release 24 hour 240 mg</i> .....	327	EMSAM.....	361
DIPENTUM.....	328	EMTRIVA ORAL CAPSULE.....	362
DOLOPHINE ORAL TABLET 10 MG .....	329	EMVERM.....	363
<i>donepezil hcl oral tablet 10 mg</i> .....	331	ENABLEX.....	364
<i>donepezil hcl oral tablet 23 mg, 5 mg</i> .....	332	ENABLEX.....	365
<i>donepezil hcl oral tablet dispersible</i> .....	332	ENBREL MINI.....	369
<i>doxepin hcl external</i> .....	333	ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	
<i>doxercalciferol oral</i> .....	334	25 MG/0.5ML.....	366
<i>dronabinol</i> .....	335	ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	
DUAVEE.....	336	50 MG/ML.....	367
DULERA.....	337	ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED.....	368
<i>duloxetine hcl oral capsule delayed release particles 20 mg, 60 mg</i> .....	338	ENBREL SURECLICK SUBCUTANEOUS SOLUTION	
<i>duloxetine hcl oral capsule delayed release particles 30 mg</i> .....	339	AUTO-INJECTOR.....	370
<i>duloxetine hcl oral capsule delayed release particles 40 mg</i> .....	339	<i>endocet oral tablet 10-325 mg, 5-325 mg</i> .....	371
DUPIXENT.....	340	ENDOCET ORAL TABLET 2.5-325 MG.....	371
DUROLANE.....	341	<i>endocet oral tablet 7.5-325 mg</i> .....	371
<i>dutasteride</i> .....	342	<i>enoxaparin sodium</i> .....	373
DUZALLO.....	343	ENSTILAR.....	374
DYANAVAL XR.....	344	<i>entecavir</i> .....	375
DYSPORT.....	345	<i>entecavir</i> .....	376
<i>econazole nitrate external</i> .....	346	ENTRESTO.....	377
EDARBI.....	347	ENTYVIO.....	378
EDARBYCLOR.....	348	EPANED ORAL SOLUTION.....	379
EDURANT.....	349	EPCLUSA.....	380
EFFIENT.....	350	<i>epinephrine injection solution auto- injector</i> .....	381
ELAPRASE.....	351	EPIPEN 2-PAK INJECTION SOLUTION AUTO-INJECTOR.....	382
ELELYSO.....	352	EPIPEN JR 2-PAK INJECTION SOLUTION AUTO-INJECTOR.....	383
ELESTRIN.....	353	EPISNAP.....	384
<i>eletriptan hydrobromide</i> .....	354	EPOGEN INJECTION SOLUTION	
ELIDEL.....	355	10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML.....	385
ELIGARD.....	356	<i>epoprostenol sodium</i> .....	386
ELMIRON.....	357		
EMBEDA.....	358		
EMEND ORAL CAPSULE 125 MG, 80 MG.....	360		

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>eprosartan mesylate</i> .....	387	<i>fenofibrate oral capsule</i> .....	423
<i>eq nicotine transdermal</i> .....	388	<i>fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg</i> .....	424
ERIVEDGE.....	389	<i>fenofibric acid oral tablet</i> .....	426
ESBRIET ORAL CAPSULE.....	390	<i>fentanyl</i> .....	427
ESBRIET ORAL TABLET 267 MG.....	391	<i>fentanyl citrate buccal</i> .....	429
ESBRIET ORAL TABLET 801 MG.....	392	FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG.....	431
<i>escitalopram oxalate oral solution</i> .....	393	FERRIPROX.....	433
<i>escitalopram oxalate oral tablet 10 mg</i> ....	394	FETZIMA.....	434
<i>escitalopram oxalate oral tablet 20 mg, 5 mg</i> .....	395	FETZIMA TITRATION.....	436
<i>esomeprazole magnesium oral capsule delayed release 40 mg</i> .....	396	FIASP.....	438
<i>estradiol transdermal patch twice weekly</i> .....	397	FIASP FLEXTOUCH.....	439
<i>estradiol transdermal patch weekly</i> .....	398	FIBRICOR.....	440
<i>estradiol-norethindrone acet</i> .....	399	<i>finasteride oral tablet 5 mg</i> .....	441
ESTROGEL.....	400	FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG.....	442
<i>eszopiclone</i> .....	401	FIRMAGON.....	444
EUFLEXXA INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE.....	402	FLEBOGAMMA DIF.....	445
EVAMIST.....	403	FLOLAN.....	446
EVEKEO.....	404	FLOVENT DISKUS.....	447
EXALGO ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 32 MG.....	405	FLOVENT HFA.....	448
EXJADE.....	407	<i>fluocinonide external cream 0.05 %</i> .....	449
EXTAVIA SUBCUTANEOUS KIT.....	408	<i>fluocinonide external cream 0.1 %</i> .....	450
<i>ezetimibe</i> .....	409	<i>fluocinonide external gel</i> .....	450
<i>ezetimibe-simvastatin</i> .....	410	<i>fluocinonide external ointment</i> .....	450
FABIOR.....	411	<i>fluocinonide external solution</i> .....	450
FABRAZYME.....	412	<i>fluoxetine hcl oral capsule delayed release</i> .....	451
FALESSA ORAL KIT 20-1-0.1 MCG-MG.....	413	<i>fluoxetine hcl oral tablet 20 mg</i> .....	452
<i>famciclovir oral tablet 125 mg, 250 mg</i> ....	414	<i>fluoxetine hcl oral tablet 60 mg</i> .....	453
<i>famciclovir oral tablet 500 mg</i> .....	415	<i>fluticasone-salmeterol</i> .....	454
FANAPT.....	416	<i>fluvastatin sodium</i> .....	455
FANAPT TITRATION PACK.....	417	<i>fluvoxamine maleate er</i> .....	458
FARXIGA.....	418	<i>fluvoxamine maleate oral tablet 100 mg</i> ..	456
FARYDAK.....	419	<i>fluvoxamine maleate oral tablet 25 mg</i> ....	457
FASLODEX INTRAMUSCULAR SOLUTION 250 MG/5ML.....	420	<i>fluvoxamine maleate oral tablet 50 mg</i> ....	457
<i>felodipine er</i> .....	421	FOCALIN XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 20 MG.....	459
FEMRING.....	422		
<i>fenofibrate micronized</i> .....	425		

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

FOCALIN XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 25 MG, 35 MG.....	459	GAMUNEX-C.....	487
FOLLISTIM AQ INJECTION SOLUTION 75 UNT/0.5ML.....	460	<i>ganirelix acetate</i> .....	488
FOLLISTIM AQ SUBCUTANEOUS.. <i>fondaparinux sodium</i> .....	460 461	GATTEX.....	489
FORA D10 2-IN-1 MONITOR.....	462	<i>gavilyte-c</i> .....	490
FORA D15G 2-IN-1 MONITOR.....	463	<i>gavilyte-g</i> .....	491
FORA D20 2-IN-1 MONITOR.....	464	GELNIQUE TRANSDERMAL GEL 10 %.....	492
FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML.....	465	GEL-ONE INTRA-ARTICULAR PREFILLED SYRINGE.....	493
FOSAMAX PLUS D.....	466	GELSYN-3.....	494
FRAGMIN SUBCUTANEOUS SOLUTION 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 2500 UNIT/0.2ML, 5000 UNIT/0.2ML, 7500 UNIT/0.3ML, 95000 UNIT/3.8ML.....	467	GENVISC 850.....	495
FREESTYLE FLASH SYSTEM.....	468	GENVOYA.....	496
FREESTYLE FREEDOM LITE.....	469	GIAZO.....	497
FREESTYLE INSULINX SYSTEM... FREESTYLE INSULINX TEST.....	470 471	GILENYA.....	498
FREESTYLE LITE TEST.....	472	GILOTRIF.....	499
FREESTYLE PRECISION NEO TEST .....	473	GLASSIA.....	500
FREESTYLE SYSTEM.....	474	<i>glatopa</i> .....	501
FREESTYLE TEST.....	475	GLUCAGEN DIAGNOSTIC.....	502
FROVA.....	476	GLUCAGEN HYPOKIT.....	503
<i>frovatriptan succinate</i> .....	477	GLYXAMBI.....	504
FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED.....	478	GONAL-F.....	505
FYCOMPA ORAL TABLET.....	479	GONAL-F RFF.....	506
<i>gabapentin oral capsule</i> .....	480	GONAL-F RFF REDIJECT.....	507
<i>gabapentin oral tablet</i> .....	481	GRALISE ORAL TABLET 300 MG... GRALISE ORAL TABLET 600 MG... GRALISE STARTER.....	508 509 510
GABITRIL ORAL TABLET 12 MG... GABITRIL ORAL TABLET 16 MG... <i>galantamine hydrobromide</i> ..... <i>galantamine hydrobromide er</i> .....	482 483 484 485	GRANIX.....	511
GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/200ML, 20 GM/400ML, 5 GM/100ML.....	486	<i>guanfacine hcl er</i> .....	512
		HAEGARDA.....	513
		<i>halobetasol propionate</i> .....	514
		HARVONI.....	515
		<i>heather</i> .....	516
		HELIXATE FS INTRAVENOUS KIT 3000 UNIT.....	517
		HEMANGEOL.....	518
		HETLIOZ.....	519
		<i>hm nicotine</i> .....	520
		<i>hm nicotine polacrilex mouth/throat lozenge 2 mg</i> .....	521
		HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG.....	522

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



HORIZANT ORAL TABLET		HYMOVIS.....	549
EXTENDED RELEASE 600 MG.....	523	HYQVIA.....	550
HP ACTHAR.....	524	HYSINGLA ER.....	551
HUMIRA PEDIATRIC CROHNS		<i>ibandronate sodium intravenous solution 3</i>	
START SUBCUTANEOUS		<i>mg/3ml.....</i>	553
PREFILLED SYRINGE KIT 40		<i>ibandronate sodium oral.....</i>	554
MG/0.8ML.....	527	IBRANCE.....	555
HUMIRA PEN SUBCUTANEOUS		<i>ibudone oral tablet 5-200 mg.....</i>	556
PEN-INJECTOR KIT.....	528	ICLUSIG ORAL TABLET 15 MG.....	558
HUMIRA PEN-CROHNS STARTER		ICLUSIG ORAL TABLET 45 MG.....	559
SUBCUTANEOUS PEN-INJECTOR		IDELVION.....	560
KIT.....	529	IDHIFA.....	561
HUMIRA PEN-PSORIASIS		ILARIS.....	562
STARTER SUBCUTANEOUS PEN-		ILARIS (150MG DELIVERED).....	563
INJECTOR KIT.....	530	<i>imatinib mesylate oral tablet 100 mg.....</i>	564
HUMIRA SUBCUTANEOUS		<i>imatinib mesylate oral tablet 400 mg.....</i>	565
PREFILLED SYRINGE KIT 10		IMBRUVICA.....	566
MG/0.2ML, 20 MG/0.4ML.....	525	<i>imiquimod external.....</i>	567
HUMIRA SUBCUTANEOUS		IMITREX NASAL SOLUTION 20	
PREFILLED SYRINGE KIT 40		MG/ACT.....	568
MG/0.8ML.....	526	IMITREX NASAL SOLUTION 5	
HUMULIN 70/30.....	531	MG/ACT.....	569
HUMULIN N.....	532	IMITREX STATDOSE SYSTEM	
HYALGAN.....	533	SUBCUTANEOUS SOLUTION	
HYCAMTIN ORAL.....	534	AUTO-INJECTOR 6 MG/0.5ML.....	570
<i>hydrocodone-acetaminophen oral solution</i>		IMPAVIDO.....	571
<i>2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325</i>		INCRELEX.....	572
<i>mg/15ml.....</i>	535	INDERAL XL ORAL CAPSULE	
<i>hydrocodone-acetaminophen oral tablet</i>		EXTENDED RELEASE 24 HOUR 80	
<i>10-300 mg, 10-325 mg, 2.5-325 mg, 5-300</i>		MG.....	573
<i>mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg....</i>	537	<i>indomethacin oral.....</i>	574
<i>hydrocodone-ibuprofen oral tablet 10-200</i>		INFLECTRA.....	575
<i>mg.....</i>	539	INGREZZA ORAL CAPSULE 40 MG.....	576
<i>hydrocodone-ibuprofen oral tablet 5-200</i>		INGREZZA ORAL CAPSULE 80 MG.....	577
<i>mg, 7.5-200 mg.....</i>	539	INLYTA.....	578
<i>hydromorphone hcl er oral tablet er 24</i>		INNOPRAN XL ORAL CAPSULE	
<i>hour abuse-deterrent 12 mg, 32 mg, 8 mg</i>	545	EXTENDED RELEASE 24 HOUR 120	
<i>hydromorphone hcl er oral tablet er 24</i>		MG.....	579
<i>hour abuse-deterrent 16 mg.....</i>	547	INNOPRAN XL ORAL CAPSULE	
<i>hydromorphone hcl oral liquid.....</i>	541	EXTENDED RELEASE 24 HOUR 80	
<i>hydromorphone hcl oral tablet.....</i>	543	MG.....	580
<i>hydromorphone hcl rectal.....</i>	541		

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

INTELENCE ORAL TABLET 100 MG, 25 MG.....	581	<i>jinteli</i> .....	611
INTELENCE ORAL TABLET 200 MG .....	582	<i>jolivette</i> .....	612
INTRAROSA.....	583	JUBLIA.....	613
INTRON A.....	584	JUXTAPID.....	615
INVOKAMET.....	585	KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 200 MG, 40 MG.....	616
INVOKAMET XR.....	586	KALBITOR.....	618
INVOKANA.....	587	KALYDECO.....	619
<i>ipratropium bromide nasal</i> .....	588	KALYDECO.....	620
IPRIVASK.....	589	KANUMA.....	621
<i>irbesartan</i> .....	590	KAZANO.....	622
<i>irbesartan-hydrochlorothiazide</i> .....	591	KEPIVANCE.....	623
IRESSA.....	592	KERYDIN.....	624
ISENTRESS HD.....	595	<i>ketoconazole oral</i> .....	626
ISENTRESS ORAL TABLET.....	593	<i>ketorolac tromethamine ophthalmic</i> .....	627
ISENTRESS ORAL TABLET CHEWABLE.....	594	<i>ketorolac tromethamine oral</i> .....	628
<i>itraconazole oral</i> .....	596	KEVEYIS.....	629
IXINITY.....	597	KEVZARA.....	630
JADENU.....	598	KHEDEZLA.....	631
JADENU SPRINKLE.....	599	KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	633
JAKAFI.....	600	KISQALI 200 DOSE.....	634
JANUMET.....	601	KISQALI 400 DOSE.....	635
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-500 MG.....	602	KISQALI 600 DOSE.....	636
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50- 1000 MG.....	603	KISQALI FEMARA 200 DOSE.....	637
JANUVIA.....	604	KISQALI FEMARA 400 DOSE.....	638
JARDIANCE.....	605	KISQALI FEMARA 600 DOSE.....	639
JENTADUETO.....	606	KOGENATE FS BIO-SET INTRAVENOUS KIT 3000 UNIT.....	641
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5- 1000 MG.....	607	KOGENATE FS INTRAVENOUS KIT 3000 UNIT.....	640
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5- 1000 MG.....	608	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5- 1000 MG.....	642
JETREA INTRAVITREAL SOLUTION 0.375 MG/0.3ML.....	609	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5- 1000 MG, 5-500 MG.....	643
JEVTANA.....	610	KORLYM.....	644
		KROGER BLOOD GLUCOSE KIT W/DEVICE.....	645

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

KROGER PREMIUM BLOOD	
GLUCOSE.....	646
KRYSTEXXA.....	647
KUVAN.....	648
KYNAMRO SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE.	649
<i>lamotrigine er oral tablet extended release</i>	
<i>24 hour 100 mg, 25 mg.....</i>	653
<i>lamotrigine er oral tablet extended release</i>	
<i>24 hour 200 mg.....</i>	654
<i>lamotrigine er oral tablet extended release</i>	
<i>24 hour 250 mg, 300 mg.....</i>	655
<i>lamotrigine er oral tablet extended release</i>	
<i>24 hour 50 mg.....</i>	656
<i>lamotrigine oral tablet dispersible 100 mg,</i>	
<i>200 mg.....</i>	650
<i>lamotrigine oral tablet dispersible 25 mg.</i>	651
<i>lamotrigine oral tablet dispersible 50 mg.</i>	652
LANTUS.....	657
LANTUS SOLOSTAR	
SUBCUTANEOUS SOLUTION PEN-	
INJECTOR.....	658
LARIN FE 1.5/30.....	659
LATUDA ORAL TABLET 120 MG, 20	
MG, 40 MG.....	660
LATUDA ORAL TABLET 60 MG.....	661
LATUDA ORAL TABLET 80 MG.....	662
LAZANDA NASAL SOLUTION 100	
MCG/ACT, 400 MCG/ACT.....	663
LAZANDA NASAL SOLUTION 300	
MCG/ACT.....	665
<i>leflunomide oral.....</i>	667
LEMTRADA.....	668
LENVIMA 10 MG DAILY DOSE.....	669
LENVIMA 14 MG DAILY DOSE.....	670
LENVIMA 18 MG DAILY DOSE.....	671
LENVIMA 20 MG DAILY DOSE.....	672
LENVIMA 24 MG DAILY DOSE.....	673
LENVIMA 8 MG DAILY DOSE.....	674
LETAIRIS.....	675
LEUKINE INTRAVENOUS.....	676
<i>leuprolide acetate injection.....</i>	677
<i>levetiracetam er oral tablet extended</i>	
<i>release 24 hour 500 mg.....</i>	678
<i>levetiracetam er oral tablet extended</i>	
<i>release 24 hour 750 mg.....</i>	679
<i>levorphanol tartrate oral.....</i>	680
LEVULAN KERASTICK.....	682
LIALDA.....	683
<i>lidocaine external ointment.....</i>	684
<i>lidocaine external patch 5 %.....</i>	686
<i>lidocaine pak.....</i>	687
<i>lidocaine-prilocaine external cream.....</i>	688
<i>lidocaine-tetracaine.....</i>	690
<i>linezolid oral suspension reconstituted.....</i>	691
<i>linezolid oral tablet.....</i>	692
LINZESS.....	693
LINZESS.....	694
LIPOFEN.....	695
LIVALO.....	696
LONSURF ORAL TABLET 15-6.14	
MG.....	697
LONSURF ORAL TABLET 20-8.19	
MG.....	698
LORCET.....	699
LORCET HD.....	701
LORCET PLUS ORAL TABLET 7.5-	
325 MG.....	703
<i>losartan potassium oral tablet 25 mg, 50</i>	
<i>mg.....</i>	705
<i>lovastatin.....</i>	706
LUCENTIS INTRAVITREAL	
SOLUTION PREFILLED SYRINGE.	707
LUMIGAN OPHTHALMIC	
SOLUTION 0.01 %.....	708
LUMIZYME.....	709
LUPANETA PACK.....	710
LUPRON DEPOT (1-MONTH).....	711
LUPRON DEPOT (3-MONTH).....	712
LUPRON DEPOT (4-MONTH).....	713
LUPRON DEPOT (6-MONTH).....	714
LUPRON DEPOT-PED (1-MONTH)..	715
LUPRON DEPOT-PED (3-MONTH)..	716
LYNPARZA ORAL CAPSULE.....	717

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update



LYNPARZA ORAL TABLET.....	718	<i>methylphenidate hcl er (la) oral capsule</i>	
LYZA.....	719	<i>extended release 24 hour 60 mg.....</i>	771
MACUGEN.....	720	<i>methylphenidate hcl er oral tablet</i>	
MAKENA.....	721	<i>extended release 10 mg.....</i>	762
<i>maprotiline hcl.....</i>	<i>722</i>	<i>methylphenidate hcl er oral tablet</i>	
<i>matzim la oral tablet extended release 24</i>		<i>extended release 18 mg, 27 mg, 54 mg.....</i>	<i>763</i>
<i>hour 180 mg, 300 mg, 360 mg.....</i>	<i>723</i>	<i>methylphenidate hcl er oral tablet</i>	
<i>matzim la oral tablet extended release 24</i>		<i>extended release 20 mg.....</i>	<i>764</i>
<i>hour 240 mg.....</i>	<i>724</i>	<i>methylphenidate hcl er oral tablet</i>	
MAVYRET.....	725	<i>extended release 24 hour 18 mg, 27 mg,</i>	
MEIJER BLOOD GLUCOSE.....	726	<i>54 mg.....</i>	<i>766</i>
MEIJER PREMIUM BLOOD		<i>methylphenidate hcl er oral tablet</i>	
GLUCOSE.....	727	<i>extended release 24 hour 36 mg.....</i>	<i>767</i>
MEKINIST ORAL TABLET 0.5 MG..	728	<i>methylphenidate hcl er oral tablet</i>	
MEKINIST ORAL TABLET 2 MG.....	729	<i>extended release 36 mg.....</i>	<i>765</i>
<i>memantine hcl oral tablet 10 mg, 5 mg....</i>	<i>730</i>	<i>methylphenidate hcl oral solution 10</i>	
MENOPUR.....	731	<i>mg/5ml.....</i>	<i>759</i>
MENOSTAR.....	732	<i>methylphenidate hcl oral solution 5</i>	
<i>meperidine hcl oral solution.....</i>	<i>733</i>	<i>mg/5ml.....</i>	<i>760</i>
<i>meperidine hcl oral tablet.....</i>	<i>735</i>	<i>methylphenidate hcl oral tablet.....</i>	<i>761</i>
MEPHYTON.....	737	<i>metoprolol succinate er oral tablet</i>	
<i>mesalamine oral tablet delayed release 1.2</i>		<i>extended release 24 hour 100 mg, 50 mg..</i>	<i>772</i>
<i>gm.....</i>	<i>738</i>	<i>metoprolol succinate er oral tablet</i>	
<i>mesalamine oral tablet delayed release</i>		<i>extended release 24 hour 200 mg.....</i>	<i>773</i>
<i>800 mg.....</i>	<i>739</i>	<i>metoprolol succinate er oral tablet</i>	
METADATE ER ORAL TABLET		<i>extended release 24 hour 25 mg.....</i>	<i>774</i>
EXTENDED RELEASE 20 MG.....	740	MIACALCIN INJECTION.....	775
<i>metaxalone oral tablet 400 mg.....</i>	<i>741</i>	<i>mimvey.....</i>	<i>776</i>
<i>methadone hcl intensol.....</i>	<i>754</i>	MIRCERA INJECTION SOLUTION	
<i>methadone hcl oral concentrate.....</i>	<i>742</i>	PREFILLED SYRINGE.....	777
<i>methadone hcl oral solution 10 mg/5ml....</i>	<i>745</i>	<i>mirtazapine oral.....</i>	<i>778</i>
<i>methadone hcl oral solution 5 mg/5ml.....</i>	<i>748</i>	MITIGARE.....	779
<i>methadone hcl oral tablet.....</i>	<i>751</i>	<i>modafinil oral tablet 100 mg.....</i>	<i>780</i>
<i>methamphetamine hcl.....</i>	<i>757</i>	<i>modafinil oral tablet 200 mg.....</i>	<i>782</i>
METHERGINE ORAL.....	758	MONONINE INTRAVENOUS	
<i>methylphenidate hcl er (cd).....</i>	<i>768</i>	SOLUTION RECONSTITUTED 1000	
<i>methylphenidate hcl er (la) oral capsule</i>		UNIT.....	784
<i>extended release 24 hour 20 mg.....</i>	<i>769</i>	MONOVISC.....	785
<i>methylphenidate hcl er (la) oral capsule</i>		<i>montelukast sodium oral.....</i>	<i>786</i>
<i>extended release 24 hour 30 mg.....</i>	<i>770</i>	<i>montelukast sodium oral.....</i>	<i>787</i>
<i>methylphenidate hcl er (la) oral capsule</i>		MORPHABOND ER.....	788
<i>extended release 24 hour 40 mg.....</i>	<i>769</i>		

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>morphine sulfate (concentrate) oral solution 100 mg/5ml, 20 mg/ml</i>	794
<i>morphine sulfate er beads</i>	802
<i>morphine sulfate er oral capsule extended release 24 hour</i>	796
<i>morphine sulfate er oral tablet extended release 100 mg, 30 mg, 60 mg</i>	798
<i>morphine sulfate er oral tablet extended release 15 mg, 200 mg</i>	800
<i>morphine sulfate oral solution</i>	790
<i>morphine sulfate oral tablet</i>	792
<i>morphine sulfate rectal</i>	790
MOZOBIL	804
MULTAQ	805
<i>mupirocin calcium</i>	807
<i>mupirocin external</i>	806
MYALEPT	808
MYDAYIS	809
MYOBLOC INTRAMUSCULAR SOLUTION 2500 UNIT/0.5ML, 5000 UNIT/ML	810
<i>myorisan oral capsule 10 mg, 20 mg, 40 mg</i>	811
MYORISAN ORAL CAPSULE 30 MG	811
MYRBETRIQ	812
MYTESI	813
<i>myzilra</i>	814
NAGLAZYME	815
NAMENDA XR	816
NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK	817
NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 28-10 MG	818
<i>naratriptan hcl</i>	819
NASONEX	820
NATPARA	821
NERLYNX	822
NESINA	823
NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	824

NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML	825
NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE	825
NEUPRO	826
NEUTEK 2TEK GLUCOSE/PRESSURE	827
<i>nevirapine er oral tablet extended release 24 hour 100 mg</i>	828
<i>nevirapine er oral tablet extended release 24 hour 400 mg</i>	829
NEXAVAR	830
NEXIUM 24HR	832
NEXIUM ORAL PACKET	831
NEXPLANON	833
<i>next choice one dose</i>	834
NICODERM CQ	835
<i>nicorelief mouth/throat gum</i>	836
NICORETTE MOUTH/THROAT GUM	837
<i>nicotine step 1</i>	839
<i>nicotine step 2</i>	840
<i>nicotine step 3</i>	841
<i>nicotine transdermal patch 24 hour</i>	838
NICOTROL	842
NICOTROL NS	843
<i>nifediac cc oral tablet extended release 24 hour 30 mg</i>	844
<i>nifedical xl oral tablet extended release 24 hour 60 mg</i>	845
<i>nifedipine er oral tablet extended release 24 hour 30 mg, 90 mg</i>	846
<i>nifedipine er oral tablet extended release 24 hour 60 mg</i>	847
<i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 90 mg</i>	848
<i>nifedipine er osmotic release oral tablet extended release 24 hour 60 mg</i>	849
NIKKI	850
NINLARO	851

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
 Last Update 12/2017  
 Next Update

<i>nisoldipine er oral tablet extended release</i> 24 hour 17 mg, 20 mg, 25.5 mg, 34 mg, 40 mg, 8.5 mg.....	852	NUTROPIN AQ NUSPIN 20.....	883
<i>nisoldipine er oral tablet extended release</i> 24 hour 30 mg.....	853	NUTROPIN AQ NUSPIN 5.....	884
<i>nitroglycerin translingual solution</i> .....	854	NUVARING.....	885
NITROSTAT.....	855	NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG.....	886
NITYR.....	856	NUVIGIL ORAL TABLET 50 MG.....	888
<i>nora-be</i> .....	857	NYMALIZE ORAL SOLUTION 60 MG/20ML.....	890
NORDITROPIN FLEXPRO.....	858	OCALIVA ORAL TABLET 5 MG.....	891
NORLYROC.....	859	OCTAGAM.....	892
NORTHERA ORAL CAPSULE 100 MG.....	860	<i>octreotide acetate injection solution 100</i> <i>mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50</i> <i>mcg/ml, 500 mcg/ml</i> .....	893
NORTHERA ORAL CAPSULE 200 MG, 300 MG.....	861	ODEFSEY.....	894
<i>novarel intramuscular solution</i> <i>reconstituted 10000 unit</i> .....	862	ODOMZO.....	895
NOVOLIN 70/30.....	863	OFEV.....	896
NOVOLIN 70/30 RELION.....	864	<i>olanzapine oral tablet 10 mg, 15 mg, 20</i> <i>mg, 5 mg, 7.5 mg</i> .....	897
NOVOLIN N.....	865	<i>olanzapine oral tablet 2.5 mg</i> .....	898
NOVOLIN N RELION.....	866	<i>olanzapine oral tablet dispersible</i> .....	897
NOVOLIN R.....	867	<i>olanzapine-fluoxetine hcl</i> .....	899
NOVOLIN R RELION.....	868	<i>olmesartan medoxomil oral</i> .....	900
NOVOLOG.....	869	<i>olmesartan medoxomil-hctz</i> .....	901
NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	870	<i>olmesartan-amlodipine-hctz</i> .....	902
NOVOLOG MIX 70/30.....	871	OLYSIO.....	903
NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR.....	872	<i>omega-3-acid ethyl esters</i> .....	904
NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE.....	873	OMNARIS.....	905
NOXAFIL ORAL TABLET DELAYED RELEASE.....	874	OMNITROPE.....	906
NUCALA.....	875	ONETOUCH ULTRA 2.....	907
NUCYNTA.....	876	ONETOUCH ULTRA BLUE.....	908
NUCYNTA ER.....	878	ONETOUCH ULTRA MINI.....	909
NUDEXTA.....	880	ONETOUCH VERIO IN VITRO STRIP.....	910
NUPLAZID.....	881	ONETOUCH VERIO IQ SYSTEM.....	911
NUTROPIN AQ NUSPIN 10.....	882	ONFI ORAL TABLET 10 MG, 20 MG.....	912
		ONGLYZA.....	913
		ONZETRA XSAIL.....	914
		OPANA ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT.....	915
		OPANA ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT.....	917
		OPSUMIT.....	919

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

ORAVIG.....	920	<i>oxycodone hcl er oral tablet er 12 hour</i>	
ORENCIA CLICKJECT.....	924	<i>abuse-deterrent 10 mg, 20 mg, 40 mg, 80</i>	
ORENCIA INTRAVENOUS.....	921	<i>mg.....</i>	950
ORENCIA SUBCUTANEOUS		<i>oxycodone hcl er oral tablet er 12 hour</i>	
SOLUTION PREFILLED SYRINGE		<i>abuse-deterrent 15 mg, 30 mg, 60 mg.....</i>	952
125 MG/ML.....	922	<i>oxycodone hcl oral capsule.....</i>	944
ORENCIA SUBCUTANEOUS		<i>oxycodone hcl oral concentrate 100</i>	
SOLUTION PREFILLED SYRINGE		<i>mg/5ml.....</i>	946
50 MG/0.4ML, 87.5 MG/0.7ML.....	923	<i>oxycodone hcl oral solution.....</i>	946
ORENITRAM.....	925	<i>oxycodone hcl oral tablet.....</i>	948
ORFADIN.....	926	<i>oxycodone-acetaminophen oral solution..</i>	954
ORKAMBI.....	927	<i>oxycodone-acetaminophen oral tablet 10-</i>	
ORKAMBI.....	928	<i>325 mg, 2.5-325 mg, 5-325 mg, 7.5-325</i>	
ORTHOVISC INTRA-ARTICULAR		<i>mg.....</i>	956
SOLUTION PREFILLED SYRINGE.	929	<i>oxycodone-aspirin oral tablet 4.8355-325</i>	
<i>oseltamivir phosphate oral capsule.....</i>	930	<i>mg.....</i>	958
OSENI.....	931	<i>oxycodone-ibuprofen.....</i>	960
OSPHENA.....	932	<b>OXYCONTIN ORAL TABLET ER 12</b>	
OTEZLA ORAL TABLET.....	933	<b>HOUR ABUSE-DETERRENT.....</b>	962
OTEZLA ORAL TABLET THERAPY		<i>oxymorphone hcl.....</i>	964
PACK.....	934	<i>oxymorphone hcl er.....</i>	966
OTREXUP SUBCUTANEOUS		<i>paliperidone er oral tablet extended</i>	
SOLUTION AUTO-INJECTOR 10		<i>release 24 hour 1.5 mg, 3 mg, 6 mg.....</i>	968
MG/0.4ML, 12.5 MG/0.4ML, 15		<i>paliperidone er oral tablet extended</i>	
MG/0.4ML, 17.5 MG/0.4ML, 20		<i>release 24 hour 9 mg.....</i>	969
MG/0.4ML, 22.5 MG/0.4ML, 25		<b>PANCREAZE.....</b>	970
MG/0.4ML.....	935	<i>paricalcitol oral.....</i>	971
OVIDREL.....	936	<i>paroxetine hcl er oral tablet extended</i>	
OXAYDO.....	937	<i>release 24 hour 12.5 mg, 37.5 mg.....</i>	974
OXTELLAR XR ORAL TABLET		<i>paroxetine hcl er oral tablet extended</i>	
EXTENDED RELEASE 24 HOUR 150		<i>release 24 hour 25 mg.....</i>	975
MG, 300 MG.....	939	<i>paroxetine hcl oral tablet 10 mg, 20 mg...</i>	972
OXTELLAR XR ORAL TABLET		<i>paroxetine hcl oral tablet 30 mg, 40 mg...</i>	973
EXTENDED RELEASE 24 HOUR 600		<i>paroxetine mesylate.....</i>	976
MG.....	940	<b>PAXIL ORAL SUSPENSION.....</b>	977
<i>oxybutynin chloride er oral tablet</i>		<i>peg 3350/electrolytes.....</i>	978
<i>extended release 24 hour 10 mg, 15 mg....</i>	942	<i>peg-3350/electrolytes.....</i>	979
<i>oxybutynin chloride er oral tablet</i>		<b>PEGASYS PROCLICK.....</b>	981
<i>extended release 24 hour 5 mg.....</i>	943	<b>PEGASYS SUBCUTANEOUS</b>	
<i>oxybutynin chloride oral tablet.....</i>	941	<b>SOLUTION.....</b>	980
		<b>PEGINTRON.....</b>	982

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

PENTASA ORAL CAPSULE EXTENDED RELEASE 250 MG.....	983	<i>pregnyl</i> .....	1014
PENTASA ORAL CAPSULE EXTENDED RELEASE 500 MG.....	984	PREMARIN ORAL.....	1015
<i>pentazocine-naloxone hcl</i> .....	985	PREMPHASE.....	1016
PERFOROMIST.....	987	PREMPRO.....	1017
PERTZYE.....	988	PREVACID SOLUTAB.....	1018
<i>phenoxybenzamine hcl oral</i> .....	989	PREZISTA ORAL SUSPENSION.....	1020
PICATO EXTERNAL GEL 0.015 %.....	990	PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG.....	1021
PICATO EXTERNAL GEL 0.05 %.....	991	PREZISTA ORAL TABLET 800 MG	1022
<i>pioglitazone hcl</i> .....	992	PRILOSEC OTC.....	1023
<i>pioglitazone hcl-glimepiride</i> .....	993	PRIMLEV.....	1024
<i>pioglitazone hcl-metformin hcl</i> .....	994	PRISTIQ.....	1026
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	997	PROCRIT.....	1028
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION		PROCYSBI ORAL CAPSULE DELAYED RELEASE 25 MG.....	1029
PREFILLED SYRINGE.....	998	PROCYSBI ORAL CAPSULE DELAYED RELEASE 75 MG.....	1030
PLEGRIDY SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	995	PRODIGY AUTOCODE BLOOD GLUCOSE KIT.....	1031
PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.	996	<i>progesterone micronized oral</i> .....	1032
PLEXION CLEANSING CLOTH EXTERNAL PAD.....	999	PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG.....	1033
POMALYST.....	1000	PROLIA.....	1034
PRADAXA.....	1001	PROMACTA.....	1035
PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	1002	PROMACTA.....	1036
<i>pramipexole dihydrochloride er</i> .....	1003	<i>propafenone hcl er</i> .....	1037
<i>pramipexole dihydrochloride er</i> .....	1004	PROVENTIL HFA.....	1038
<i>prasugrel hcl</i> .....	1005	PRUDOXIN.....	1039
<i>pravastatin sodium</i> .....	1006	PULMICORT FLEXHALER.....	1040
PRECISION PCX.....	1007	PULMOZYME.....	1041
PRECISION PCX PLUS TEST.....	1008	PURIXAN.....	1042
PRECISION POINT OF CARE TEST .....	1009	QBRELIS.....	1043
PRECISION QID TEST.....	1010	QNASL.....	1044
PRECISION SOF-TACT TEST.....	1011	QNASL CHILDRENS.....	1045
PRECISION XTRA BLOOD GLUCOSE.....	1012	QUDEXY XR ORAL CAPSULE ER 24 HOUR SPRINKLE 100 MG, 25 MG, 50 MG.....	1046
PREFEST.....	1013	QUDEXY XR ORAL CAPSULE ER 24 HOUR SPRINKLE 150 MG, 200 MG.....	1047

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



<i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg</i> .....	1052	REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	1070
<i>quetiapine fumarate er oral tablet extended release 24 hour 300 mg</i> .....	1053	REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	1068
<i>quetiapine fumarate er oral tablet extended release 24 hour 400 mg</i> .....	1054	REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	1071
<i>quetiapine fumarate er oral tablet extended release 24 hour 50 mg</i> .....	1055	RECTIV.....	1072
<i>quetiapine fumarate oral tablet 100 mg, 50 mg</i> .....	1048	REGANEX.....	1073
<i>quetiapine fumarate oral tablet 200 mg</i> ..	1049	RELENZA DISKHALER.....	1074
<i>quetiapine fumarate oral tablet 25 mg</i> ...	1050	RELISTOR ORAL.....	1075
<i>quetiapine fumarate oral tablet 300 mg, 400 mg</i> .....	1051	RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML.....	1076
QUILLICHEW ER ORAL TABLET CHEWABLE EXTENDED RELEASE 20 MG, 40 MG.....	1056	RELISTOR SUBCUTANEOUS SOLUTION 8 MG/0.4ML.....	1077
QUILLICHEW ER ORAL TABLET CHEWABLE EXTENDED RELEASE 30 MG.....	1057	RELPAK.....	1078
QUILLIVANT XR.....	1058	REMICADE.....	1079
<i>ra nicotine transdermal</i> .....	1059	REMODULIN.....	1080
<i>rabeprazole sodium</i> .....	1060	<i>repaglinide-metformin hcl</i> .....	1081
RANEXA.....	1061	REPATHA.....	1082
<i>rasagiline mesylate oral</i> .....	1062	REPATHA PUSHTRONEX SYSTEM .....	1083
RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML.....	1063	REPATHA SURECLICK.....	1084
RAVICTI.....	1064	RESCULA.....	1085
RAYALDEE.....	1065	RETIN-A MICRO PUMP EXTERNAL GEL 0.08 %.....	1086
RAYOS.....	1066	REVATIO INTRAVENOUS.....	1088
REBETOL ORAL SOLUTION.....	1067	REVATIO ORAL SUSPENSION RECONSTITUTED.....	1089
REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	1069	REVLIMID.....	1090
		REXULTI.....	1091
		REYATAZ ORAL CAPSULE 150 MG .....	1092
		REYATAZ ORAL CAPSULE 200 MG .....	1093
		REYATAZ ORAL CAPSULE 300 MG .....	1092
		RHOFADE.....	1094
		<i>riluzole</i> .....	1095
		<i>risedronate sodium oral tablet 150 mg</i> ...	1096

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

<i>risedronate sodium oral tablet 30 mg, 5 mg</i> .....	1097	SAMSCA ORAL TABLET 30 MG.....	1122
<i>risedronate sodium oral tablet 35 mg</i> .....	1098	SANCUSO.....	1123
<i>risedronate sodium oral tablet delayed release</i> .....	1098	SANDOSTATIN LAR DEPOT.....	1124
RISPERIDONE M-TAB ORAL TABLET DISPERSIBLE 0.5 MG, 1 MG, 2 MG.....	1102	SANTYL.....	1125
RISPERIDONE M-TAB ORAL TABLET DISPERSIBLE 3 MG.....	1103	SAPHRIS.....	1126
RISPERIDONE M-TAB ORAL TABLET DISPERSIBLE 4 MG.....	1104	SAVAYSA.....	1127
<i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> .....	1099	SAVELLA.....	1128
<i>risperidone oral tablet 3 mg</i> .....	1100	SAVELLA TITRATION PACK.....	1129
<i>risperidone oral tablet 4 mg</i> .....	1101	SEEBRI NEOHALER.....	1130
<i>risperidone oral tablet dispersible 0.5 mg</i> .....	1099	SELZENTRY ORAL SOLUTION.....	1131
<i>risperidone oral tablet dispersible 1 mg, 2 mg</i> .....	1099	SELZENTRY ORAL TABLET 150 MG.....	1132
<i>risperidone oral tablet dispersible 3 mg..</i>	1100	SELZENTRY ORAL TABLET 25 MG.....	1133
<i>risperidone oral tablet dispersible 4 mg..</i>	1101	SELZENTRY ORAL TABLET 75 MG.....	1132
RITUXAN INTRAVENOUS SOLUTION.....	1105	SENSIPAR.....	1134
<i>rivastigmine</i> .....	1106	SEREVENT DISKUS.....	1135
<i>rivastigmine tartrate</i> .....	1107	SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 200 MG.....	1136
RIXUBIS.....	1108	SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 300 MG, 400 MG, 50 MG.....	1138
<i>rizatriptan benzoate</i> .....	1109	SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG.....	1140
<i>ropinirole hcl er oral tablet extended release 24 hour 12 mg</i> .....	1110	<i>sertraline hcl oral tablet 100 mg</i> .....	1141
<i>ropinirole hcl er oral tablet extended release 24 hour 2 mg, 4 mg, 6 mg, 8 mg.</i>	1111	<i>sertraline hcl oral tablet 25 mg</i> .....	1142
<i>rosuvastatin calcium</i> .....	1112	<i>sertraline hcl oral tablet 50 mg</i> .....	1143
ROZEREM.....	1113	SHAROBEL.....	1144
RUBRACA.....	1114	SIGNIFOR.....	1145
RUCONEST.....	1115	<i>sildenafil citrate oral</i> .....	1146
RYDAPT.....	1116	SILIQ.....	1147
SABRIL.....	1117	SIMPONI ARIA.....	1149
SABRIL.....	1118	SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	1148
SAIZEN.....	1119	SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	1148
SAIZEN CLICK.EASY.....	1120	<i>simvastatin oral</i> .....	1150
SAMSCA ORAL TABLET 15 MG.....	1121	SIRTURO.....	1151
		SIVEXTRO ORAL.....	1152

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

SKYLA.....	1153	<i>sumatriptan succinate subcutaneous</i>	
<i>sm nicotine transdermal</i> .....	1154	<i>solution 6 mg/0.5ml</i> .....	1184
<i>sodium phenylbutyrate oral powder 3</i>		<i>sumatriptan succinate subcutaneous</i>	
<i>gmltsp</i> .....	1155	<i>solution auto-injector 4 mg/0.5ml</i> .....	1185
<i>sodium phenylbutyrate oral tablet</i> .....	1155	<i>sumatriptan succinate subcutaneous</i>	
<i>solia</i> .....	1156	<i>solution auto-injector 6 mg/0.5ml</i> .....	1186
SOLQUA.....	1157	SUPARTZ FX.....	1189
SOMATULINE DEPOT.....	1158	SUPARTZ INTRA-ARTICULAR	
SOMAVERT.....	1159	SOLUTION PREFILLED SYRINGE	1188
SOOLANTRA.....	1160	SUPPRELIN LA.....	1190
SOVALDI.....	1161	SUTENT ORAL CAPSULE 12.5 MG	1191
SPIRIVA HANDIHALER.....	1162	SUTENT ORAL CAPSULE 25 MG...	1192
SPIRIVA RESPIMAT.....	1163	SUTENT ORAL CAPSULE 37.5 MG,	
SPRITAM.....	1164	50 MG.....	1193
SPRYCEL ORAL TABLET 100 MG,		SYLATRON SUBCUTANEOUS KIT	
140 MG.....	1165	200 MCG, 300 MCG, 600 MCG.....	1194
SPRYCEL ORAL TABLET 20 MG, 50		SYMBICORT.....	1195
MG, 70 MG, 80 MG.....	1166	SYMLINPEN 120 SUBCUTANEOUS	
STELARA INTRAVENOUS.....	1167	SOLUTION PEN-INJECTOR.....	1196
STELARA SUBCUTANEOUS		SYMLINPEN 60 SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE	1168	SOLUTION PEN-INJECTOR.....	1197
STIOLTO RESPIMAT.....	1169	SYMPROIC.....	1198
STIVARGA.....	1170	SYNAGIS.....	1199
STRATTERA ORAL CAPSULE 10		SYNALGOS-DC.....	1200
MG, 18 MG, 25 MG, 40 MG, 60 MG.	1171	SYNAREL.....	1202
STRATTERA ORAL CAPSULE 100		SYNERA.....	1203
MG, 80 MG.....	1172	SYNJARDY.....	1204
STRENSIQ.....	1173	SYNJARDY XR ORAL TABLET	
STRIBILD.....	1174	EXTENDED RELEASE 24 HOUR 10-	
STRIVERDI RESPIMAT.....	1175	1000 MG, 12.5-1000 MG, 5-1000 MG.	1205
SUBOXONE SUBLINGUAL FILM		SYNJARDY XR ORAL TABLET	
12-3 MG.....	1176	EXTENDED RELEASE 24 HOUR 25-	
SUBOXONE SUBLINGUAL FILM 2-		1000 MG.....	1206
0.5 MG, 4-1 MG, 8-2 MG.....	1177	SYNRIBO.....	1207
SUBSYS.....	1178	SYNVISC INTRA-ARTICULAR	
<i>sulfasalazine oral</i> .....	1180	SOLUTION PREFILLED SYRINGE	1208
<i>sulfazine</i> .....	1181	SYNVISC ONE INTRA-ARTICULAR	
<i>sumatriptan nasal</i> .....	1182	SOLUTION PREFILLED SYRINGE	1209
<i>sumatriptan succinate oral</i> .....	1183	SYPRINE.....	1210
<i>sumatriptan succinate refill subcutaneous</i>		TACLONEX EXTERNAL	
<i>solution cartridge</i> .....	1187	SUSPENSION.....	1211
		<i>tacrolimus external</i> .....	1212

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update



TAFINLAR.....	1214	tetrabenazine oral tablet 12.5 mg.....	1248
TAGRISSO.....	1215	tetrabenazine oral tablet 25 mg.....	1249
take action.....	1216	TGT BLOOD GLUCOSE	
TALTZ.....	1217	MONITORING.....	1250
TAMIFLU ORAL CAPSULE.....	1218	tgt nicotine step one.....	1251
TAMIFLU ORAL SUSPENSION		tgt nicotine step three.....	1252
RECONSTITUTED 6 MG/ML.....	1219	tgt nicotine step two.....	1253
TANZEUM.....	1220	THALOMID.....	1254
TARCEVA.....	1221	THIOLA.....	1255
TARGRETIN EXTERNAL.....	1222	thrive mouth/throat gum 2 mg.....	1256
TASIGNA.....	1223	tiagabine hcl oral tablet 2 mg.....	1257
tazarotene external.....	1224	tiagabine hcl oral tablet 4 mg.....	1258
TAZORAC.....	1225	TIROSINT.....	1259
taztia xt oral capsule extended release 24		TIVICAY.....	1260
hour 120 mg, 180 mg, 300 mg, 360 mg...	1226	TIVICAY.....	1261
taztia xt oral capsule extended release 24		TIVORBEX.....	1262
hour 240 mg.....	1227	TOBI PODHALER.....	1263
TECFIDERA.....	1228	tobramycin inhalation.....	1264
TECFIDERA.....	1229	tolterodine tartrate er.....	1265
TECHNIVIE.....	1230	TOUJEO SOLOSTAR.....	1266
TEKTURNA.....	1231	TOVIAZ.....	1267
TEKTURNA HCT.....	1232	TRACLEER.....	1268
telmisartan.....	1233	TRADJENTA.....	1269
telmisartan-amlodipine.....	1234	tramadol hcl er (biphasic).....	1274
telmisartan-hctz.....	1235	tramadol hcl er oral tablet extended	
temazepam oral capsule 22.5 mg, 7.5 mg		release 24 hour.....	1272
.....	1236	tramadol hcl oral.....	1270
TEMOVATE EXTERNAL CREAM.....	1237	tramadol-acetaminophen.....	1276
temozolomide.....	1238	tranexamic acid oral.....	1278
testosterone cypionate intramuscular		TRELEGY ELLIPTA.....	1279
solution 100 mg/ml.....	1246	TRELSTAR MIXJECT.....	1280
testosterone cypionate intramuscular		TREMFYA.....	1281
solution 200 mg/ml.....	1247	tretinoin external cream.....	1282
testosterone transdermal gel 10 mg/lact		tretinoin external gel 0.01 %, 0.025 %...	1282
(2%).....	1239	tretinoin microsphere.....	1284
testosterone transdermal gel 12.5 mg/lact		tretinoin microsphere pump.....	1286
(1%).....	1240	TRETIN-X EXTERNAL CREAM	
testosterone transdermal gel 25 mg/l2.5gm		0.075 %.....	1288
(1%).....	1242	TREZIX ORAL CAPSULE 320.5-30-16	
testosterone transdermal gel 50 mg/l5gm		MG.....	1290
(1%).....	1240	TRIBENZOR.....	1292
testosterone transdermal solution.....	1244	TRINTELLIX.....	1293

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

TRIPTODUR.....	1295	<i>valganciclovir hcl oral tablet</i> .....	1325
TRIUMEQ.....	1296	<i>valsartan</i> .....	1326
TROKENDI XR.....	1297	<i>valsartan-hydrochlorothiazide</i> .....	1327
<i>tropium chloride</i> .....	1298	VANTAS.....	1328
<i>tropium chloride er</i> .....	1299	VARUBI ORAL.....	1329
TRUERESULT BLOOD GLUCOSE.....	1300	VASCEPA ORAL CAPSULE 0.5 GM.....	1330
TRUETRACK BLOOD GLUCOSE		VASCEPA ORAL CAPSULE 1 GM..	1331
KIT.....	1301	VECAMYL.....	1332
TRUETRACK SMART SYSTEM.....	1302	VELETRI.....	1333
TRULICITY.....	1303	VELTASSA.....	1334
TRUVADA.....	1304	VELTIN.....	1335
TUDORZA PRESSAIR		VEMLIDY.....	1336
INHALATION AEROSOL POWDER		VENCLEXTA ORAL TABLET 10 MG	
BREATH ACTIVATED.....	1305	.....	1337
TUSSICAPS.....	1306	VENCLEXTA ORAL TABLET 100	
TYBOST.....	1307	MG.....	1338
TYKERB.....	1308	VENCLEXTA ORAL TABLET 50 MG	
TYMLOS.....	1309	.....	1339
TYSABRI.....	1310	VENCLEXTA STARTING PACK....	1340
TYVASO.....	1311	<i>venlafaxine hcl er oral capsule extended</i>	
TYVASO REFILL.....	1312	<i>release 24 hour 150 mg</i> .....	1345
TYVASO STARTER.....	1313	<i>venlafaxine hcl er oral capsule extended</i>	
UCERIS ORAL.....	1314	<i>release 24 hour 37.5 mg, 75 mg</i> .....	1346
UCERIS RECTAL.....	1315	<i>venlafaxine hcl er oral tablet extended</i>	
ULESFIA.....	1316	<i>release 24 hour 225 mg</i> .....	1347
ULORIC.....	1317	<i>venlafaxine hcl oral tablet 100 mg, 25 mg</i>	
ULTRAVATE EXTERNAL LOTION		.....	1341
.....	1318	<i>venlafaxine hcl oral tablet 37.5 mg</i> .....	1342
UPTRAVI ORAL TABLET 1000		<i>venlafaxine hcl oral tablet 50 mg</i> .....	1343
MCG, 1200 MCG, 1400 MCG, 1600		<i>venlafaxine hcl oral tablet 75 mg</i> .....	1344
MCG, 400 MCG, 600 MCG, 800 MCG		VENTAVIS.....	1348
.....	1319	<i>verapamil hcl er oral capsule extended</i>	
UPTRAVI ORAL TABLET 200 MCG		<i>release 24 hour 100 mg, 300 mg</i> .....	1349
.....	1320	<i>verapamil hcl er oral capsule extended</i>	
UPTRAVI ORAL TABLET		<i>release 24 hour 200 mg</i> .....	1350
THERAPY PACK.....	1320	VERDROCET.....	1351
UTIBRON NEOHALER.....	1321	VERSACLOZ.....	1353
VALCHLOR.....	1322	VERZENIO.....	1354
VALCYTE ORAL SOLUTION		VESICARE.....	1355
RECONSTITUTED.....	1323	VIBERZI.....	1356
<i>valganciclovir hcl oral solution</i>		<i>vicodin es oral tablet 7.5-300 mg</i> .....	1359
<i>reconstituted</i> .....	1324	<i>vicodin hp oral tablet 10-300 mg</i> .....	1361

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary

Last Update 12/2017

Next Update

<i>vicodin oral tablet 5-300 mg</i> .....	1357	XIGDUO XR ORAL TABLET	
VICTOZA SUBCUTANEOUS		EXTENDED RELEASE 24 HOUR 10-	
SOLUTION PEN-INJECTOR.....	1363	1000 MG, 10-500 MG, 5-500 MG.....	1398
VIEKIRA PAK.....	1364	XIGDUO XR ORAL TABLET	
VIEKIRA XR.....	1365	EXTENDED RELEASE 24 HOUR 5-	
<i>vigabatrin</i> .....	1366	1000 MG.....	1399
VIIBRYD ORAL TABLET.....	1367	XOLAIR.....	1400
VIMIZIM.....	1368	XOPENEX HFA.....	1401
VIMPAT ORAL SOLUTION.....	1369	XTAMPZA ER.....	1402
VIMPAT ORAL TABLET.....	1370	XTANDI.....	1404
VIOKACE.....	1371	XULANE.....	1405
<i>viorele</i> .....	1372	XULTOPHY.....	1406
VIREAD ORAL TABLET.....	1373	XURIDEN.....	1407
VISTOGARD.....	1374	XYLON.....	1408
VIVLODEX.....	1375	XYREM.....	1409
VOLTAREN TRANSDERMAL.....	1376	YERVOY.....	1410
VONVENDI.....	1377	<i>zafirlukast</i> .....	1411
VOSEVI.....	1378	<i>zaleplon</i> .....	1412
VOTRIENT.....	1379	ZALTRAP.....	1413
VPRIV.....	1380	ZARXIO.....	1414
VRAYLAR ORAL CAPSULE 1.5 MG		ZAVESCA.....	1415
.....	1381	ZEGERID OTC.....	1416
VRAYLAR ORAL CAPSULE 3 MG	1382	ZEJULA.....	1417
VRAYLAR ORAL CAPSULE 4.5 MG,		ZELBORAF.....	1418
6 MG.....	1383	ZEMAIRA.....	1419
VRAYLAR ORAL CAPSULE		ZEMBRACE SYMTOUCH.....	1420
THERAPY PACK.....	1384	<i>zenatane oral capsule 10 mg, 20 mg, 40</i>	
VYTORIN.....	1385	<i>mg</i> .....	1421
VYVANSE.....	1386	ZENATANE ORAL CAPSULE 30 MG	
VYVANSE.....	1387	.....	1422
XADAGO.....	1388	ZENZEDI ORAL TABLET 10 MG, 5	
XALKORI.....	1389	MG.....	1423
XATMEP.....	1390	ZEPATIER.....	1424
XELJANZ.....	1391	ZETIA.....	1425
XELJANZ XR.....	1392	ZETONNA.....	1426
XEOMIN.....	1393	ZIANA.....	1427
XERMELO.....	1394	<i>zileuton er</i> .....	1428
XGEVA.....	1395	ZINBRYTA.....	1429
XIFAXAN ORAL TABLET 200 MG	1396	ZIOPTAN.....	1430
XIFAXAN ORAL TABLET 550 MG	1397	<i>ziprasidone hcl</i> .....	1431
		ZOHYDRO ER ORAL CAPSULE ER	
		12 HOUR ABUSE-DETERRENT.....	1432

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update

ZOLADEX.....	1434
<i>zoledronic acid intravenous concentrate</i> .....	1435
<i>zoledronic acid intravenous solution</i> .....	1435
ZOLINZA.....	1436
<i>zolmitriptan oral tablet 2.5 mg</i> .....	1437
<i>zolmitriptan oral tablet 5 mg</i> .....	1438
<i>zolmitriptan oral tablet dispersible 2.5 mg</i> .....	1439
<i>zolmitriptan oral tablet dispersible 5 mg</i>	1440
<i>zolpidem tartrate er</i> .....	1442
<i>zolpidem tartrate oral</i> .....	1441
ZOMIG NASAL SOLUTION 5 MG..	1443
ZONALON.....	1444
ZONTIVITY.....	1445
ZORBTIVE.....	1446
ZORVOLEX.....	1447
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 0.7-0.18 MG.....	1448
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 1.4-0.36 MG, 11.4-2.9 MG, 2.9-0.71 MG, 5.7-1.4 MG, 8.6-2.1 MG.....	1449
ZURAMPIC.....	1450
ZYBAN.....	1451
ZYDELIG.....	1452
ZYFLO.....	1453
ZYFLO CR.....	1454
ZYKADIA.....	1455
ZYTIGA ORAL TABLET 250 MG....	1456
ZYTIGA ORAL TABLET 500 MG....	1457

2017 Aetna Pharmacy Drug Guide - Five Tier Open Value Plus Small Group Formulary  
Last Update 12/2017  
Next Update